university of groningen lamotrigine in bipolar depression ... · bipolar disorder (manic-depressive...
TRANSCRIPT
University of Groningen
Lamotrigine in bipolar depressionvan der Loos, Marcus Lambertus Maria
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.
Document VersionPublisher's PDF, also known as Version of record
Publication date:2011
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):van der Loos, M. L. M. (2011). Lamotrigine in bipolar depression: a randomised placebo-controlled trial onthe acute and long-term outcome of lamotrigine as add-on to lithium with the possibility of the addition ofparoxetine. Groningen: [s.n.].
CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.
Download date: 02-08-2020
Stellingen
1. Detoevoegingvanlamotrigineaanlithiumbijpatiëntenmeteenbipolairestoornisgedurendeeendepressieveepisodeiseffectiefenveilig(ditproefschrift).
2. Verschillendestappenvanadditievanmedicatietijdenseendepressieveepisodevandebipolairestoornisisnietalleen‘careasusual’,hetisookteonderbouwen(ditproefschrift).
3. Onderzoeknaaradditie-strategieënbijdebehandelingvanbipolairestoornissenisnodig,nuttigenmogelijk(ditproefschrift).
4. Hetismogelijkombinnenéénstudiedrieachtereenvolgendestappenindebehandelingvandebipolairestoornisteonderzoeken(ditproefschrift).
5. Dekwaliteitvanhetseparatiebeleidineenpsychiatrischziekenhuisafmetenaaneenverplichtedalingvanhetaantalseparatiesmet10procentisabsurdendoetgeenrechtaandeernstvandesituatievandepatiënt.
6. Deangstvoorsamenwerkingmetdefarmaceutischeindustrieiseenremopkwalitatiefhoogwaardigonderzoeken‘evidencebasedmedicine’.
7. Marketeerszijneringeslaagdmensentedoengelovendatkamperenhetoptimumaanvrijheidenprivacybetekent.
8. Hetbelangvanhethebbenvaneeneigenmeningwordtinhetalgemeenschromelijkoverschat.
9. Gelukkigzijnernogsteedsmensendienietdoenwatzezeggenenvooralnietzeggenwatzedenken.
10.Hysterieisalsdiagnosenietverdwenenomdathetziektebeeldnietmeerbestaatmaaromdatdisproportioneelreagerennormaalisgeworden.
11.‘Socialmedia’iseencontradictiointerminus.
MarcvanderLoos
Lamotrigine in bipolar depression: a randomised placebo-controlled trial on the acute and long-term outcome
of lamotrigine as add-on to lithium with the possibility of the addition of paroxetine
28september2011
LAMOTRIGINEIN BIPOLAR DEPRESSIONa randomised placebo-controlled trial on the acute and long-term outcome of lamotrigine as add-on to lithium with the possibility of the addition of paroxetine
Marc van der Loos
Cover designKoen Kloosterhuis, May 2011
Design and lay-outGoedbezigNaarden, the Netherlands
PrintBrügemann B.V.Hilversum, the Netherlands
ISBN: 978-90-9026249-9
Copyright© 2011 M.L.M. van der Loos
No part of this book may be reproduced in any form without permission of the author.
RIJKSUNIVERSITEIT GRONINGEN
Proefschrift
ter verkrijging van het doctoraat in de Medische Wetenschappen
aan de Rijksuniversiteit Groningen op gezag van de
Rector Magnificus, dr E. Sterken,in het openbaar te verdedigen op woensdag 28 september 2011
om 11.00 uur
door
Marcus Lambertus Maria van der Loosgeboren op 10 maart 1958
te Amsterdam
LAMOTRIGINEIN BIPOLAR DEPRESSIONa randomised placebo-controlled trial on the acute and long-term outcome of lamotrigine as add-on to lithium
with the possibility of the addition of paroxetine
Promotor: Prof dr W.A. Nolen
Beoordelingscommissie: Prof dr R.A. Schroevers
Prof dr R.W. Kupka
Prof J.R. Calabrese M.D.
Ah, si j’avais pu travailler sans cette sacré maladie! Que de chôses j’aurais fait isolé des
autres selon que le pays m’en dirait. Mais oui - c’est bien fini ce voyage ci.
Ah, if I’d been able to work without this bloody illness! How many things I could have done,
isolated from the others, according to what the land would tell me.
But yes - this journey is well and truly finished
To Theo van Gogh. Saint-Rémy-de-Provence, on or about Thursday, 1 May 1890
Letter 865, Vincent van Gogh
Contents
Chapter1 Introduction.......................................................................... 11
Chapter2 Lamotrigine in bipolar disorder: an overview........................... 25
Chapter3 Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression: A Multicenter, Double-Blind, Placebo-Controlled Trial......................................................... 47
Chapter4 Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine.................................................... 71
Chapter5 Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design............................. 95
Chapter6 Discussion.......................................................................... 115
Summary........................................................................... 135
Samenvatting..................................................................... 145
Curriculum Vitae M.L.M. van der Loos................................... 155
Dankwoord (Acknowledgments)........................................... 161
12
13
1
Introduction
14 Chapter 114
Foreword
Bipolardisorder(manic-depressiveillness)isoneofthegreatandmaybethemostintriguingofpsychiatricdiseases,notonlybecauseofitshighprevalencebutalsobecauseofitsspreadingthroughtimeandcultures.ThechangeofmoodoverashorttimehasalreadybeendescribedbyancientGreeksasadisturbanceoftheequilibriumbetweenyellowandblackbile.Whereanexcessofyellowbilewasresponsiblefor(hypo)manicepisodes,anexcessofblackbilewasacauseofmelancholia.Thetermmanic-depressiveillness(manisch-depressieveIrresein)wasintroducedbyKraepelin(1)in1899.Themoderntermbipolardisorder(whichgivesalsothelesssevere(hypo)manicepisodesaplaceanddifferentiatesbetweenunipolarandbipolardisorders)wasintroducedin1957byLeonard(2).
Thecorecharacteristicofbipolardisorderisthealternationinmoodbetweenhigh,lowand‘normal’.Moreover,therearechangesinenergy,selfesteem,sexualdesire,needofsleep,keepingrelationswithotherpeople.Inthemostseriousformspsychosis,rage,andsuicidecandestroyorevenendlives.InthisthesiswewillusetheclassificationofbipolardisordersaccordingtotheDSM-IV(3)(table1,page18,19,20and21).
Theinstabilityofthecorecharacteristicsofthe‘self’ofpatientsmaybeoneoftheheaviestburdensofthisdisease.“WhoamI?Anenergetic,attractive,confidentoutgoingbigspenderwhorulestheworldortheslow,gloomy,tired,suicidalbunchofmiseryormaybesomethinginbetween?HowcanIrelyonmyself,makeappointments,livetogether,raisechildren,followastudy,findandkeepajob,etceterawhenthereisnostable‘Me’?”Questionsenoughforpatientsbutalsoforrelativesandtreatingphysicians.
Therecanbeagreatdiscrepancybetweenthegoalsofthephysicianandthepatient.Themainproblemisthedefinitionof‘stability’.Whereaspatientsmayperceivestabilityasplainandboring,familymembersanddoctorsmay
15
1Introduction 15
regardsuchasituationasdesirable.ThefrequentlyusedquestionnairestoassessseverityofillnesssuchastheMontgomery-ÅsbergDepressionRatingScale(MADRS)(4),theHamiltonDepressionRatingScale(HAM-D)(5),andtheYoungManiaRatingScale(YMRS)(6)arealldesignedtomeasurethepresenceandseverity(orabsence)ofsymptoms.Theydon’tsaymuchaboutfunctioningofthepatientorhissatisfactionwithlife.Formanypatientshypomaniaorevenmaniaisthemostsoughtaftersituation.Asonepatientoncestated:“IpreferbeingsecludedonceinafewyearsaslongasIdon’thavetotakelithiumandfeelnothingatall”.
Inoursocietythereisagreatpressureonbeingenthusiastic,active,outgoing,sexualactive,etcetera.Infactthesecharacteristicscanalsoberegardedassymptomsofhypomania.Forthatreasonitisnotsostrangethatdrugslikecocaineandamphetamineswhichcanbringusersinaeuphoric(or“hypomanic”)state,aresopopular.Andeventhedepressionandinsomniawhichcomeaftertheeuphoria,arecomparablewiththedepressiveepisodeswhichcomessooftenaftera(hypo)manicepisode.Inthebeginningthesedrugsweremostlyusedintheglamorousworldofart,filmandfashion.Butalsoinbipolardisorderthereisalwaysahintofromanticismandartistry.In1993KayRedfieldJamesonwrote‘Touchedwithfire’,abookabouttheassociationoftheartistictemperamentwithbipolardisorder.ThefirstsentenceofthisbookisaquotefromLordByron:“Wewritersareallinsane”.Thisromanticviewofdiseaseisinthemedicalworldexclusiveforpsychiatricdiseases;Patientssufferingfromaddictionareviewedas‘bohemien’,schizophrenicpatientsarehiddengeniuses(see:AbeautifulMind(SylviaNasar1998))andlastbutnotleastbipolarpatientsare‘artists’.Especiallyhypomanicepisodeswerehardlyseenaspartofadiseasebutmoreastheholygrailofpsychiatry.Astateofmindwhichgiveswaytoallkindsofartisticeruptions.Theothersideofthishighmood;thedepressionisafarlesssexykindofmooddisorder,aprizetobepaidpreferentiallyinsilence.Thissilenceisbestdemonstratedwith932hitsinPubmed®forthecombinationofthesearchterms‘bipolardepression’and‘randomisedcontrolledtrial’versus13066hitsforthecombination’depression’
16 Chapter 116
and‘randomisedcontrolledtrial’. Inthisthesiswetrytoaddsomeknowledgetothetreatmentofthebipolardepression;anunderstudiedbutverysignificantmedicalproblem.
Stabilizing mood and treatment of depression
Althoughsufferingandalsomortalityduetosuicideishighinbipolardepression,thefocusofresearchintothetreatmentofbipolardisorderhasuntilrecentlybeenmostlyontheacutetreatmentofmanicepisodes(e.g.withantipsychotics)andonmaintenancetreatment(e.g.withlithium).Thetreatmentofbipolardepressionwashardlystudiedasapparentlythesametreatmentswereusedasforunipolar(i.e.non-bipolar)depression:initiallysincethe1940ieselectroconvulsivetherapy(ECT)andsincethe1950iesand1960iestheantidepressants,originallythetricyclicantidepressants(TCAs)andmonoamineoxidaseinhibitors(MAOIs)andlatertheselectiveserotoninreuptakeinhibitors(SSRIs)andotherrelatedcompounds.Onlyafterthe1980iestherebecamesomeinterestforalternativesforthesetreatments,especiallywhenitbecameevidentthattheregularantidepressantsmightalsoinduceaswitchto(hypo)maniaandanincreaseofepisodefrequency;cycleacceleration(7;8).
Withtheintroductionoflithiuminthe1970ies(9)therebecamealsointerestintreatmentsthatwereeffectiveagainstbothpoles(maniaanddepression)oftheillness,notonlytoreducethesymptomsofthemoodepisodes(asacutetreatment)butalsotopreventfurtherepisodes,aslong-termormaintenancetreatment.Forthelatterpurposethequestwasfora‘moodstabilizer’.Themainproblemwiththisconceptisthattheterm‘moodstabilizer’hasmanydefinitions.Themoststringentdefinitionisthatatrue‘moodstabilizer’demonstratesefficacyintheacutetreatmentofbothmanicanddepressiveepisodesandpreventsagainstfurthermanicanddepressiveepisodes(fig1).
17
1Introduction 17
Figure 1. Whatisamoodstabilizer?
1. Effective in treating acute mania
• Bothacutelyandincontinuation
• Withoutcausingdepression
2.Effectiveintreatingacutebipolardepression
• Bothacutelyandincontinuation
• Withoutcausingmania
3.Effectiveinpreventingrecurrenceofbothmaniaanddepression(prophylaxis)
• (Andalsoinrapidcycling)
Figure 2.Treatments“fromabove”and“frombelow”
Stabilizefrombothsides
Stabilizefromabove
Stabilizefrombelow
Treatfrombelow
Treatfromabove
Mania
Symptoms
“Normalcy”
Symptoms
Depression
18 Chapter 118
Theloosestdefinitionrequiresefficacyinonlyonepolewithoutworseningoftheotherpole.Althoughitisinouropinionjustifiedtouseastrictdefinition,itmakessensetodifferentiatebetweenmoodstabilizingfrombelow(i.e.todiminishdepression)andmoodstabilizingfromabove(i.e.todiminishmania)(10).
Untilrecentlylithiumcameclosesttomeetingthestrictestdefinitionasa‘moodstabilizer’.Alsovalproicacid/valproateandcarbamazepineclaimedthistermbutunfortunatelyallthreecompoundswereconsidered(andpartlyalsofound)moreeffectiveintreatingandpreventingmanicepisodesthandepressiveepisodes.Asaresult,bipolardepressedpatientsweremostlytreatedwithantidepressantswhichhadlargelybeentestedonlyinunipolardepression.Asevidencegrewthattheefficacyofantidepressantsislimited(11;12)andthattheremaybetheriskofinductionof(hypo)maniaorcycleacceleration(7;8),thetreatmentofbipolardepressionbecameanunmetneed:foramoodstabilizerfrombelowwithoutinducinga(hypo)manicepisode(fig2).
Lamotrigine
Aftersomecasereportsinthe1990ies(13;14)itbecameclearthatlamotriginemightbesuchadrug.In1999,thefirstrandomized,placebo-controlledtrialshowedefficacyoflamotrigineintheacutetreatmentofbipolardepression,althoughnotontheapriorichosenprimaryoutcomemeasure(theHAM-D)butonlyonsecondaryoutcomemeasures(e.g.theMADRS)(15).However,foursubsequentstudiescouldnotreplicatethisfinding(16).Atthesametimetwootherrandomizedplacebo-controlledtrialsstudyingthelong-termeffectoflamotrigineshowedapreventiveeffectagainstfurtherdepressiveepisodesbutnotagainstmanicepisodes,whileinthesamestudieslithiumwasfoundeffectiveinthepreventionofmanicepisodesbutnotofdepressiveepisodes(17;18).
Thisbroughtustotheideatostartadouble-blindrandomizedplacebo-controlledtrialintotheeffectoflamotrigineasadd-ontoongoingtreatment
19
1Introduction 19
withlithiuminpatientswithabipolardepression.DuringPhaseIofthatstudylamotrigineorplacebowasaddedtoongoingtreatmentwithlithiumfor8weeks.After8weeksresponderscontinuedtheircombinationofmedicationwhereasparoxetinewasaddedopenlabelinnon-respondersinbothgroups(lithiumpluslamotrigineandlithiumplusplacebo)(PhaseII).At16weeksresponderscontinuedtheirmedicationregimeandwerefolloweduntilanewdepressiveor(hypo)manicrelapseoruntilthemaximumdurationofthestudy(68weeks)(Follow-up).
Outline of this thesis
InchapterIIwewillreviewthepharmacologicalprofileandtheplaceoflamotrigineinbipolardisorder. InchapterIIItheresultsobtainedduringthefirst8weeksofthestudy(phaseI)willbediscussed. InchapterIVtheresultsobtainedduringweek9-16(phaseII)willbediscussed. InchapterVtheresultsobtainedduringfollow-up(until68weeks)ofrespondersatweek16willbediscussed. InchapterVItheoverallresultsofourstudyandmorespecificallytheplaceoflamotrigineamongtheotheroptionsinthetreatmentofbipolardepressionandtheadvantagesanddisadvantagesofthedesignofourstudyincomparisonwithotherlong-termstudiesthathavebeenperformedinbipolardisorderwillbediscussed.Finally,somesuggestionsforfutureresearchwillbepresented.
20 Chapter 120
Bipolar II Disorder-Diagnostic Features
TheessentialfeatureofBipolarIIDisorderisaclinicalcoursethatischaracterizedbytheoccurrenceofoneormoreMajorDepressiveEpisodesaccompaniedbyatleastoneHypomanicEpisode.HypomanicEpisodesshouldnotbeconfusedwiththeseveraldaysofeuthymiathatmayfollowremissionofaMajorDepressiveEpisode.EpisodesofSubstance-InducedMoodDisorder(duetothedirecteffectsofamedication,orothersomatictreatmentsfordepression,adrugofabuse,ortoxinexposure)orofMoodDisorderDuetoaGeneralMedicalConditiondonotcounttowardadiagnosisofBipolarIDisorder.Inaddition,theepisodesarenotbetteraccountedforbySchizoaffectiveDisorderandarenotsuperimposedonSchizophrenia,SchizophreniformDisorder,DelusionalDisorder,orPsychoticDisorderNotOtherwiseSpecified.
Criteria for Major Depressive Episode
A.Five(ormore)ofthefollowingsymptomshavebeenpresentduringthesame2-weekperiodandrepresentachangefrompreviousfunctioning;atleastoneofthesymptomsiseither(1)depressedmoodor(2)lossofinterestorpleasure
Note:Donotincludesymptomsthatareclearlyduetoageneralmedicalcondition,ormood-incongruentdelusionsorhallucinations.
1.depressedmoodmostoftheday,nearlyeveryday,asindicatedbyeithersubjectivereport(e.g.,feelssadorempty)orobservationmadebyothers(e.g.appearstearful).Note:Inchildrenandadolescents,canbeirritablemood.
2.markedlydiminishedinterestorpleasureinall,oralmostall,activitiesmostoftheday,nearlyeveryday(asindicatedbyeithersubjectiveaccountorobservationmadebyothers)
3.significantweightlosswhennotdietingorweightgain(e.g.,achangeofmorethan5%ofbodyweightinamonth),ordecreaseorincreaseinappetitenearlyeveryday.Note:Inchildren,considerfailuretomakeexpectedweightgains.
4.insomniaorhypersomnianearlyeveryday5.psychomotoragitationorretardationnearlyeveryday(observablebyothers,
notmerelysubjectivefeelingsofrestlessnessorbeingsloweddown)6.fatigueorlossofenergynearlyeveryday
Table 1
21
1Introduction 21
7.feelingsofworthlessnessorexcessiveorinappropriateguilt(whichmaybedelusional)nearlyeveryday(notmerelyself-reproachorguiltaboutbeingsick)
8.diminishedabilitytothinkorconcentrate,orindecisiveness,nearlyeveryday(eitherbysubjectiveaccountorasobservedbyothers)
9.recurrentthoughtsofdeath(notjustfearofdying),recurrentsuicidalideationwithoutaspecificplan,orasuicideattemptoraspecificplanforcommittingsuicide
B.ThesymptomsdonotmeetcriteriaforaMixedEpisode.
C.Thesymptomscauseclinicallysignificantdistressorimpairmentinsocial,occupational,orotherimportantareasoffunctioning.
D.Thesymptomsarenotduetothedirectphysiologicaleffectsofasubstance(e.g.,adrugofabuse,amedication)orageneralmedicalcondition(e.g.,hypothyroidism).
E.Thesymptomsarenotbetteraccountedforbybereavement,i.e.,afterthelossofalovedone,thesymptomspersistforlongerthan2monthsorarecharacterizedbymarkedfunctionalimpairment,morbidpreoccupationwithworthlessness,suicidalideation,psychoticsymptoms,orpsychomotorretardation.
Criteria for Manic Episode
A.Adistinctperiodofabnormallyandpersistentlyelevated,expansive,orirritablemood,lastingatleast1week(oranydurationifhospitalizationisnecessary).
B.Duringtheperiodofmooddisturbance,three(ormore)ofthefollowingsymptomshavepersisted(fourifthemoodisonlyirritable)andhavebeenpresenttoasignificantdegree:1.inflatedself-esteemorgrandiosity2.decreasedneedforsleep(e.g.,feelsrestedafteronly3hoursofsleep)3.moretalkativethanusualorpressuretokeeptalking4.flightofideasorsubjectiveexperiencethatthoughtsareracing5.distractibility(i.e.,attentiontooeasilydrawntounimportantorirrelevant
externalstimuli)
22 Chapter 122
6.increaseingoal-directedactivity(eithersocially,atworkorschool,orsexually)orpsychomotoragitation
7.excessiveinvolvementinpleasurableactivitiesthathaveahighpotentialforpainfulconsequences(e.g.,engaginginunrestrainedbuyingsprees,sexualindiscretions,orfoolishbusinessinvestments)
C.ThesymptomsdonotmeetcriteriaforaMixedEpisode.
D.Themooddisturbanceissufficientlyseveretocausemarkedimpairmentinoccupationalfunctioningorinusualsocialactivitiesorrelationshipswithothers,ortonecessitatehospitalizationtopreventharmtoselforothers,ortherearepsychoticfeatures.
E.Thesymptomsarenotduetothedirectphysiologicaleffectsofasubstance(e.g.,adrugofabuse,amedication,orothertreatments)orageneralmedicalcondition(e.g.,hyperthyroidism).
Note:Manic-likeepisodesthatareclearlycausedbysomaticantidepressanttreatment(e.g.,medication,electroconvulsivetherapy,lighttherapy)shouldnotcounttowardadiagnosisofBipolarIDisorder.
Criteria for Mixed Episode
A.ThecriteriaaremetbothforaManicEpisodeandforaMajorDepressiveEpisode(exceptforduration)nearlyeverydayduringatleasta1-weekperiod.
B.Themooddisturbanceissufficientlyseveretocausemarkedimpairmentinoccupationalfunctioningorinusualsocialactivitiesorrelationshipswithothers,ortonecessitatehospitalizationtopreventharmtoselforothers,ortherearepsychoticfeatures.
C.Thesymptomsarenotduetothedirectphysiologicaleffectsofasubstance(e.g.,adrugofabuse,amedication,orothertreatment)orageneralmedicalcondition(e.g.,hyperthyroidism).
Criteria for Hypomanic Episode
23
1Introduction 23
A.Adistinctperiodofpersistentlyelevated,expansive,orirritablemood,lastingthroughoutatleast4days,thatisclearlydifferentfromtheusualnondepressedmood.
B.Duringtheperiodofmooddisturbance,three(ormore)ofthefollowingsymptomshavepersisted(fourifthemoodisonlyirritable)andhavebeenpresenttoasignificantdegree:1.inflatedself-esteemorgrandiosity2.decreasedneedforsleep(e.g.,feelsrestedafteronly3hoursofsleep)3.moretalkativethanusualorpressuretokeeptalking4.flightofideasorsubjectiveexperiencethatthoughtsareracing5.distractibility(i.e.,attentiontooeasilydrawntounimportantorirrelevant
externalstimuli)6.increaseingoal-directedactivity(eithersocially,atworkorschool,orsexually)
orpsychomotoragitation7.excessiveinvolvementinpleasurableactivitiesthathaveahighpotentialfor
painfulconsequences(e.g.,engaginginunrestrainedbuyingsprees,sexualindiscretions,orfoolishbusinessinvestments)
C.Theepisodeisassociatedwithanunequivocalchangeinfunctioningthatisuncharacteristicofthepersonwhennotsymptomatic.
D.Thedisturbanceinmoodandthechangeinfunctioningareobservablebyothers.
E.Theepisodeisnotsevereenoughtocausemarkedimpairmentinsocialoroccupationalfunctioning,ortonecessitatehospitalization,andtherearenopsychoticfeatures.
F.Thesymptomsarenotduetothedirectphysiologicaleffectsofasubstance(e.g.,adrugofabuse,amedication,orothertreatment)orageneralmedicalcondition(e.g.,hyperthyroidism).
Note:Hypomanic-likeepisodesthatareclearlycausedbysomaticantidepressanttreatment(e.g.,medication,electroconvulsivetherapy,lighttherapy)shouldnot
counttowardadiagnosisofBipolarIIDisorder.
24 Chapter 124
References
1. E.Kraepelin.Psychiatrie.EinLehrbuchfurStudirendeundAerzte.IIBandSechsteAuflage.Leipzig,VerlagvonJohannAmbrosiusBarth.1899.
2. K.Leonhard.AufteilungderEndogenenPsychosen.Berlin,AcademieVerlag.1957.
3. AmericanPsychiatricAssociation.DiagnosticandStatisticalManualofMentalDisorders,4thEdition(DSM-IV).WashingtonDC,AmericanPsychiatricPress.1994.
4. MontgomerySA,ÅsbergM.Anewdepressionscaledesignedtobesensitivetochange.BrJPsychiatry1979Apr;134:382-9.
5. HAMILTONM.Aratingscalefordepression.JNeurolNeurosurgPsychiatry1960Feb;23:56-62.
6. YoungRC,NysewanderRW,SchreiberMT.Maniascalescores,signs,andsymptomsinfortyinpatients.JClinPsychiatry1983Mar;44(3):98-100.
7. AltshulerLL,PostRM,LeverichGS,MikalauskasK,RosoffA,AckermanL.Antidepressant-inducedmaniaandcycleacceleration:acontroversyrevisited.AmJPsychiatry1995Aug;152(8):1130-8.
8. LichtRW,GijsmanH,NolenWA,AngstJ.Areantidepressantssafeinthetreatmentofbipolardepression?Acriticalevaluationoftheirpotentialrisktoinduceswitchintomaniaorcycleacceleration.ActaPsychiatrScand2008Nov;118(5):337-46.
9. SCHOUM,JUEL-NIELSENN,STROMGRENE,VOLDBYH.Thetreatmentofmanicpsychosesbytheadministrationoflithiumsalts.JNeurolNeurosurgPsychiatry1954Nov;17(4):250-60.
10. KetterTA,CalabreseJR.Stabilizationofmoodfrombelowversusabovebaselineinbipolardisorder:anewnomenclature.JClinPsychiatry2002Feb;63(2):146-51.
11.GhaemiSN,WingoAP,FilkowskiMA,BaldessariniRJ.Long-termantidepressanttreatmentinbipolardisorder:meta-analysesofbenefitsandrisks.ActaPsychiatrScand2008Aug24.
25
1Introduction 25
12. SachsGS,NierenbergAA,CalabreseJR,MarangellLB,WisniewskiSR,GyulaiL,etal.Effectivenessofadjunctiveantidepressanttreatmentforbipolardepression.NEnglJMed2007Apr26;356(17):1711-22.
13. SmithD,BakerG,DaviesG,DeweyM,ChadwickDW.Outcomesofadd-ontreatmentwithlamotrigineinpartialepilepsy.Epilepsia1993Mar;34(2):312-22.
14.CalabreseJR,FatemiSH,WoyshvilleMJ.Antidepressanteffectsoflamotrigineinrapidcyclingbipolardisorder.AmJPsychiatry1996Sep;153(9):1236.
15.CalabreseJR,BowdenCL,SachsGS,AscherJA,MonaghanE,RuddGD.Adouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithbipolarIdepression.Lamictal602StudyGroup.JClinPsychiatry1999Feb;60(2):79-88.
16.CalabreseJR,HuffmanRF,WhiteRL,EdwardsS,ThompsonTR,AscherJA,etal.Lamotrigineintheacutetreatmentofbipolardepression:resultsoffivedouble-blind,placebo-controlledclinicaltrials.BipolarDisord2008Mar;10(2):323-33.
17.CalabreseJR,BowdenCL,SachsG,YathamLN,BehnkeK,MehtonenOP,etal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlydepressedpatientswithbipolarIdisorder.JClinPsychiatry2003Sep;64(9):1013-24.
18. BowdenCL,CalabreseJR,SachsG,YathamLN,AsgharSA,HomplandM,etal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlymanicorhypomanicpatientswithbipolarIdisorder.ArchGenPsychiatry2003Apr;60(4):392-400.
26
27
Lamotrigine in bipolar disorder: an overview
MarcL.M.vanderLoos(1)JosephR.Calabrese,M.D.(2)WillemA.Nolen(3)DavidJ.Muzina,M.D.(4)
1.DepartmentofPsychiatry,IsalaKlinieken,locationSophia,Zwolle,theNetherlands
2.CaseWesternReserveUniversitySchoolofMedicine,UniversityHospitalsofCleveland,Cleveland,Ohio,USA
3.DepartmentofPsychiatry,UniversityMedicalCenterGroningen,UniversityofGroningen,Groningen,theNetherlands
4.DepartmentofPsychiatryandPsychology,ClevelandClinicFoundation,Cleveland,Ohio
Thischapterisanadaptationfrom:Chapter 4 Pharmacological profile and clinical utility of lamotrigine in mood disordersBipolar Psychopharmacotherapy: Caring for the Patient, 2nd EditionHagopS.Akiskal(Editor),MauricioTohen(Editor)Wiley-BlackwellJohnWiley&Sons,Ltd.
2
28 Chapter 228
Introduction
Thereremainsapressingneedforadditionaltreatmentoptionsformooddisorders,particularlythoserefractoryordifficulttotreatdisorderssuchasbipolardisorder.EstimatesoftheprevalenceofbipolarIdisorderacrossdiverseculturesandethnicgroupsareconsistent,rangingbetween0.4%and1.6%inadults(Weissman1996andRegeer2004).Recentestimatesoftheoverallprevalenceofbipolardisorder(typesIandIIaswellasNOS)suggestthat4-5%suffersfromthisdebilitatingmentaldisorder(Hirschfeld.2003;Regeer2004).Bipolardisorderscarriesahighburden,negativelyaffectinglivesinmanyareas,mostnotablytheperformanceofwork-related,leisure,andinterpersonalactivities(Calabrese2003).Thegreatestneedexistsinthetreatmentofdepressiveepisodesassociatedwithbipolardisordersassymptomsofdepressionaremuchmorecommonlyexperiencedandmoredifficulttotreatthanmanicsymptoms(Post2002;Judd2002andKupka2005). Reportsoflamotrigine’sbeneficialeffectsonmoodinepilepsypatientsledtoitsuseandstudyinaffectivedisorders.Studiesinvolvingbipolarpatientssuggestedthatlamotriginepossessedabroadspectrumoftherapeuticactivityinbipolardisorder,withlaterdescriptionsofgreaterefficacyfordepressivethanformanicsymptoms.Giventhesignificantburden,prevalence,andrecurrentnatureofbipolardisorder-especiallybipolardepression–lamotrigineappearstobegintoaddressanareaofseriousunmetpublichealthneed(Calabrese2003).
Clinical Pharmacology of Lamotrigine
Pharmacodynamics Lamotrigineisanantiepilepticdrugofthephenyltriazineclassthathasdemonstratedefficacyasadd-ontreatmentofpartialseizures(Mikati1989;Matsuo1993)andasmaintenancetreatmentofbipolarIdisordertodelaythetimeofoccurrenceofmoodepisodes(Bowden2003;Calabrese2003).Althoughitsmechanismoftherapeuticactioninhumansisnotdefinitivelyunderstood,lamotrigineisthoughttopossessmodulatoryandprotectiveeffects
2929
2
Lamotrigine in bipolar disorder: an overview
onneurotransmissionandintracellularsignaltransductionprocesses. Structurallydistinctfromotherantiepilepticdrugs,lamotrigineinteractspreferentiallyontheslowinactivatedstateofpresynapticneuronalsodiumandcalciumchannelstoprolonginactivationoftheneuronandpromotestabilizationoftheneuronalmembrane(Xie1998).Thiseffectisaugmentedbyause-dependentactioninwhichfurtherinhibitionbythedrugdevelopsduringrapid,repetitivestimulation(i.e.,epileptiformbursts).Consequently,thereleaseoftheexcitatoryaminoacidglutamateisantagonized(Fitton1995,LiandKetter2002).Lamotriginehasalsobeenobservedtoinhibitcorticalandamygdaloidkindling(Gilman1995,Leach1986andXie1995). Lamotriginehasnosubstantialinvitroaffinityforadenosine,adrenergic,dopaminergic,muscarinicandopioidreceptorsatclinicallyapplicableconcentrationsandbindsonlyweaklytoinhibitserotonin5HT3receptors(Leach1991).Lamotriginelacksclinicallymeaningfulactivityatthe5HT1Areceptor,wherechangesin5HT1Areceptor-mediatedcyclicadenosinemonophosphatepathwayhavebeenimplicatedinaffectivedisorders(Shiah1998andVinod2002). Inearlyepilepsystudieswithlamotrigineitwasnotedthatmanypatientsreportedimprovementinmoodandpsychologicalwell-beingindependentfromreductioninseizurefrequency,whichledtoitsinvestigationforuseinaffectivedisorders(Smith1993a;Smith1993b).Significantly,lamotriginehasminimalnegativeeffectsoncognitive,memory,orpsychomotorfunctionandisnotassociatedwithsedativeeffectsorweightgain(Goa1993,Cohen1985andGinsberg2003).
Pharmacokinetics Lamotrigineisextensivelyabsorbeddemonstratinglinearkinetics,resultingin98%bioavailability(Garnett1997).Peakplasmaconcentrationsareattainedafter1-3hourswithmeanplasmaproteinbindingof55-68%(Cohen1987,Ramsay,1991andRambeck1993).Lamotriginereadilycrossestheplacentalbarriercausingfetalbloodconcentrationssimilartomaternallevelsandpassesintobreastmilkreaching40-80%ofthematernallamotrigine
30 Chapter 230
concentration(Ohman,2000andPennell2003). Therate-limitingstepintheeliminationoflamotrigineisN-glucoronidationbytheliverwithaplasmaeliminationhalf-lifeof25+10hours(Cohen1987).Autoinductionofitsownmetabolismdoesnotoccurandtherearenoactivemetabolites.Pregnancyincreaseslamotrigineclearancebymorethan50%earlyduringpregnancyandrevertsquicklyafterdelivery(Tran2002).Clearancemaybereducedintheelderlyandinpatientswithmoderatetoseverehepaticdysfunction.
Drug Interactions Lamotrigineadministrationaffectshardlytheserumconcentrationsofotherdrugs.However,enzyme-inhibitingdrugssuchasdivalproexsodiumincreaselamotrigineconcentrationsbysignificantlycompetingformetabolismthroughglucoronidationeffectivelyincreasingthemeanhalf-lifeoflamotriginetoabout70hours(Yuen1992andAnderson1996).Enzyme-inducingdrugs,suchasphenytoin,carbamazepine,andphenobarbital,reducethelamotrigine’smeaneliminationhalf-lifetoabout12hoursanddecreaselamotrigineconcentrations(Hachad2002).Therearepharmacokineticinteractionsbetweenlamotrigineandanti-conceptivemedication.(Sidhu2005).Theclearanceoflevonogestrelisincreasedwithapossibledecreaseoftheanti-conceptivereliability.Ontheotherhandistheclearanceoflamotrigineenhancedbyanti-conceptivemedication,withaloweringoflamotrigineplasmalevels. Lamotriginedoesnotsignificantlyaffectthepharmacokineticsoflithium(Chen2000).
Lamotrigine and Mood Disorders
Acute treatment of bipolar depression TheobservationsofSmithandcolleagues(Smith1993a,1993b)thatpatientstreatedwithadd-onlamotrigineforpartialseizuresexperiencedimprovedmoodapartfromeffectsonepilepsystimulatedinvestigationsoflamotrigine’sefficacytotreatmooddisorders.Earlycasereportsinvolving
3131
2
Lamotrigine in bipolar disorder: an overview
bipolarpatientssuggestedthatlamotriginepossessedabroadspectrumoftherapeuticactivityinbipolardisorder,includingrapidcyclingandmixedstates(Weisler1994,Calabrese1996andWalden1996).Asubsequentopen-labelstudyprovidedpreliminarydatathatlamotriginewaseffectiveforpatientswithrefractorybipolardisorder,with68%ofdepressedpatientsand84%ofmanic/hypomanic/mixedpatientsshowingmoderatetomarkedresponse(Calabrese1999a). Anopennaturalisticstudyoftwenty-twodepressedbipolarpatientswhowererefractorytotreatmentwithacombinationofdivalproexsodiumandanothermoodstabilizerordivalproexsodiumandanantidepressantfor6weeksweretreatedwithadd-onlamotrigine.Sixteenoutof22(72%)respondedbytheendofweek4,suggestingthatlamotriginemaybeusefulinbipolardepression(Kusumakar1997).Inadouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithnonrapid-cyclingbipolarIdepression,treatmentwithlamotrigineover7weeks(50or200mg/day)didnotresultinasignificantdifferenceversusplaceboontheprimaryoutcomemeasure(HAM-D),butdidsoonseveralsecondaryoutcomemeasuresincludingtheMADRS,particularlyinthe200mggroup,comparedwithplacebo(Calabrese1999b).Improvementswereobservedasearlyasweek3. AfterthisfirstpositiveresultforlamotrigineinaRCT,lamotriginewastestedagainstplaceboinfourotherRCT’s(Calabrese2007andGoldsmith2003).NoneoftheseRCT’sdiscriminatedsignificantlybetweenlamotrigineandplaceboontheprimaryoutcomecriteria.Partofthisnegativeresultwasbecauseofahighplaceboresponseinallfourstudies.Nevertheless,ameta-analysisofallfivestudiesshowedasignificantalthoughmodestbenefitforlamotrigine.(Geddes2009) Thirty-onepatientswithrefractorybipolarandunipolarmooddisordersparticipatedinadouble-blind,randomized,crossoverstudyofthree6-weekmonotherapyevaluationsincludinglamotrigine,gabapentin,andplacebo.UsingtheClinicalGlobalImpressionsScaleforBipolarIllness(CGI-BP)astheprimaryoutcomevariable,thisstudyreporteda52%responserate(CGI-BPasmuchorverymuchimproved)forlamotrigine,comparedto26%forgabapentinand23%
32 Chapter 232
forplacebo-treatedpatients(Frye2000). Thefinalstudy(n=410)comparedlamotrigine(doseuptitratedto200mg/day)witholanzapine/fluoxetine(dose6/25,6/50,12/25or12/50mg/day)(Brown.2006)andshowedasmallbutsignificantadvantage(improvementontheMADRSafter7weeksof14.91vs12.92respectivelyp=0.002)fortheolanzapine/fluoxetinecombination.
Acute treatment of mania / mixed states The1999open-labelstudybyCalabreseandcolleaguesobservedarobustresponsetolamotrigine(primarilyasadd-ontherapy)in84%ofmanic/hypomanic/mixedpatients(Calabrese1999a).Inthefirstdouble-blind,randomized,controlledstudyoflamotrigineinacutemanialamotriginetitratedto100mg/dayoverthreeweekswasaseffectiveaslithium800mg/day(meanbloodlevel0.77mmol/L)inreducingmanicsymptoms(Ichim2000).However,lamotriginehasnotshownanti-manicactivityinplacebo-controlledstudies(Bowden2003).Unpublishedstudies(dataonfile,GlaxoSmithKline2003)inpatientswithacutemanicormixedexacerbationsofbipolarIdisorderhavefoundnosignificantdifferencefrombaselineinthe11-itemManiaRatingScale(MRS)betweenlamotrigineandplacebo(Goldsmith2003).
Maintenance therapy Theinitiallamotriginemaintenancestudywasadouble-blind,placebo-controlledstudyinrapidcyclingbipolardisorder(Calabrese2000).Openlabellamotrigineaddedtothetreatmentregimensof324patientsmeetingDSM-IVcriteriaforrapidcyclingbipolardisorderresultedin182stabilizedpatientswhowerethenrandomlyassignedtothedouble-blindmaintenancephaseafterbeingstratifiedforbipolarIorIIdisorder.Otherpsychotropicagentsweretaperedandpatientsrandomlyassignedtoeitherlamotriginemonotherapyorplaceboina1:1ratioforthesix-monthmaintenancephase.Overall49placebopatients(56%)and45lamotrigine-treatedpatients(50%)requiredtreatmentofanemergingmoodepisodewithadditionalpharmacotherapy.Althoughtherewasnostatisticalsignificancebetweenthesetwotreatmentgroupsontheprimary
3333
2
Lamotrigine in bipolar disorder: an overview
outcomemeasureoftimetoadditionalpharmacotherapy(medianof12weeksforplaceboversus18weeksforlamotrigine),lamotriginewassignificantlymoreeffectivethanplacebointhesurvivalinstudyanalysis(medianof8weeksforplaceboversus14weeksforlamotrigine).Inthesub-analysisaccordingtodiseasetype,lamotriginewassignificantlymoreeffectivethanplaceboindelayingtimetoadditionalpharmacotherapyforbipolarIIpatientsthanbipolarIpatients.Forty-sixpercentofbipolarIIpatientsonlamotriginemonotherapywerestablewithoutrelapseafter6monthscomparedtoonly18%ofplacebo-treatedbipolarIIpatients.(Calabrese2000).TheseresultswereconfirmedinaposthocanalysisofthesamepatientsamplewiththeLifechartmethod.Measuredwiththelifechartatleastonceweeklypatientstakinglamotriginewere1,8timesmorelikelytoachieveeuthymiathanthosetakingplacebo(Goldberg2008).Inanunpublishedstudy(dataonfile,GlaxoSmithKline2003),thesefindingswerenotreplicated.However,significantlyfewerlamotriginetreatedrapidcyclersrequiredinterventionforadepressiveepisode.Collectively,theseresultssuggestthatlamotriginemaybeausefultreatmentforrapidcyclingbipolarpatients,especiallyfortypeIIandforthepreventionofdepressiverelapses. Two18-monthmaintenancestudies(Bowden2003andCalabrese2003)comparinglamotrigine,lithium,andplaceboprovidedfurthersupportfortheuseoflamotrigineasamoodstabilizerandledtoitsapprovalbytheUSFDAinJune2003asamaintenancetreatmentforbipolarIdisorder.Thesecomplementarystudiesenrolledpatientsinadouble-blindphaseofmaintenancetherapyafterarecentdepressed,hypomanic,ormanicepisoderemitted(CGI-Sscoreof<3for4consecutiveweeks)duringopen-labelstabilizationduringwhichlamotriginewasinitiatedasadjunctiveormonotherapyandotherpsychotropicsdiscontinued.Inbothstudies,50%ofpatientsachievedstabilizationcriteriaallowingforprogressionintodouble-blindedmaintenancetherapywithlamotrigine(50-400mg/day),lithium(0.8-1.1mEq/L),orplacebo.Theprimaryefficacyendpointusedwastimetointerventionforanymoodepisode. Inbothofthesestudies,lamotrigineandlithiumdemonstratedeffectiveprophylaxisagainstanyemergingmoodepisodecomparedwithplacebo.Therewerestatisticallyfewerrelapsingmoodepisodesandlongermediansurvivalin
34 Chapter 234
lamotrigineandlithiumtreatedpatientscomparedwithplacebo.Mediansurvivalbeforeinterventionforanymoodepisodeforlamotrigine-treatedpatientsrangedfrom118-256days,significantlybetterthanplacebo(85-93days).Lithiumalsooutperformedplacebowithamediansurvivalof170-292days.However,therewereimportantdifferencesinthespectraofmaintenanceefficacy. Inbothstudies,lithium,butnotlamotriginewassuperiortoplaceboatdelayingthetimetointerventionforamanicorhypomanicepisode.Intotalforbothstudies123hypomanic/maniceventsemergedduringmaintenance,with25%ofplacebotreatedpatientsexperiencingahypomanic,manic,ormixedepisode(47of188);21%ofthelamotriginegrouprelapsed(58of273),butonly11%ofpatientsinthelithium-treatmentarmhadbreakthroughmaniaorhypomania(18of164).LithiumwasclearlymoreeffectivethanplaceboandlamotrigineinpreventingmanicandhypomanicrelapseinrecentlysymptomaticbipolarIpatients. Incontrast,lamotrigineappearstobemoreeffectivethanlithiuminthepreventionofdepressiverelapseinbipolarIpatients.Inbothstudies,lamotriginebutnotlithium,wassignificantlybetterthanplaceboatprolongingtimetointerventionforadepressivemoodepisode.Therewere209depressiverelapsesinthepatientsobservedinthetwostudies,withahigherrateofrelapseintheplacebo(68of188,or36%)andlithiumtreatmentgroups(56of164,or34%);lamotriginewasbetteratpreventingrecurrenceofdepressionwitha31%rateofdepressiverelapseandalongermediansurvivalbeforetreatmentofdepressionwasnecessary.Thedifferencewasparticularlyevidentinthetreatmentofrecentlymanicorhypomanicpatientsinwhomonly14%ofthosereceivinglamotrigine(8of58)neededinterventionforemergentdepressioncomparedwith23%ofpatientsreceivinglithium(10of44)and30%receivingplacebo(21of69).Inaposthocanalysisofthefirst6monthsofthebipolarIpatients(indexepisodedepression)therewasnoevidenceforagreaterriskformooddestabilization(emergent(hypo)manicsymptoms)inthelamotriginegroupversustheplacebogroup(Goldberg2009).
3535
2
Lamotrigine in bipolar disorder: an overview
Safety
Rash Rashesrequiringhospitalizationanddiscontinuationoftreatmenthavebeenreportedwithlamotrigine.Thereportedrashrateis10%inadultpatientswithepilepsytreatedwithadjunctivelamotrigineand7%inbipolarIadultstreatedwithmonotherapy;theplaceborateis5%inbothpopulations(lamotriginepackageinsert).Seriousrashratesareconsiderablylowerat0.8%inpediatricepilepsypatients,0.3%inepilepticadultsasmonotherapyand0.13%asadjunctivetherapy.Aretrospectiveanalysisconductedofratesoflamotrigine-relatedrashin12multicenterstudiesoflamotrigineformooddisorders(n=1955),including1openstudy,7randomizedcontrolledacutetrials,and4randomizedcontrolledmaintenancetrialsfrom1996to2001reportedseriousrashin0%withlamotrigine,0.1%(n=1)withplacebo,and0%withcomparators(Calabrese2002).Acrossallbipolardisorderstudieswith2,272patientsonlamotrigine,seriousrashwasobservedinthreepatientsforanoverallrateof0.1%(lamotriginepackageinsert).OneofthesethreepatientsexperiencedamildStevens-Johnsonsyndromeonadjunctivelamotrigineanddidnotrequirehospitalization. InarandomizedtrialUsualCarePrecautionswerecomparedwithDermatologicPrecautions(UCPplusadditionalspecificprecautionsintendedtodecreasetheriskofrash)for12weeks(Ketter2006).Lamotriginewasadded(targetdose200mg/day)toongoingmedicationwithaslowuptitration.
UsualCareprecautionswere:1.notexceedingtheinitialdoseordose-escalationschedule2.ifarashdevelopedduringthestudythepatientcontactedtheinvestigator
immediately3.lamotriginewasstoppedincaseofrash.PatientsintheDermatologicPrecautionsgroupwere,besidesUCP,advisednotto:4.takenewmedicationsorfoods,usenewcosmetics,deodorants,detergentsor
36 Chapter 236
fabricsofteners5.stimulatetheimmunesystemthroughexcessivesunexposure6.participateinactivitiesthatmightleadtoexposuretopoisonoakorpoisonivy7.receiveanyimmunizations
1175patientswereincluded.Inbothgroupstherewerenoreportsofseriousrash.Therateofnon-seriousrashwaslowforUCPaswellasforDP(8.8%and8.6%respectively,OR0.99).whichiscomparablewithratesofrashinpreviousstudies.Clinicalresponsewas50%with29%remissionoverbothgroups(accordingtotheClinicalGlobalImpressionsBipolarversion). AGermanregistrythatdocumentstheincidencesofseriousrashhasbeeninplacesince1990andascertainshospitalizedcasesofStevens-Johnsonsyndrome(SJS)andtoxicepidermalnecrolysis(TEN)relatedtoantiepilepticdruguse(Rzany1996).Reportedcasesareconfirmedbyaregistryphysicianandreviewedbyadermatologicalexpertcommitteeensuringhighdiagnosticaccuracy.TheincidenceofseriousrashrisingtothelevelofSJS/TENdiagnosisintheGermanregistrywas0.02%from1993-2001(Messenheimer2002). Riskofrashisnotedtobehigherinpediatricpatientsandmaybeincreasedbyco-administrationofdivalproexsodiumorexceedingtherecommendedinitialdoseordoseescalationscheduleforlamotrigine.Womenmaybeatincreasedriskforrashcomparedwithmen,witharelativeriskof1.8(Wong1999).
Other side effects and tolerability Lamotrigineisknowntobegenerallywelltoleratedinthetreatmentofepilepsy(Choi2003).Agreatdealofdatageneratedbythe18-monthlamotriginemaintenancetrials(Bowden2003andCalabrese2003)confirmsclinicalexperienceandepilepsymanagementreportsoflamotrigine’sfavorablesideeffectprofileinthetreatmentofbipolarpatients.In280patientsonmaintenancelamotrigineduringdouble-blindedtreatmentinbothtrialscombined,only23(8.2%)discontinuedstudyparticipationprematurelyduetoanadverseevent;7.9%ofplacebotreatedpatientsexperiencedadverseeventsthatledto
3737
2
Lamotrigine in bipolar disorder: an overview
endofstudy(15of191).Overthe18monthsrandomizedphase,lamotriginetreatedpatientsexhibiteda4.9poundmeandecreaseinbodyweight,comparedtoa2.6poundmeanweightgainintheplacebogroup.Inacombinedanalysisofbothstudies,theincidenceofmania/hypomania/mixedepisodesreportedasadverseeventswas5%forpatientstreatedwithlamotrigine,4%forpatientstreatedwithlithium,and7%forpatientstreatedwithplacebo.Ingeneral,lamotrigineexhibitsplacebolevelratesoftreatment-emergentadverseeventsandisbettertoleratedthanlithium(Calabrese2003).Table1liststreatment-emergentadverseeventsforthecombinedmaintenancestudiesduringrandomizedphase.
Table 1. Adverseeventsobservedduringrandomizedphaseoflamotriginemaintenancestudies(inpercent)*
Event Lamotrigine(n=227) Placebo(n=190)
Nausea 14 11
Insomnia 10 6
Somnolence 9 7
Backpain 8 6
Fatigue 8 5
Rhinitis 7 4
Benignrash 7 5
Abdominalpain 6 3
Drymouth 6 4
Constipation 5 2
Vomiting 5 2
Coughexacerbation 5 3
Pharyngitis 5 4
*Adverseeventslistedhadincidence>5%andwerenumericallygreaterthanplacebo.[Bowden2003;Calabrese2003;Dataonfile,GlaxoSmithKline]
38 Chapter 238
Clinical applications for lamotrigine
Bipolar depression Forthemanagementofacutebipolardepression,theAPAPracticeGuidelinesof2002recommendedlamotrigineasafirst-lineoptionwithmoderateclinicalconfidence(Hirschfeld2002).Sincethenotheroptionshavebecomeavailable,especiallyquetiapineandthecombinationofolanzapineplusfluoxetine.Withthedatathatbecameavailableafterthe2002guideline,lamotriginehasaplaceinthetreatmentofacutebipolardepression,especiallyinpatientsexperiencingadepressiveepisodedespiteadequatetreatmentwithlithium.Inthesepatientslamotriginecanberecommendedasadd-ontherapywithsubstantialclinicalconfidence. Dosingshouldfollowpublishedtitrationschedulestominimizetheriskofrash,withaminimumdoseof50mg/dayandatargetdoseof200mg/dayformostpatients(table2).Thereisnopharmacokineticinteractionwithlithium,However,inbipolarpatientsexperiencingabreakthroughdepressiononcarbamazepineorvalproate,lamotrigineshouldbeaddedwhilekeepinginmindpharmacokineticinteractionsthatmayaffectdosing:doubledoseoflamotrigineincombinationwithcarbamazepine,halfthedoseincombinationwithvalproate.
Table 2. RecommendedLamotriginedosingschedule
Concomitant
medication?
Week
1&2
Week
3&4
Week5 Week6 Week7
Notondivalproexor
carbamazepine
25mgqd 50mgqd 100mg
qd
200mg
qd
200mg
qd
Ondivalproex 25mg
qod
25mgqd 50mgqd 100mg
qd
100mg
qd
Oncarbamazepine
orphenytoin
50mgqd 100mg
qd
200mg
qd
300mg
qd
300mg
qd
3939
2
Lamotrigine in bipolar disorder: an overview
Mania / mixed states LamotriginemonotherapyisnotrecommendedfortheacutemanagementofmaniaormixedstatesassociatedwithbipolarIdisorder.Despitelimitedcasereportsandearlydatasuggestingthatlamotriginemaypossessanti-manicproperties,furtherstudyhasledtotheconclusionthatlamotriginehasonlymildtomoderateefficacyinmaniaandshouldnotbereliablyusedasmonotherapyintheseurgentabovebaselinemooddisturbances.Theadditionoflamotriginetootherfirst-lineantimanicagents,suchaslithium,divalproex,olanzapine,orquetiapinemayhastenorcompleterecoveryfromacutemanicormixedstates.LamotrigineshoulddefinitelybeconsideredasaninitialadjunctivetreatmentforthesebipolarIpatientstoaddresstheneedtopreventfuturemoodepisodesafterrecoveryfromthecurrentmanicormixedepisode.Again,dosingguidelinesshouldbefollowedasindicatedpreviouslyandinthepackageinserttoavoidincreasedriskofrash. InbipolarIIpatientsexperiencingacutehypomania,lamotriginecanbeusedasamonotherapyorinconjunctionwithanothermoodstabilizersuchaslithium.Oneeffectivestrategyistheprescriptionoflamotrigineplusashort-termatypicalantipsychotic
Maintenance therapy LamotrigineisindicatedbytheUSFDAandtheEMEAforthemaintenancetreatmentofbipolarIdisordertodelaythetimetooccurrenceofmoodepisodes.Itshouldthereforebeconsideredinthetreatmentofallbipolarpatientsduetotheinherentnaturaltendencyfortheillnesstobechronicandrecurrent. Maintenancemonotherapywithlamotriginecanbeconsideredinthoseindividualswithnon-bipolarIillness,milderformsofbipolarIIdisorderwithpredominantdepressivecourse,andinotherbipolarspectrumdisorderssuchascyclothymicorhyperthymicpersonalities.Intheory,lamotriginemonotherapycouldalsobeconsideredasamaintenancetherapyaftersuccessfulECTforeitherunipolarorbipolardepression.Inmostpatients,lamotrigineshouldbepartofacombinedpharmacologicalstrategytopreventrelapse.Althoughlamotrigine
40 Chapter 240
hasbeendemonstratedaneffectivemaintenancetreatmentforbipolarIdisorder,itsabilitytopreventmanicepisodeswasconsiderablylessrobustthanitsantidepressantability.Acomprehensivebipolarmaintenancemedicationtreatmentplanmustaddresspreventionofdepressiveandmanicphases,andlamotrigineisonlymoderatelyeffectiveinthedelayofmanicepisodesnecessitatinguseofothermoodstabilizerswithacomplementaryefficacyprofile,suchaslithium,divalproex.oratypicalantipsychotics.
Use in women Therehavebeenreportsoflamotrigineserumconcentrationsdecreasinginwomenafterstartingoralcontraceptivesandincreasingafteroralcontraceptiveswerediscontinued(Sidhu2005).Dosageadjustmentsmayhavetobemadeinwomentakinglamotrigineduringtimesoforalcontraceptiveinitiationortermination,althoughnoknownlinkexistsbetweenbloodlevelsandtherapeuticeffectsforaffectivedisorders. LamotriginecarriesaCategoryCFDAwarningforuseduringpregnancy.Pregnantwomenmaintainedonlamotrigineduringpregnancyshouldhavebloodlevelsoflamotriginecheckedmonthlyasitsclearanceincreasessignificantlyaspregnancyprogresses.Apreconceptiondeterminationoflamotriginebloodlevelinastablebipolarwomanmayprovideatargetdoserangetomaintainduringpregnancy.Clearanceoflamotriginedropsquicklyafterdelivery,requiringdosagereductioninmostpostpartumpatients.Breast-feedingisnotrecommendedtonursingmothersonlamotriginesincesignificantlevelsoflamotriginearepresentinbreastmilkandlongtermeffectsofexposuretoneonatesisunknown.Althoughtherearesomereportsofanincreasedriskforisolatedcleftpalateorlipdeformityafterexposuretolamotriginemonotherapyduringthefirsttrimesterofpregnancy(Holmes2008)theoverallriskformajorbirthdefectsappeartobesimilartothatofthegeneralpopulation(Cunnington2005).
4141
2
Lamotrigine in bipolar disorder: an overview
Summary
Thediscoveryoflamotrigine’spositiveeffectsonmoodinepilepsypatientsledtoitsinvestigationsinandeventualapprovalfortreatingbipolarIdisorder.Althoughtheexactmoodstabilizingmechanismofactionforthisnovelanticonvulsantisunknown,itisthoughttoworkbyinhibitingvoltage-sensitivesodiumcurrents,inthismannerstabilizingneuronalmembranesandasaresultmodulatingthepresynaptictransmitterreleaseofexcitatoryaminoacidssuchasglutamate.Itisapprovedformaintenancetreatmentofbipolardisordertopreventdepressiveepisodes.Inaddition,itdeservesaplaceinthetreatmentofacutebipolardepression,withthestrongestevidenceasadd-ontreatmenttolithium(thisthesis).Lamotrigineiswelltolerated,themajorriskisasevererash,anditrequirescarefuldosemonitoring.
42 Chapter 242
References
Anderson,G.D.,Yau,M.K.,Gidal,B.E.,Harris,S.J.,Levy,R.H.,Lai,A.A.,Wolf,K.B.,Wargin,W.A.andDren,A.T.(1996),Bidirectionalinteractionofvalproateandlamotrigineinhealthysubjects,ClinPharmacolTher,60,145-56.
Bowden,C.L.(2003),Acuteandmaintenancetreatmentwithmoodstabilizers,IntJNeuropsychopharmacol,6,269-75.
Bowden,C.L.,Calabrese,J.R.,Sachs,G.,Yatham,L.N.,Asghar,S.A.,Hompland,M.,Montgomery,P.,Earl,N.,Smoot,T.M.andDeVeaugh-Geiss,J.(2003),Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlymanicorhypomanicpatientswithbipolarIdisorder,ArchGenPsychiatry,60,392-400.
BrownE.B.,McElroyS.L.,KeckP.E.,DeldarA.,AdamsD.H.,TohenM.andWilliamsonD.J.(2006),Olanzapine/FluoxetineCombinationVersusLamotrigineintheTreatmentofBipolarIDepression,J.ClinPsychiatry,67,1025-33
Calabrese,J.R.,Bowden,C.L.,McElroy,S.L.,Cookson,J.,Andersen,J.,Keck,P.E.,Jr.,Rhodes,L.,Bolden-Watson,C.,Zhou,J.andAscher,J.A.(1999),Spectrumofactivityoflamotrigineintreatment-refractorybipolardisorder,AmJPsychiatry,156,1019-23.
Calabrese,J.R.,Bowden,C.L.,Sachs,G.,Yatham,L.N.,Behnke,K.,Mehtonen,O.P.,Montgomery,P.,Ascher,J.,Paska,W.,Earl,N.andDeVeaugh-Geiss,J.(2003),Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlydepressedpatientswithbipolarIdisorder,JClinPsychiatry,64,1013-24.
Calabrese,J.R.,Bowden,C.L.,Sachs,G.S.,Ascher,J.A.,Monaghan,E.andRudd,G.D.(1999),Adouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithbipolarIdepression.Lamictal602StudyGroup,JClinPsychiatry,60,79-88.
Calabrese,J.R.,Fatemi,S.H.andWoyshville,M.J.(1996),Antidepressanteffectsoflamotrigineinrapidcyclingbipolardisorder,AmJPsychiatry,153,1236.
Calabrese,J.R.,Hirschfeld,R.M.,Reed,M.,Davies,M.A.,Frye,M.A.,Keck,P.E.,Lewis,L.,McElroy,S.L.,McNulty,J.P.andWagner,K.D.(2003),ImpactofbipolardisorderonaU.S.communitysample,JClinPsychiatry,64,425-32.
Calabrese,J.R.;Huffman,R.F.;White,R.L.;Edwards,S.;Thompson,T.R.andAscher,J.A.(2007)AdditionalclinicaltrialdataandaretrospectivepooledanalysisofresponseratesacrossallrandomizedtrialsconductedbyGSK.,BipolarDisorders8(suppl.1),323-33.
4343
2
Lamotrigine in bipolar disorder: an overview
Calabrese,J.R.,Sullivan,J.R.,Bowden,C.L.,Suppes,T.,Goldberg,J.F.,Sachs,G.S.,Shelton,M.D.,Goodwin,F.K.,Frye,M.A.andKusumakar,V.(2002),Rashinmulticentertrialsoflamotrigineinmooddisorders:clinicalrelevanceandmanagement,JClinPsychiatry,63,1012-9.
Calabrese,J.R.,Suppes,T.,Bowden,C.L.,Sachs,G.S.,Swann,A.C.,McElroy,S.L.,Kusumakar,V.,Ascher,J.A.,Earl,N.L.,Greene,P.L.andMonaghan,E.T.(2000),Adouble-blind,placebo-controlled,prophylaxisstudyoflamotrigineinrapid-cyclingbipolardisorder.Lamictal614StudyGroup,JClinPsychiatry,61,841-50.
Calabrese,J.R.,Vieta,E.andShelton,M.D.(2003),Latestmaintenancedataonlamotrigineinbipolardisorder,EurNeuropsychopharmacol,13Suppl2,S57-66.
Chen,C.,Veronese,L.andYin,Y.(2000),Theeffectsoflamotrigineonthepharmacokineticsoflithium,BrJClinPharmacol,50,193-5.
Choi,H.andMorrell,M.J.(2003),Reviewoflamotrigineanditsclinicalapplicationsinepilepsy,ExpertOpinPharmacother,4,243-51.
Cohen,A.F.,Ashby,L.,Crowley,D.,Land,G.,Peck,A.W.andMiller,A.A.(1985),Lamotrigine(BW430C),apotentialanticonvulsant.Effectsonthecentralnervoussystemincomparisonwithphenytoinanddiazepam,BrJClinPharmacol,20,619-29.
Cohen,A.F.,Land,G.S.,Breimer,D.D.,Yuen,W.C.,Winton,C.andPeck,A.W.(1987),Lamotrigine,anewanticonvulsant:pharmacokineticsinnormalhumans,ClinPharmacolTher,42,535-41.
Cunnington,M,TennisP.andtheInternationalLamotriginePregnancyRegistryScientificAdvisoryCommittee(2005),Lamotrigineandtheriskofmalformationsinpregnancy,Neurology,64,955-60
Fitton,A.andGoa,K.L.(1995),Lamotrigine.Anupdateofitspharmacologyandtherapeuticuseinepilepsy,Drugs,50,691-713.
Frye,M.A.,Ketter,T.A.,Kimbrell,T.A.,Dunn,R.T.,Speer,A.M.,Osuch,E.A.,Luckenbaugh,D.A.,Cora-Ocatelli,G.,Leverich,G.S.andPost,R.M.(2000),Aplacebo-controlledstudyoflamotrigineandgabapentinmonotherapyinrefractorymooddisorders,JClinPsychopharmacol,20,607-14.
Garnett,W.R.(1997),Lamotrigine:pharmacokinetics,JChildNeurol,12Suppl1,S10-5.
Geddes,J.R.,Calabrese,J.R,Goodwin,G.M.(2009)Lamotriginefortreatmentofbipolardepression:independentmeta-analysisandmeta-regressionofindividualpatientdatafrom
44 Chapter 244
fiverandomisedtrials,Br.J.ofPsychiatry194,4-9
Gilman,J.T.(1995),Lamotrigine:anantiepilepticagentforthetreatmentofpartialseizures,AnnPharmacother,29,144-51.
Ginsberg,L.,Sachs,G.andKetter,T.(2003)InAmericanPsychiatricAssociation2003AnnualMeetingSanFrancisco,CA,pp.173-4.
Goa,K.L.Ross,S.R.andChrisp,P.(1993),Lamotrigine.Areviewofitspharmacologicalpropertiesandclinicalefficacyinepilepsy,Drugs,46,152-76.
Goldberg,J.F.,Bowden,C.L.,Calabrese,J.R.,Ketter,T.A.,Dann,R.S,FryeM.A.Suppes,TandPostR.M,(2008)Six-MonthProspectiveLifeChartingofMoodSymptomswithLamotrigineMonotherapyVersusPlaceboinRapidCyclingBipolarDisorder,BiologicalPsychiatry,63,125-30
Goldberg,J.F.,Calabrese,J.R.Saville,B.R.,Frye,M.A.Ketter,T.A.Suppes,T,Post,R.M.andF.K.Goodwin,(2009),MoodStabilizationandDestabilizationDuringAcuteandContinuationPhaseTreatmentforBipolarIDisorderWithLamotrigineorPlacebo,JClinPsychiatry70,1273–80
Goldsmith,D.R.,Wagstaff,A.J.,Ibbotson,T.andPerry,C.M.(2003),Lamotrigine:areviewofitsuseinbipolardisorder,Drugs,63,2029-50.
Hachad,H.,Ragueneau-Majlessi,I.andLevy,R.H.(2002),Newantiepilepticdrugs:reviewondruginteractions,TherDrugMonit,24,91-103.
Hirschfeld,R.M.,Calabrese,J.R.,Weissman,M.M.,Reed,M.,Davies,M.A.,Frye,M.A.,Keck,P.E.,Jr.,Lewis,L.,McElroy,S.L.,McNulty,J.P.andWagner,K.D.(2003),Screeningforbipolardisorderinthecommunity,JClinPsychiatry,64,53-9.
Holmes,L.B.,BaldwinE.J.,SmithC.R.,HabeckerE.,GlassmanL.,WongS.L.andWyszynskiD.F.(2008),Increasedfrequencyofisolatedcleftpalateininfantsexposedtolamotrigineduringpregnancy,Neurology,70,2152-58
Ichim,L.,Berk,M.andBrook,S.(2000),Lamotriginecomparedwithlithiuminmania:adouble-blindrandomizedcontrolledtrial,AnnClinPsychiatry,12,5-10.
Judd,L.L.,Akiskal,H.S.,Schettler,P.J.,Endicott,J.,Maser,J.,Solomon,D.A.,Leon,A.C.,Rice,J.A.andKeller,M.B.(2002),Thelong-termnaturalhistoryoftheweeklysymptomaticstatusofbipolarIdisorder,ArchGenPsychiatry,59,530-7.
4545
2
Lamotrigine in bipolar disorder: an overview
Kupka,R.W.,Luckenbaugh,D.A,.Post,R.M,Suppes,T.,Altshuler,L.L.,Keck,P.E.,Jr,Frye,M.A.,Denicoff,K.D.,Grunze,H.,Leverich,G.S.,McElroy,S.L.,Walden,J.andNolen,W.A.(2005),Comparisonofrapid-cyclingandnon-rapid-cyclingbipolardisorderbasedonprospectivemoodratingsin539outpatients,Am.JPsychiatry,162,1273-80.
Ketter,T.A.,GreistJ.H.,Graham,J.A.,Roberts,J.N.,Thompson,T.R.andNanry,K.P.,(2006),TheeffectofDermatologicPrecautionsontheIncidenceofRashWithAdditionofLamotrigineintheTreatmentofBipolarIDisorder:ARandomizedTrial,JClin.Psychiatry67,400-6
Kusumakar,V.andYatham,L.N.(1997),Anopenstudyoflamotrigineinrefractorybipolardepression,PsychiatryRes,72,145-8.
Leach,M.J.,Baxter,M.G.andCritchley,M.A.(1991),Neurochemicalandbehavioralaspectsoflamotrigine,Epilepsia,32Suppl2,S4-8.
Leach,M.J.,Marden,C.M.andMiller,A.A.(1986),Pharmacologicalstudiesonlamotrigine,anovelpotentialantiepilepticdrug:II.Neurochemicalstudiesonthemechanismofaction,Epilepsia,27,490-7.
Li,X.,Ketter,T.A.andFrye,M.A.(2002),Synaptic,intracellular,andneuroprotectivemechanismsofanticonvulsants:aretheyrelevantforthetreatmentandcourseofbipolardisorders?,JAffectDisord,69,1-14.
Matsuo,F.,Bergen,D.,Faught,E.,Messenheimer,J.A.,Dren,A.T.,Rudd,G.D.andLineberry,C.G.(1993),Placebo-controlledstudyoftheefficacyandsafetyoflamotrigineinpatientswithpartialseizures.U.S.LamotrigineProtocol0.5ClinicalTrialGroup,Neurology,43,2284-91.
Messenheimer,J.A.(2002)InAmericanAcademyofNeurologyAnnualMeetingDenver,CO.
Mikati,M.A.,Schachter,S.C.,Schomer,D.L.,Keally,M.,Osborne-Shafer,P.,Seaman,C.A.,Sheridan,P.H.,Ashworth,M.,Kupferberg,H.,Valakas,A.and(1989),Long-termtolerability,pharmacokineticandpreliminaryefficacystudyoflamotrigineinpatientswithresistantpartialseizures,ClinNeuropharmacol,12,312-21.
Ohman,I.,Vitols,S.andTomson,T.(2000),Lamotrigineinpregnancy:pharmacokineticsduringdelivery,intheneonate,andduringlactation,Epilepsia,41,709-13.
Pennell,P.B.(2003),Antiepilepticdrugpharmacokineticsduringpregnancyandlactation,Neurology,61,S35-42.
46 Chapter 246
Post,R.M.,Denicoff,K.D.,Leverich,G.S.andal.,e.(2002),Presentationsofdepressioninbipolarillness,ClinNeurosciRes,2,142-157.
Rambeck,B.andWolf,P.(1993),Lamotrigineclinicalpharmacokinetics,ClinPharmacokinet,25,433-43.
Ramsay,R.E.,Pellock,J.M.,Garnett,W.R.,Sanchez,R.M.,Valakas,A.M.,Wargin,W.A.,Lai,A.A.,Hubbell,J.,Chern,W.H.,Allsup,T.and(1991),Pharmacokineticsandsafetyoflamotrigine(Lamictal)inpatientswithepilepsy,EpilepsyRes,10,191-200.
Regeer,E.J.,ten,HaveM.,Rosso,M.L.,Hakkaart-van,RoijenL.,Vollebergh,W.andNolenW.A.(2004),Prevalenceofbipolardisorderinthegeneralpopulation:aReappraisalStudyoftheNetherlandsMentalHealthSurveyandIncidenceStudy.ActaPsychiatr.Scand.110,5374-82.
RzanyB.,Mockenhaupt,M.,Baur,S.,Schroder,W.,Stocker,U.,Mueller,J.,Hollander,N.,Bruppacher,R.andSchopf,E.(1996),Epidemiologyoferythemaexsudativummultiformemajus,Stevens-JohnsonsyndromeandtoxicepidermalnecrolysisinGermany(1990-1992):structureandresultsofapopulation-basedregistry,JClinEpidemiol,49,769-73.
Shiah,I.S.,Yatham,L.N.,Lam,R.W.andZis,A.P.(1998),Effectsoflamotrigineonthe5-HT1Areceptorfunctioninhealthyhumanmales,JAffectDisord,49,157-62.
SidhuJ.,JobS.,SinghS.andPhilipsonR.,Thepharmacokineticandpharmacodynamicconsequencesoftheco-administrationoflamotrigineandacombinedoralcontraceptiveinhealthyfemalesubjects.Br.J.ofClin.Pharmacol.61,191-99
Smith,D.,Baker,G.,Davies,G.,Dewey,M.andChadwick,D.W.(1993),Outcomesofadd-ontreatmentwithlamotrigineinpartialepilepsy,Epilepsia,34,312-22.
Smith,D.,Chadwick,D.,Baker,G.,Davis,G.andDewey,M.(1993),Seizureseverityandthequalityoflife,Epilepsia,34Suppl5,S31-5.
Tran,T.A.,Leppik,I.E.,Blesi,K.,Sathanandan,S.T.andRemmel,R.(2002),Lamotrigineclearanceduringpregnancy,Neurology,59,251-5.
Vinod,K.Y.andSubhash,M.N.(2002),Lamotrigineinducedselectivechangesin5-HT(1A)receptormediatedresponseinratbrain,NeurochemInt,40,315-9.
Walden,J.,Hesslinger,B.,vanCalker,D.andBerger,M.(1996),Additionoflamotriginetovalproatemayenhanceefficacyinthetreatmentofbipolaraffectivedisorder,Pharmacopsychiatry,29,193-5.
4747
2
Lamotrigine in bipolar disorder: an overview
Weisler,R.,Risner,M.,Ascher,J.andHouser,T.(1994)InAmericanPsychiatricAssociation1994AnnualMeetingPhiladelphia,PA.
Weissman,M.M.,Bland,R.C.,Canino,G.J.,Faravelli,C.,Greenwald,S.,Hwu,H.G.,Joyce,P.R.,Karam,E.G.,Lee,C.K.,Lellouch,J.,Lepine,J.P.,Newman,S.C.,Rubio-Stipec,M.,Wells,J.E.,Wickramaratne,P.J.,Wittchen,H.andYeh,E.K.(1996),Cross-nationalepidemiologyofmajordepressionandbipolardisorder,Jama,276,293-9.
Wong,I.C.,Mawer,G.E.andSander,J.W.(1999),Factorsinfluencingtheincidenceoflamotrigine-relatedskinrash,AnnPharmacother,33,1037-42.
Xie,X.andHagan,R.M.(1998),Cellularandmolecularactionsoflamotrigine:Possiblemechanismsofefficacyinbipolardisorder,Neuropsychobiology,38,119-30.
Xie,X.,Lancaster,B.,Peakman,T.andGarthwaite,J.(1995),InteractionoftheantiepilepticdruglamotriginewithrecombinantratbraintypeIIANa+channelsandwithnativeNa+channelsinrathippocampalneurones,PflugersArch,430,437-46.
Yuen,A.W.,Land,G.,Weatherley,B.C.andPeck,A.W.(1992),Sodiumvalproateacutelyinhibitslamotriginemetabolism,BrJClinPharmacol,33,511-3.
4848
MarcL.M.vanderLoos,M.D.;PaulG.H.Mulder,Ph.D.;ErwinG.Th.M.Hartong,M.D.,Ph.D.;MarcB.J.Blom,M.D.;AntonC.Vergouwen,M.D.,Ph.D.;HermanJ.U.E.M.deKeyzer,M.D.;PeterJ.H.Notten,M.D.;MarijkeL.Luteijn,M.D.;ManuelaA.Timmermans,M.Sc.;EduardVieta,M.D.,Ph.D.;andWillemA.Nolen,M.D.,Ph.D.,fortheLamLitStudyGroup
FromtheDepartmentofPsychiatry,IsalaKlinieken,locationSophia,Zwolle(Dr.vanderLoos);theDepartmentofEpidemiology&Biostatistics,ErasmusUniversityMedicalCenter,Rotterdam(Dr.Mulder);theDepartmentofPsychiatry,Canisius-WilhelminaHospital,Nijmegen(Dr.Hartong);ParnassiaPsychiatricInstitute,TheHague(Dr.Blom);theDepartmentofPsychiatry,St.LucasAndreasHospital,Amsterdam(Dr.Vergouwen);GroupPractice:BiologicalPsychiatryandPsychotherapy,Retranchement(Dr.deKeyzer);theDepartmentofPsychiatry,St.ElisabethHospital,Tilburg(Dr.Notten);theDepartmentofPsychiatry,AlbertSchweitzerHospital,Dordrecht(Dr.Luteijn);ClinicalOperations,GlaxoSmithKline,Zeist(Ms.Timmermans);BipolarDisordersProgram,DepartmentofPsychiatry,UniversityMedicalCenterGroningen,UniversityofGroningen(Dr.Nolen),theNetherlands;andInstituteofNeuroscience,HospitalClinic,UniversityofBarcelona,IDIBAPS,CIBER-SAM,Catalonia,Spain(Dr.Vieta).
The Journal of Clinical Psychiatry 2009; 70: 223-231
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial
3
50 Chapter 350
Abstract
Objective:Lamotrigineisoneofthepharmacologicoptionsforthetreatmentofbipolardepressionbuthasonlybeenstudiedasmonotherapy.Thisstudycomparedtheacuteeffectsoflamotrigineandplaceboasadd-ontherapytoongoingtreatmentwithlithiuminpatientswithbipolardepression. Method:Outpatients(n=124)aged18yearsandolderwithaDSM-IVbipolarIorIIdisorderandamajordepressiveepisode(Montgomery-ÅsbergDepressionRatingScale[MADRS]score≥18andClinicalGlobalImpressions-BipolarVersion[CGI-BP]severityofdepressionscore≥4)whilereceivinglithiumtreatment(0.6–1.2mmol/L)wererandomlyassignedto8weeksofdouble-blindtreatmentwithlamotrigine(titratedto200mg/d)orplacebo.TheprimaryoutcomemeasurewasmeanchangefrombaselineintotalscoreontheMADRSatweek8.Secondaryoutcomemeasureswereresponse(definedasareductionof≥50%ontheMADRSand/orchangeofdepressionscoreontheCGI-BPof“muchimproved”or“verymuchimproved”comparedtobaseline)andswitchtomaniaorhypomania(definedasaCGI-BPseverityofmaniascoreofatleastmildlyillatanyvisit).PatientswereincludedinthestudybetweenAugust2002(SpainstartedinOctober2003)andMay2005. Results:EndpointmeanchangefrombaselineMADRStotalscorewas–15.38(SE=1.32)pointsforlamotrigineand–11.03(SE=1.36)pointsforplacebo(t=–2.29,df=104,p=.024).SignificantlymorepatientsrespondedtolamotriginethantoplaceboontheMADRS(51.6%vs.31.7%,p=.030),butnotontheCGI-BPchangeofdepression(64.1%vs.49.2%,p=.105).Switchtomaniaorhypomaniaoccurredin5patients(7.8%)receivinglamotrigineand2patients3.3%)receivingplacebo(p=.441). Conclusion:Lamotriginewasfoundeffectiveandsafeasadd-ontreatmenttolithiumintheacutetreatmentofbipolardepression.
51
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 51
Introduction
Patientswithbipolardisorderspendmoretimedepressedthanmanicorhypomanic(1–4),whilemostmoodstabilizers(lithium,valproate,carbamazepine)aremoreeffectiveagainstmanicepisodesthandepressiveepisodes(5–7).Thesameappearstrueforatypicalantipsychotics,althougholanzapine(aloneaswellasincombinationwithfluoxetine(8))andquetiapine(9)havedemonstratedefficacyintheacutetreatmentofbipolardepression. Asaconsequence,manybipolarpatientsalsoreceiveantidepressants,mostlyincombinationwithothertherapies.Thefindingthattheeffectsizeforthecombinationofolanzapinewithfluoxetinewassuperiortotheeffectsizeofolanzapinemonotherapyunderscorestheimportanceofcombinationtherapystudies(10).Whilesomestudiesfoundthatantidepressants,eitherasmonotherapyorcombinationtherapywithmoodstabilizers,areeffectiveinthetreatmentofacutebipolardepression(11),otherstudiesfoundnoeffectoftheadditionofantidepressantstomoodstabilizers(12,13).Inaddition,theirusemaybeassociatedwiththeriskofswitchtomaniaorhypomania(11,14) Theanticonvulsantlamotrigineprovidesanadditionaltreatmentoption.Afterafewcasereportsandsomeopenlabelstudies(15–17),thefirstdouble-blindrandomizedcontrolledtrial(18)ontheefficacyoflamotriginemonotherapyintheacutetreatmentofbipolardepressionfounditmoreeffectivethanplaceboatdosesof50and200mg/dayonseveralsecondaryoutcomemeasures,includingtheMontgomery-ÅsbergDepressionRatingScale(MADRS),butnotontheprimaryoutcomemeasure,i.e.,theHamiltonRatingScaleforDepression(HAM-D).Subsequently,itsefficacyintheacutetreatmentofbipolardepressionwasstudiedin4otherrandomizedcontrolledtrials.Althoughthosestudieswereallnegativeontheprimaryoutcomecriterion(19),ameta-analysisofthe5studiesshowedasmallbutsignificantpositiveresult(20,21).Inanotherstudy,lamotriginewasslightlylesseffectivebutbettertoleratedthanacombinationofolanzapineandfluoxetine(22).Collaborativeresultswerealsoobtainedfromacrossoverstudythatcomparedlamotrigineandgabapentintoplacebo(23).In2long-termstudiesofbipolarIpatientswithacurrent(orrecent)manicor
52 Chapter 352
depressiveepisode(24,25),lamotrigine(titratedupto200–400mg/day)wasaddedtoongoingtreatmentwithotherpsychotropicdrugsover8to16weeks.Concomitantdrugsweregraduallywithdrawn,afterwhichstabilizedpatientswererandomlyassignedtocontinuationoflamotrigineortolithiumorplacebo(eachasmonotherapy)forupto18months.Inbothstudies,lamotrigineandlithiumwerestatisticallymoreeffectivethanplaceboontheprimaryoutcomemeasure(timefromrandomizationtointerventionforanymoodepisode),butlithiumwaspredominantlyeffectiveagainstmanicepisodesandlamotriginepredominantlyagainstdepressiveepisodes,suggestingthatlithiumandlamotriginehavedifferentialandpotentiallycomplementaryeffects. Inthisarticle,wereporttheresultsofthefirstplacebocontrolledstudyaddressingtheefficacyandsafetyoflamotrigineasadd-ontolithiumintheacutetreatmentofpatientswithbipolardepression.
Method
Study Design Thisstudyisthefirstphaseofaninvestigator-initiated(W.A.N.)randomized,double-blind,placebo-controlledtrial,with23recruitingcenters(of25selected)intheNetherlandsand3recruitingcenters(of5selected)inSpain. RecruitmenttookplacebetweenAugust2002andMay2005(SpainstartedinOctober2003).ThestudywasapprovedbytheethicalreviewboardoftheUniversityMedicalCenterUtrecht,theNetherlands,andbylocalinstitutionalreviewboardsinbothcountries.Allpatientsgavewritteninformedconsentpriortoinitiationofanystudyprocedure.
Patients Outpatients(menorwomen)aged18yearsoroldercouldbeincludediftheymetcriteriaforDSM-IVbipolarIorIIdisorder,currentmajordepressiveepisodeconfirmedbytheMini-InternationalNeuropsychiatricInterviewPlus(MINI-Plus)(26)withascoreof≥18pointsontheMADRS(27)andascoreof≥4(moderatelyill)ontheClinicalGlobalImpressions-BipolarVersion(CGI-BP)
53
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 53
severityofdepressionrating(28).Allpatientshadtobereceivingtreatmentwithlithiumwithastabledose(plasmalevel,0.6–1.2mmol/L)duringatleast2weekspriortothestudy. Exclusioncriteriawerethefollowing:thepresenceofpsychoticfeatures,asevererapidcyclingcoursewith≥10episodesoverthelast12months(rapidcyclingwith4–9episodesintheprevious12monthswasallowed),severesuicidality(scoreof≥5onitem10oftheMADRS),ahistoryofalcoholorsubstanceabusewithin1monthordependencewithin12monthsofenrollment,aseverepersonalitydisordersuggestingnoncompliance,orasevereneurologicorothersomaticillnessandtheuseofsomaticmedicationthatcouldaffectmood.Womenofchild-bearingpotentialwereonlyeligibleforthestudyiftheyhadanegativepregnancytestatscreeningandagreedtoutilizeaneffectivecontraceptivemethod.Exceptforlithium,patientswerenotallowedtohaveusedanantipsychoticoranantidepressantwithin2weeks(fluoxetine,4weeks)ofrandomization.Benzodiazepineswereallowedatamaximumof2-mglorazepamequivalentsperdaythroughoutthestudy,i.e.,forstandingaswellasrescuemedication,foranxiety,agitation,orsleepproblems.
Treatments Afterinclusioninthestudy,patientswererandomlyassigned1:1toeitherlamotrigineorplaceboinblocksof2asadjunctivetreatmenttoongoingtreatmentwithlithiumaccordingtoarandomizationlist.Stratificationwasdonebysite.Thecodeofeachpatientwaskeptinasealedenvelopeatthepharmacyofeachparticipatingcenterandcouldbeopenedbythepharmacistonlyincaseofmedicalemergency.Thestudyblindwaspreserveduntilafterthelastpatientevaluation. Studymedicationwasadministeredoncedailyinthemorning.Lamotriginewasstartedat25mg/dayinweeks1and2andwasincreasedto50mg/dayinweeks3and4,to100mg/dayinweeks5and6,and,finally,to200mg/dayinweeks7and8.Placebowasadministeredbyutilizingtabletsidenticalinappearanceandnumber.Thelithiumdosageremainedstableduringthestudywithmonitoringofplasmalevels(tobekeptat0.6–1.0mmol/L)at
54 Chapter 354
baselineandweek8. Toestablishmedicationcompliance,apillcountwasdoneateveryvisit.Patientsreturningmorethan30%oftheirprescribedmedicationorreportinganinterruptionofmedicationformorethan3dayswerewithdrawnfromthestudy.Patientswhomissedtheirstudymedicationfor1,2,or(maximum)3daysrestartedatthesamedose.
Outcome Measures Atbaseline,diagnosiswasconfirmedwiththeMINI-Plussectionsdepressiveepisode,manicepisode,hypomanicepisode,alcoholabuseanddependence,andsubstanceabuseanddependence.Inaddition,clinicianscompletedtheClinicalQuestionnaireforBipolarIllness(CQBP-C),withitemsonillnessandtreatmenthistory,asusedbytheformerStanleyFoundationBipolarNetwork(29).Severityofsymptomswasassessedatbaselineandatweeks2,4,6,and8byusingtheMADRSandtheCGI-BPseverityofdepressionandseverityofmania.Adverseeventswereassessedateachvisitbyinquiringaboutanyunpleasantfeelingsincethelastvisitand,ifpresent,ratedmild,moderate,orsevere. TheprotocolaswellasthecaserecordformwerewritteninEnglishbutincludedvalidatedDutchandSpanishtranslationsoftheMADRSandtheCGI-BP.IntheNetherlands,therewere4researchmeetings,includingMADRStrainingsessions;27ratersscoredatleast4patientswithanintraclasscoefficient=0.95.AfterreceivinganinitialMADRStraininginSpain,allSpanishresearchersparticipatedinaresearchmeetingintheNetherlandswithadditionalMADRStraining. TheprimaryoutcomemeasurewasthemeanchangefrombaselineintotalMADRSscoreatweek8.Secondaryoutcomemeasureswereresponse(definedasareductionof≥50%ontheMADRSand/orCGI-BPchangeofdepressionscoreof“muchimproved”or“verymuchimproved”comparedtobaseline)andswitchintomaniaorhypomania(definedasaCGI-BPseverityofmaniascoreofatleastmildlyillatanyvisit).Posthoc,wealsoanalyzedon
55
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 55
whichitemsoftheMADRSthereweresignificantdifferencesbetweenlamotrigineandplaceboatweek8. Switchtomaniaorhypomaniaisanundesirableoutcomeinthetreatmentofbipolardepressionbutcanoccurfollowingrecoveryfromdepression.However,itoftenremainsunclearinpublicationswhetherpatientswhoswitchedwerealsocountedasresponders.Therefore,inaposthocanalysis,weassessedwhetherpatientsreachedthecriteriaforbothresponse(MADRSand/orCGI-BPchangeofdepression)andnoswitchtomaniaorhypomania(CGI-BP),whichistheultimategoalinthetreatmentofbipolardepression. Thestudywasinitiallyaimedatcomparing2groupsof110patientsinordertodetectameandifferenceof4pointsinMADRSscoresbetweenthe2groups,with80%powerandαof.05(2-sided).Thestandarddeviation(SD)oftheMADRSscorewasinitiallysetat11points.Becauseofdifficultiesinrecruitingtheplannednumberofpatients,thesamplesizewasrecalculatedafterinclusionofatotalof43patients.TheMADRSscoresbasedontheseactuallyobservedpatients,whowereevaluatedblindlytooutcome,resultedinanSDof8pointsandacorrespondingrecalculatedsamplesizeof60patientspergroup.
Analysis Mixed-modelanalysisofvariance(ANOVA)forrepeatedmeasureswasprospectivelychosenasmethodofanalysisforMADRSscores.Theindependentvariablesinthisanalysisweretimeandtreatmentandtheirinteraction.TimeascategoricalvariableallowedestimatingandtestingmeandifferencesinMADRSscorebetweenthe2treatmentsatanyvisit,includingtheprimaryefficacymeasure:scorechangefrombaselineatweek8.ForthispurposetherelevantcontrastswerespecifiedinthemodelforwhichtheANOVAproducedtheestimates,SEs,confidenceintervals(CIs),andappropriatettestspervisit.Inordertomakeinferenceaboutanoveralltreatmenteffectoverallvisits,timewasconsideredanumerictrendvariableinthemodel.ThisallowedestimatingandtestingadownwardtrendintimeofthemeanMADRSscoreineithertreatment
56 Chapter 356
groupandthedifferenceintimetrendbetweenthe2treatmentsasasingleefficacymeasure,forwhichthemixed-modelANOVAproducedtheestimateSE,CI,andappropriatettest.Inaccordancewiththeintent-to-treatprinciple,allrandomlyassignedsubjectscontributedtotheseanalyses,missingvaluesofMADRSbeingproperlyadjustedforbytherestrictedmaximumlikelihoodestimationprocedureusedinthemixed-modelANOVAs.ClinicalGlobalImpression-BipolarVersionseverityscoresweresimilarlyanalyzedbyusingmixed-modelANOVA,withtimeascategoricalvariable.Dichotomousoutcomescores(response,switch,orpresenceofadverseeffects)weremadecompletebyusingthelast-observation-carried-forwardmethodandthenwereanalyzedbycomparingpercentagesbetweenthe2treatmentgroupsusingFisherexacttest.Differencesinthedistributionofcategoricalnominalvariablesbetweenthe2treatmentgroupsweretestedusingFisherexacttest;forcategoricalordinalvariablestheexactχ2trendtestwasused.Foreachtest,a2-sidedpvaluebelow.05wasconsideredtodenotestatisticalsignificance.
Results
Patients and Illness Characteristics Intotal,128patientswererecruited(fig1):mostpatients(n=82)fromthe23centersintheNetherlands,34patientsviaadvertisementsinDutchnewspapers,and12patientsfromthe3centersinSpain.Therangeofincludedpatientspercenterwasbetween1and25. Fourpatientswerenotincludedintheanalysis:atbaseline,1patientappearedtouseanantipsychotic;1patienthadusedanantidepressantinthe2weeksbeforerandomization;1patienthadhypothyroidism;and1patientnevertookanymedication.Thus,124patientswererandomlyassignedandincludedintheanalysis:64patientstolithiumpluslamotrigineand60patientstolithiumplusplacebo.Therewerenostatisticallysignificantdifferencesbetweenthe2groupsinpatientcharacteristicsandillnessseverityatbaseline(table1).
57
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 57
Figure 1. Flowchartofpatientsrandomlyassignedtolamotrogineorplaceboasadd-ontreatmenttolithium
AssessedforEligibility(n=128)
Randomlyassigned(n=124)
Lamotrigine(n=64)
LosttoFollow-Up (n=0)Discontinued (n=12)
Completed (n=52)Analyzed (n=64)
LackofEfficacy (n=2)AdverseEffects (n=4)WithdrawnConsent(n=1)ProtocolViolation (n=2)Noncompliance (n=1)Other (n=2)
LackofEfficacy (n=3)AdverseEffects (n=2)WithdrawnConsent(n=1)ProtocolViolation (n=0)Noncompliance (n=1)Other (n=2)
LosttoFollow-Up (n=1)Discontinued (n=9)
Completed (n=50)Analyzed (n=60)
Placebo(n=60)
Excluded(n=4)NotmeetinginclusionCriteria(n=3)NotTakingStudyMedication (n=1)
58 Chapter 358
Table 1. Baselinepatientandillnesscharacteristicsinpatientsrandomlyassignedtolamotrogineorplaceboasadd-ontreatmenttolithium
CGI-BP=ClinicalGlobalImpressions-BipolarVersion,MADRS=Montgomery-ÅsbergDespressionRatingScale,MAOI=monoamineoxidaseinhibitor,SSRI=selectiveserotoninreuptakeinhibitor,SNRI=serotonin-norepinephrinereuptakeinhibitor,TCA=tricyclicantidepressant.
Lamotriginen=64
Placebon=60
Totaln=124 Statistic Value df P
Femalegender(n,%) 37 57.8 30 50 67 54.0 Fisher’s - - 0.471Age(years)(mean,SD) 45.2 12.1 47.6 11.6 46.4 11.9 t-test 1.13 122 0.261IlnesscharacteristicsBipolarIdisorder(n,%) 43 67.2 41 68.3 84 67.7 Fisher’s - - 1.000Rapidcyclingcourse–last12months(n,%)
12 18.8 4 6.7 16 12.9 Fisher’s - - 0.061
MADRS(mean,SD) 28.25 5.97 28.82 6.24 28.52 6.08 t-test 0.52 122 0.606CGI-BPdepressionseverity(mean,SD)
4.56 0.64 4.53 0.57 4.55 0.60 ChiSq.trend
0.07 1 0.882
CGI-BPmaniaseverity(mean,SD)
1.03 0.18 1.03 0.18 1.03 0.18 Fisher’s - - 1.000
PrevioustreatmentsforindexdepressiveepisodeLithiumBaselineplasmalevel(mEq)(mean,SD)
0.82 0.16 0.84 0.16 0.83 0.16 t-test 0.48 122 0.634
Durationoftreatmentbeforerandomisation2to4weeks(n,%) 1 1.9 4 8.0 - - Fisher’s - - N.S.1-3months(n,%) 6 11.3 4 8.0 - - Fisher’s - - N.S≥3months(n,%) 46 86.8 42 84.0 - - Fisher’s - - N.S.Unknown/missing(n,%) 11 10
TCA(n,%) 6 9.4 4 6.7 10 8.1 Fisher’s - - 0.745SSRI/SNRI(n,%) 15 23,4 16 26.7 31 25.0 Fisher’s - - 0.836MAO-inhibitor(n,%) 1 1.6 3 5.0 4 3.2 Fisher’s - - 0.353Antipsychotic,typical(n,%)
4 6.3 3 5.0 7 5.6 Fisher’s - - 1.000
Antipsychotic,atypical(n,%)
15 23.4 11 18.3 26 21.0 Fisher’s - - 0.317
Valproicacid(n,%) 5 7.8 2 3.3 7 5.6 Fisher’s - - 0.247Carbamazepine(n,%) 1 1.6 3 5.0 4 3.2 Fisher’s - - 0.285Benzodiazepine(n,%) 44 68.8 35 58.3 79 63.7 Fisher’s - - 0.154Other(n,%) 3 4.7 4 6.7 7 5.6 Fisher’s - - 0.464
59
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 59
Inbothgroups,morethan80%ofthepatientshadbeenreceivinglithiummaintenancetreatmentforatleast3months. Atbaseline,lithiumplasmalevelswerewithinthepredefinedrangefor119patients(0.6–1.2mmol/L),while5patientshadmarginallylowerplasmalevels(allabove0.53mmol/L).Astheselevelswereonlymarginallylowerthantherequiredlevelof0.6mmol/L,adecisiontoincludethesepatientsintheanalysiswasmadepriortobreakingofthetreatmentblind.Therewasnosignificantdifferencebetweenlithiumplasmalevelsintheplacebogroupversusthelamotriginegroupatbaseline(t=0.48,df=122,p=.63;0.84[SD=0.16]mmol/Land0.82[SD=0.16]mmol/L,respectively)norat8weeks(t=1.36,df=100,p=.18;0.80[SD=0.14]mmol/Land0.76[SD=0.16]mmol/L,respectively). Inthelamotriginegroup,52patients(81%)completedthe8-weekstudyperiodversus50patients(83%)intheplacebogroup.Ofthe12patientswhodiscontinuedthetrialinthelamotriginegroup,2discontinuedbecauseoflackofefficacyand4becauseofadverseeffects.Intheplacebogroup,10patientsdiscontinuedthetrial:3becauseoflackofefficacyand2becauseofadverseeffects.Otherreasonsinbothgroupsfordiscontinuingwerewithdrawnconsent,protocolviolation,noncompliance,andlosttofollow-up.
Efficacy ResultsarepresentedinTables2and3.Ontheprimaryoutcomemeasure,changeintheMADRSscorefrombaselinetoweek8,lamotriginewassignificantlymoreeffectivethanplacebo(decreaseof15.38vs.11.03,respectively,p=.024)(table2).ThelamotriginegroupalsohadsignificantlylowerMADRSscoresatweeks6and8comparedtotheplacebogroup(Figure2).Startingfromanoverallaveragebaselinelevelof28.4points,theMADRSscoredecreasedonaverageby3.77pointsper2weeks(95%CI=3.15to4.38;p<.0005)duringthefirst8weeksoftreatmentinthelamotriginegroup.Intheplacebogroup,thedecrementwasonaverage2.59pointsper2weeks(95%CI=1.96to3.22;p<.0005).Hence,themeanMADRSscoreinthelamotriginegroupbecameincreasinglylowerthanthemeanscoreintheplacebo
60 Chapter 360
groupby,onaverage,1.17pointsper2weeks(95%CI=0.33to2.02;p=.007)duringthefirst8weeksoftreatment.Response,definedasareductionoftheMADRSscoreof≥50%,wasstatisticallygreater(p=.03)inthelamotriginegroup(51.6%)thanintheplacebogroup(31.7%)(table3).ResponseaccordingtoCGI-BPchangeofdepressionscores≤2andresponseaccordingtoeithercriterion(MADRSand/orCGI-BPchangeofdepression)showednosignificantdifferences.
Table 2.EfficacyResults(mixedmodelestimates):severityscales
CGI-BP=ClinicalGlobalImpressions-BipolarVersion,MADRS=Montgomery-ÅsbergDepressionRatingScale.Boldvaluesindicatesignificantlevels<0.05
Lamotrigine(n=64)
Placebo(n=60) Difference
tTest df PMeasure Mean SE Mean SE Mean SEMADRSscorechangefrombaseline(primaryoutcomemeasure)Week2 -5.30 0.87 -3.74 0.91 -1.56 1.26 -1.23 121 .220Week4 -9.22 1.25 -6.24 1.29 -2.98 1.80 -1.66 110 .101Week6 -12.84 1.35 -9.31 1.39 -3.53 1.90 -1.82 104 .071Week8 -15.38 1.32 -11.03 1.36 -4.35 1.90 -2.29 104 .024
MADRSscoreateachvisitBaseline 28.25 0.76 28.82 0.79 -0.57 1.10 -0.52 122 .606Week2 22.95 1.02 25.08 1.06 -2.12 1.47 -1.44 121 .153Week4 19.03 1.28 22.58 1.32 -3.55 1.84 -1.93 113 .056Week6 15.41 1.30 19.50 1.34 -4.09 1.87 -2.19 106 .031Week8 12.87 1.23 17.79 1.27 -4.92 1.77 -2.78 104 .006
CGI-BPseverityofdepressionscoreateachvisitBaseline 4.56 0.08 4.53 0.08 0.03 0.11 0.27 122 0.789Week2 4.14 0.14 4.15 0.14 -0.01 0.20 -0.03 121 0.976Week4 3.69 0.17 3.86 0.18 -0.17 0.24 -0.70 111 0.486Week6 3.07 0.18 3.48 0.19 -0.40 0.27 -1.52 104 0.131Week8 2.63 0.18 3.10 0.19 -0.47 0.26 -1.79 103 0.077
CGI-BPchangeofdepressionscorefrombaselineWeek2 3.49 0.13 3.44 0.14 0.05 0.19 0.27 121 0.788Week4 3.37 0.16 3.46 0.17 -0.09 0.24 -0.37 101 0.710Week6 2.79 0.17 3.21 0.18 -0.42 0.25 -1.68 90 0.097Week8 2.52 0.19 2.96 0.19 -0.44 0.27 -1.65 117 0.101
CGI-BPseverityofmaniascoreateachvisitBaseline 1.03 0.02 1.03 0.02 0.00 0.03 -0.07 122 0.948Week2 1.11 0.04 1.07 0.04 0.04 0.06 0.68 121 0.496Week4 1.13 0.05 1.07 0.05 0.06 0.07 0.92 79 0.360Week6 1.07 0.03 1.07 0.03 0.00 0.05 0.08 54 0.940Week8 1.15 0.06 1.13 0.06 0.02 0.08 0.31 78 0.757
61
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 61
Because12patients(18.8%)receivinglamotrigineversus4patients(6.7%)intheplacebogrouphadbeenrapidcyclersinthepastyear(differenceapproachingstatisticalsignificance[p=.06,Fisherexacttest]),thissubgroupwasthesubjectofaposthocanalysis,revealing8(66.7%)lamotrigineand1(25%)placeborespondersbyMADRSand/orCGI-BPchangeofdepression(p=.26,Fisherexacttest).Fourpatients(25%)ofthe16rapidcyclingpatients(all4receivinglamotrigine)hadamanicorhypomanicepisodeversus3patients(2.8%)of108non–rapidcyclingpatients(1patientreceivinglamotrigine,2patientsreceivingplacebo).Overbothtreatmentconditions,theswitchratetomaniaorhypomaniawassignificantlyhigherintherapidcyclingversusthenon–rapidcyclingpatients(p=.005,Fisherexacttest). OnthedifferentMADRSitems,therewasasignificantdifferenceafter8weeksbetweenlamotrigineandplaceboonapparentsadness,reportedsadness,reducedappetite,lassitude,inabilitytofeel,andsuicidalthoughts.Thesamplesizewastoosmalltodetectthefollowingtreatment-by-subgroupinteractions:bipolarIversusII,rapidcyclingversusnon–rapidcycling,andsevereversuslessseveredepressionatbaseline.Asite-bytreatmentanalysiswasnotdoneasitwasnotforeseenintheprotocol.
62 Chapter 362
Figure 2. SeverityofdepressionaccordingtothemeanMADRSscoreateachvisitforpatientsreceivingplaceboorlamotrigine
Table 3. Efficacyresults:responseandswitchto(hypo)mania*
Boldvaluesindicatesignificantlevels<0.05*adjustedforgender,bipolarI/II,age,lithiumandrapidcycling**1missing***CGI-BPseverityofmania≥3****ReductionMADRS≥50%and/orCGI-BPchangeofdepression≤2andCGI-BPseverityof
mania<3
Lamotriginen=64
Placebon=60
Statistic PResponse N % N %ReductionMADRS≥50%
33 51.6 19 31.7 fisher 0.030
CGI-BPchangeofdepression≤2
41 64.1 29 49.2** fisher 0.105
Eitherorboth 42 65.6 29 49.2** fisher 0.065Switchto(hypo)mania***
5 7.8 2 3.3 fisher 0.441
Responseandnoswitchto(hypo)mania****
39 60.9 28 46.7 fisher 0.149
MADRS=Montgomery-ÅsbergDepressionRatingScale
*p=.031**p=.006
30
25
20
15
10
5
0Baseline Wk2 Wk4 Wk6 Wk8
PlaceboLamotrigine
***
MA
DRS
Sco
re,m
ean
63
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 63
Safety
Fivepatientshadaseriousadverseevent(SAE).Onepatientintheplacebogroupexperiencedasevererash.Asthiswasanunexpectedfinding,wecheckedtherandomizationcodeforpossiblemistakesandaskedthelaboratorytocheckthepillsdirectly;bothchecksrevealedthatthemedicationwasindeedplacebo.Sowedecidedthatthiswasachancefinding.FourSAEsoccurredinthelamotriginegroup.Onepatientdevelopedamanicpsychoticepisoderequiringhospitalization.Theepisoderesolvedcompletelyafterstoppingofthestudymedicationandwithadditionaltreatment.The3otherSAEswithlamotrigineinvolved1patientwithseverehypertensionthatwasconsideredtobeunrelatedtostudydrug,1patientwithanonseverelithiumintoxication(lithiumlevel,1.36mmol/L,unexplainedandprobablynottheresultofanautointoxication),and1patientwhohadtobehospitalizedduetodeteriorationofdepressivesymptoms.Studymedicationwascontinuedinthepatientswiththelithiumintoxicationandthehypertensionandwasstoppedintheotherpatients. Otheradverseeventsoccurringinmorethan5%ineithergrouparepresentedintable4.Mostoftheadverseeventsweremildormoderate.Therewerenostatisticallysignificantdifferencesbetweenthe2groupsinoccurrenceofadverseevents.Inparticular,therewasnodifferenceintheincidenceofskinrash(4.7%forlamotriginevs.6.7%forplacebo,p=.71). Asmentionedbefore,1patientinthelamotriginegroupdevelopedamanicepisodewithpsychoticfeaturesforwhichhewashospitalized(SAE).Inadditiontothispatient,4patientsreceivinglamotrigineand2patientsreceivingplacebodevelopedahypomanicepisode(CGI-BPseverityofmania=3).Thenumberofmanicorhypomanicswitcheswasnotstatisticallydifferent.Combinedresponseandnoswitchintomaniaorhypomaniawasobtainedin39patients(60.9%)receivinglamotrigineand28patients(46.7%)receivingplacebo(p=.149).
64 Chapter 364
Table 4. Adverseeventsoccuringin≥5%ofpatientsinanygroup
Discussion
Toourknowledgethisisthefirstrandomizedcontrolledtrialtoassesstheefficacyoflamotrigineasadd-ontreatmenttoongoinglithiumtherapyinpatientswithbipolardepression.Theresultsshowaclinicallysignificant(>4points)differenceinfavoroflamotrigineontheprimaryoutcomemeasure(changefrombaselineinMADRSscore)andonseveralsecondaryoutcomemeasures,includingMADRSscoresatweeks6and8,thepercentageofMADRSrespondersatendpoint,and6of10itemsontheMADRS,includingcoredepressivesymptomsasapparentsadness,reportedsadness,inabilitytofeel,andsuicidalthoughts.ResultsobtainedwiththeCGI-BPchangeofdepressionwereequivocal,withweeklyscoresandoverallresponseratesnumericallyfavoringlamotriginebutnotreachingstatisticalsignificance.ThiscouldbeduetolimitationsinthesensitivityoftheCGI-BP.Anotherpossibilityisthatthisresultedfromamoreoptimisticimpressionamongthephysicianswhenassessingtheeffectoftreatmentsincestartoftreatment,comparedwiththecross-sectionally–
Lamotrigine(n=64)
Placebo(n=60)
AdverseEvent N % N % PHeadache 12 18.8 9 15.0 0.64Fatigue 9 14.1 7 11.7 0.79Nausea 8 12.5 4 6.7 0.37Flu-likesymptoms 7 10.9 4 6.7 0.52Insomnia 6 9.4 1 1.7 0.12Tremor 5 7.8 1 1.7 0.21Skinproblems/mildrash 5 7.8 1 1.7 0.21Dizziness 1 1.6 5 8.3 0.17Abdominalpain 4 6.3 3 5.0 1.00Rash 3 4.7 4 6.7 0.71Joint/musclepain 2 3.1 4 6.7 0.43Backpain 2 3.1 3 5.0 0.67Agitation 1 1.6 3 5.0 0.35
65
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 65
assessedMADRS.However,previouslamotriginestudiesdidshowsignificantchangeinCGIratingsofdepressedbipolarpatients(23–25). Thisstudyindicatesefficacyforlamotrigineintheacutetreatmentofbipolardepression,whichcomplementssimilarfindingsin2previousstudieswithlamotriginemonotherapy(17,23).However,4subsequentplacebocontrolledtrialswithlamotriginemonotherapywereallnegative,possiblybecauseofhighplaceboresponse(35%–47%asassessedbyMADRSorHAM-D-17)orlackofintrinsicefficacy(20),whileinanotherstudylamotriginewaslesseffectivebutbettertoleratedthanacombinationofolanzapineandfluoxetine(22). Besidesthepossibilityofachanceeffect,thereareseveralpossibleexplanationsforourpositivefindingcomparedwithprevious,mostlynegativestudies.First,thiswasanadd-onstudyinwhichallpatientsreceivedlithium,atreatmentthatappearstohavesomeefficacyonitsowninthetreatmentofbipolardepression(30).Thecombinationoflithiumandlamotriginemayhaveproducedadditiveeffects,ortheefficacyoflamotriginemayhavebeenenhancedbyconcurrentlithiumtreatment.Althoughthismightbespeculative,thepotentiallysynergicactioncouldcomeasaresultofcommonfinaltherapeuticpathwaysinvolvingpresynapticserotoninreleaseandincreasedneuroplasticity(31,32).Apharmacokineticinteractionseemsunlikelyinviewofapreviouslyconducteddruginteractionstudy(33).Ontheotherhand,theadd-ondesigncouldhavereducedthechanceofpositivefindings,since,asageneralrule,thistypeoftrialislesslikelytobesuccessfulinbipolardisorder(34). Second,therelativelylowoveralldropoutrate(17.7%)inthecurrentstudypermittedarobustefficacyassessmentduetofewermissingdata.Thus,itaffirmstheutilityofadd-onstudydesignsinthispatientpopulation.Thelowdropoutratemaybeattributabletovariousreasons.First,allpatientshadtheoptiontogetanantidepressantduringthesecondphaseofthestudy,iftheyshouldnotrespondtothestudydrugattheendofthedouble-blindtrial.Second,thereisadifferenceinhealthcaresystemsinthecountriesinwhichourstudywasconductedcomparedtothehealthcaresystemsinwhichpreviouslamotriginestudies(21)wereconducted.IntheNetherlandsandSpainallinhabitantshaveamandatoryhealthinsuranceprogramthatpaysforthetreatmentofbipolar
66 Chapter 366
disorder,whereasthisisnotthecaseintheUnitedStates,whereallthenegativeacutetrialswereconducted.Thismeansthatmostpatientscouldstaywiththeirownphysician,evenduringtheirparticipationinthetrial. Theresponsetolamotrigineoccurredratherlate.In2recenttrialscomparingquetiapinewithplaceboinbipolardepressionandinthetrialwiththecombinationofolanzapineplusfluoxetineversusplacebo,therewasaseparationbetweenmedicationandplaceboafter1week(8,9).Inourstudy,thisseparationoccurredat6weeks,whichiscomparablewiththeseparationat5weeksinthepriorpositivestudywithlamotriginemonotherapy(18)Thisdelayedeffectoflamotriginemightbeduetotheslowtitrationoflamotrigine. Switchtomaniaorhypomaniaoccurredin7patients:in5patientswhoweretakinglamotrigineandin2patientstakingplacebo.Changingmoodstatesformthecorefeatureofbipolardisorder;placeboresponseisalwaysafactortoconsider,especiallyinrapidcyclingpatientswhotypicallyhavefrequentepisodesofrelativelyshortduration.Althoughsevererapidcycling(morethan10episodesinthelastyear)wasanexclusioncriterion,nearly13%ofenrolledpatientsmetDSM-IVcriteriaforrapidcycling(4–9episodes),whichiscomparablewiththeoverallfrequency(15%)ofrapidcyclingreportedinpreviousstudies(3).Inthequetiapineversusplacebostudy(9),18.2%ofthepatientswererapidcyclers.Intheolanzapine(plusfluoxetine)versusplacebostudy(8),morethan35%ofthepatientswererapidcyclers.Althoughtherapidcyclingpatientsshowedmoreswitchesthanthenon-rapidcyclingpatients,wedidnotdetectadifferenceinefficacy,unlike2recentstudies(35,36),whichindicatedagreatershort-termresponsetoolanzapineorclozapineinrapidcyclingversusnon-rapidcyclingpatients.However,detectionofanysuchdifferencemayhavebeenhamperedbylackofstatisticalpowerforthissubgroupandconfoundedbyanear-significantdifferenceintheincidenceofrapidcyclingbetweenthelamotrigineandplacebogroups. Inthisstudy,thecombinationoflithiumandlamotriginewaswelltolerated.Therewererelativelyfewseriousadverseeventsforthispopulationandotheradverseeventswereallmildormoderateanddidnotdifferinfrequencyfromplacebo.Therelativelylowrateofskinrashobservedinthis
67
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 67
studymaybeattributabletoslowtitrationoflamotrigineinaccordancewiththemanufacturer’srecommendationsandconfirmsthatlithiumdoesnotincreasetheriskoflamotrigine-inducedrash.Themostimportantlimitationofourstudyistherelativelysmalloverallsamplesize(smallerthaninitiallyplanned),whichdidnotpermitsubgroupanalysesforassessmentofresponsepredictorsandmoderators.Anotherlimitationisthatwehavenoreliabledataregardingthenumberofbipolarpatientsinthestudycenterswhodevelopedadepressiveepisodewhilebeingtreatedwithlithiumandwhowerenotselectedforthestudy.Finally,wehavenosufficientdataonpatients’recenttreatmenthistoriestosuggestwherethecombinationoflithiumandlamotriginemightfitwithintreatmentalgorithms. Becausemanybipolardepressedpatientsdonotrespondadequatelytomonotherapy,thereisanurgentneedforstudiesaddressingtheefficacyofothertreatmentregimens,includingcombinationswithmoodstabilizers.Currentlypublishedplacebo-controlledstudieshaveonlyaddressedthecombinationofanantidepressant(paroxetineorimipramine)withlithium(13),ofolanzapineplusfluoxetine(8)andoftheadditionofanantidepressanttovariousmoodstabilizersand/oratypicalantipsychotics(12).Ourstudyisthefirstplacebo-controlledstudythataddressedthecombinationoflamotrigineandlithiuminbipolardepression.Thiscombinationhasbeenconsideredinteresting,especiallysinceinthe2long-termstudiescomparingbothlamotrigineandlithiumwithplacebo,lithiumwasespeciallyeffectiveinthepreventionofmanicepisodesandlamotrigineespeciallyeffectiveinthepreventionofdepressiveepisodes(24,25). Regardingclinicalconsequences,severalquestionsremainabouttheplaceofthecombinationoflamotrigineandlithiuminthetreatmentofbipolardepression.Antidepressantsremainanotherpossibleoptioninthetreatmentofbipolardepressioninpatientsusinglithium(8,11,37–39). However,theirusemaybeassociatedwiththeriskofaswitchtomaniaorhypomania(8,11,37–39).Furtherstudiesareneededtocomparetheseandotheroptions,suchas(combinationswith)atypicalantipsychotics.Anotherquestioniswhethertheeffectsoflamotrigineandlithiumwillbemaintainedintheresponders;thiswillbeaddressedinthenotyetanalyzed,1-yearcontinuationphaseofthisstudy.
68 Chapter 368
References
1. JuddLL,AkiskalHS,SchettlerPJ,etal.Aprospectiveinvestigationofthenaturalhistoryofthelong-termweeklysymptomaticstatusofbipolarIIdisorder.ArchGenPsychiatry2003;60:261–269
2. JuddLL,AkiskalHS,SchettlerPJ,etal.Thelong-termnaturalhistoryoftheweeklysymptomaticstatusofbipolarIdisorder.ArchGenPsychiatry2002;59:530–537
3. KupkaRW,LuckenbaughDA,PostRM,etal.Comparisonofrapid-cyclingandnon-rapid-cyclingbipolardisorderbasedonprospectivemoodratingsin539outpatients.AmJPsychiatry2005;162:1273–1280
4. CalabreseJR,HirschfeldRMA,FryeMA,etal.Impactofdepressivesymptomscomparedwithmanicsymptomsinbipolardisorder:resultsofaUScommunity-basedsample.JClinPsychiatry2004;65(11)1499–1504
5. ErnstCL,GoldbergJF.Antidepressantpropertiesofanticonvulsantdrugsforbipolardisorder.JClinPsychopharmacol2003;23:182–192
6. MalhiGS,MitchellPB,SalimS.Bipolardepression:managementoptions.CNSDrugs2003;17:9–25
7. GeddesJR,BurgessS,HawtonK,etal.Long-termlithiumtherapyforbipolardisorder:systematicreviewandmeta-analysisofrandomizedcontrolledtrials.AmJPsychiatry2004;161:217–222
8. TohenM,VietaE,CalabreseJ,etal.Efficacyofolanzapineandolanzapine-fluoxetinecombinationinthetreatmentofbipolarIdepression.ArchGenPsychiatry2003;60:1079–1088
9. CalabreseJR,KeckPEJr.,MacfaddenW,etal.Arandomized,doubleblind,placebo-controlledtrialofquetiapineinthetreatmentofbipolarIorIIdepression.AmJPsychiatry2005Jul;16(7)2:1351–1360
10.GaoK,GajwaniP,ElhajO,etal.Typicalandatypicalantipsychoticsinbipolardepression.JClinPsychiatry2005;66(11):1376–1385
11.GijsmanHJ,GeddesJR,RendellJM,etal.Antidepressantsforbipolardepression:asystematicreviewofrandomized,controlledtrials.AmJPsychiatry2004;161:1537–1547
69
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 69
12. SachsGS,NierenbergAA,CalabreseJR,etal.Effectivenessofadjunctiveantidepressanttreatmentforbipolardepression.NEnglJMed2007;356:1711–1722
13.NemeroffCB,EvansDL,GyulaiL,etal.Double-blind,placebo-controlledcomparisonofimipramineandparoxetineinthetreatmentofbipolardepression.AmJPsychiatry2001;158:906–912
14.AltshulerLL,PostRM,LeverichGS,etal.Antidepressant-inducedmaniaandcycleacceleration:acontroversyrevisited.AmJPsychiatry1995;152:1130–1138
15. SpornJ,SachsG.Theanticonvulsantlamotrigineintreatment-resistantmanic-depressiveillness.JClinPsychopharmacol1997;17:185–189
16. KusumakarV,YathamLN.Anopenstudyoflamotrigineinrefractorybipolardepression.PsychiatryRes1997;72:145–148
17.CalabreseJR,FatemiSH,WoyshvilleMJ.Antidepressanteffectsoflamotrigineinrapidcyclingbipolardisorder.AmJPsychiatry1996;153(9):1236
18.CalabreseJR,BowdenCL,SachsGS,etal.Adouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithbipolarIdepression.Lamictal602StudyGroup.JClinPsychiatry1999;60(2):79–88
19.GoldsmithDR,WagstaffAJ,IbbotsonT,etal.Lamotrigine:areviewofitsuseinbipolardisorder.Drugs2003;63:2029–2050
20.CalabreseJR,HuffmanRF,WhiteRL,etal.Lamotrigineintheacutetreatmentofbipolardepression:resultsoffivedouble-blind,placebo-controlledclinicaltrials.BipolarDisord2008;10:323–333
21.GeddesJ,HuffmanRF,PaskaW,etal.Lamotrigineforacutetreatmentofbipolardepression:additionalclinicaltrialdataandaretrospectivepooledanalysisofresponseratesacrossallrandomizedtrialsconductedbyGSK.BipolarDisord2007;8(suppl1):32
22. BrownEB,McElroySL,KeckPE,Jr.,etal.A7-week,randomized,double-blindtrialofolanzapine/fluoxetinecombinationversuslamotrigineinthetreatmentofbipolarIdepression.JClinPsychiatry2006;67(7):1025–1033
23. FryeMA,KetterTA,KimbrellTA,etal.Aplacebo-controlledstudyoflamotrigineandgabapentinmonotherapyinrefractorymooddisorders.JClinPsychopharmacol2000;20:607–614
70 Chapter 370
24.CalabreseJR,BowdenCL,SachsG,etal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlydepressedpatientswithbipolarIdisorder.JClinPsychiatry2003;64(9):1013–1024
25. BowdenCL,CalabreseJR,SachsG,etal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlymanicorhypomanicpatientswithbipolarIdisorder.ArchGenPsychiatry2003;60:392–400
26. SheehanDV,LecrubierY,SheehanKH,etal.TheMini-InternationalNeuropsychiatricInterview(M.I.N.I.):thedevelopmentandvalidationofastructureddiagnosticpsychiatricinterviewforDSM-IVandICD-10.JClinPsychiatry1998;59(suppl20):22–33
27.MontgomerySA,ÅsbergM.Anewdepressionscaledesignedtobesensitivetochange.BrJPsychiatry1979;134:382–389
28. SpearingMK,PostRM,LeverichGS,etal.Modificationoftheclinicalglobalimpressions(CGI)scaleforuseinbipolarillness(BP):theCGI-BP.PsychiatryResearch1997;73:159–171
29. LeverichGS,NolenWA,RushAJ,etal.TheStanleyFoundationBipolarTreatmentOutcomeNetwork.I.Longitudinalmethodology.JAffectDisord2001;67(1–3):3344
30. BhagwagarZ,GoodwinGM.Theroleoflithiuminthetreatmentofbipolardepression.ClinNeurosciRes2002;2:222–227
31.ConsoniFT,VitalMA,AndreatiniR.Dualmonoaminemodulationfortheantidepressant-likeeffectoflamotrigineinthemodifiedforcedswimmingtest.EurNeuropsychopharmacol2006;16:451–458
32.CorbellaB,VietaE.Moleculartargetsoflithiumaction.ActaNeuropsychiatrica2003;15:1–25
33.ChenC,VeroneseL,YinY.Theeffectsoflamotrigineonthepharmacokineticsoflithium.BrJClinPharmacol2000;50:193–195
34. VietaE,CarneX.Theuseofplaceboinclinicaltrialsonbipolardisorder:anewapproachforanolddebate.PsychotherPsychosom2005;74:10–16
35. VietaE,CalabreseJR,HennenJ,etal.Comparisonofrapid-cyclingandnon-rapid-cyclingbipolarImanicpatientsduringtreatmentwitholanzapine:analysisofpooleddata.JClinPsychiatry2004(10);65:1420–1428
71
3
Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial 71
36. SuppesT,OzcanME,CarmodyT.Responsetoclozapineofrapidcyclingversusnon-cyclingpatientswithahistoryofmania.BipolarDisord2004;6:329–332
37. PostRM,AltshulerLL,LeverichGS,etal.Moodswitchinbipolardepression:comparisonofadjunctivevenlafaxine,bupropionandsertraline.BrJPsychiatry2006;189:124–131
38. VietaE,Martinez-AranA,GoikoleaJM,etal.Arandomizedtrialcomparingparoxetineandvenlafaxineinthetreatmentofbipolardepressedpatientstakingmoodstabilizers.JClinPsychiatry2002;63(6):508–512
39. LeverichGS,AltshulerLL,FryeMA,etal.Riskofswitchinmoodpolaritytohypomaniaormaniainpatientswithbipolardepressionduringacuteandcontinuationtrialsofvenlafaxine,sertraline,andbupropionasadjunctstomoodstabilizers.AmJPsychiatry2006;163:232–239
7272
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine
4
M.L.M.vanderLoos1,P.Mulder2,E.G.Th.M.Hartong3,M.B.J.Blom4,A.C.Vergouwen5,M.S.vanNoorden6,M.A.Timmermans7,E.Vieta8,W.A.Nolen9,fortheLamLitStudyGroup.
1 DepartmentofPsychiatry,IsalaKlinieken,LocationSophia,Zwolle,
2 DepartmentofBiostatistics,ErasmusUniversityMedicalCenter,Rotterdam,
3 DepartmentofPsychiatry,Canisius-WilhelminaHospital,Nijmegen,
4 ParnassiaPsychiatricInstitute,TheHague,5 DepartmentofPsychiatrySintLucasAndreasHospital,
Amsterdam,6 DepartmentofPsychiatry,LeidenUniversityMedicalCenter,
Leiden,7 PraktijkondersteuningZuidOostBrabant,Veldhoven,
theNetherlands,8 BipolarDisordersProgram,CIBERSAMInstituteof
Neuroscience,HospitalClinic,UniversityofBarcelona,IDIBAPS,Barcelona,Catalonia,Spainand
9 DepartmentofPsychiatry,UniversityMedicalCenterGroningen,UniversityofGroningen,Groningen,theNetherlands
Acta Psychiatrica Scandinavica 2010; 122: 246-254
74 Chapter 474
Abstract
Objective:Inapreviouspaper,wereportedabouttheefficacyoftheadditionoflamotriginetolithiuminpatientswithbipolardepression.Inthesecondphaseofthisstudyparoxetinewasaddedtoongoingtreatmentinnon-responders. Method:Bipolardepressedpatients(n=124)treatedwithlithiumwererandomizedtoadditionoflamotrigineorplacebo.Innonrespondersafter8weeks,paroxetine20mgwasaddedforanother8weekstoongoingtreatment. Results:After8weekstheimprovementinpatientstreatedwithlamotriginevs.patientstreatedwithplacebowassignificant.Afteradditionofparoxetinethisdifferencedisappearedasaresultofgreaterfurtherimprovementinthenon-responderstoplacebo. Conclusion:Additionoflamotriginetolithiumwasfoundeffectiveinbipolardepressedpatients.Furtheradditionofparoxetineinnonresponderstolithiumpluslamotriginedidnotappeartoprovideadditionalbenefit,whileitappearedtodosoinnon-responderstolithiumplusplacebo.
Significant outcomes
• Additionoflamotrigineismoreeffectivethantheadditionofplaceboinbipolardepressedpatientsalreadyusinglithium.
• Paroxetineadditioninnon-responderstotheformertreatmentappearedtoprovidebenefitfornonresponderstolithiumplusplacebobutnotfornon-responderstolithiumpluslamotrigine.
• Thecombinationoflithiumpluslamotrigineplusparoxetinewaswelltoleratedandsafe.Tremorwastheonlyadverseeventthatseparatedbetweenlamotrigineandplacebo.Therewerenodifferencesbetweenlamotrigineandplaceboinseriousadverseevents.
75
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 75
Limitations
• Thesamplesizeofthenon-responderstolithiumpluslamotrigineorplacebowasrelativelysmall.
• Theadditionofparoxetineinthesecondphaseofthestudywasopenanduncontrolled.
• Thedurationofthisstudywasshortinregardtothelifelongpatternofmoodepisodesinbipolardisorder.Efficacyandsafetyoftwotreatmentalgorithmsinbipolardepression.
Introduction
Since1993casereportsontheeffectivenessoflamotrigineintheacutetreatmentofbipolardepressionhavebeenpublished(1–3).Thefirstplacebo-controlledrandomizedcontrolledtrial(RCT)showingefficacyoflamotriginemonotherapywasnegativeontheprimaryoutcomecriteriontheHamiltonRatingScaleforDepression(HAMD)(4)butpositiveonseveralsecondaryoutcomemeasuresincludingtheMontgomery-ÅsbergDepressionRatingScale(MADRS)(5,6).Fourmonotherapystudiesthereafter(7)(1999–2006)wereallnegativeontheprimaryoutcomecriterion(theMADRS),althoughameta-analysisofallthesefivestudiesshowedasmallbutstatisticallysignificantpositiveresult(8).Paroxetineisaselectiveserotoninre-uptakeinhibitor(SSRI)whichisverybroadlyusedforthetreatmentofmajordepressivedisorder,andwhichhasalsobeentestedinseveralRCTsinbipolardepressionbothasmonotherapyandasadjunctivetherapy(9–13).AlthoughthesestudieswerenotpositiveandSSRIsarecurrentlynotviewedasafirst-linetreatmentoptioninthetreatmentofbipolardepression,theymayplayaroleinpatientswhoareresistanttofirst-linetherapies(14).Inapreviouspaper,wedescribedtheresultsofaplacebo-controlledRCTexaminingtheefficacyandsafetyoftheadditionoflamotrigineduring8weeksinbipolarpatientswithabreak-throughdepressionduringtreatmentwithlithium(15).ChangeinMADRSscorescomparedwithbaselinewassignificantlygreateraftertheadditionoflamotriginetolithiumthanafterthe
76 Chapter 476
additionofplacebo.Responserate(definedasadecreaseofatleast50%oftheinitialMADRSscore)wasalsosignificantlygreaterwithlamotriginecomparedtoplacebo.Inthispaper,wedescribetheresultsoftwodifferenttreatmentalgorithms;treatmentwithlamotrigineaddedtolithiumduringthefirst8weeks(firstphase)followedbyfurtheradditionofparoxetineinnon-respondersduringweeks9–16(secondphase)vs.8weeksoftreatmentwithlithiumplusplacebo(firstphase)alsofollowedbyfurtheradditionofparoxetineinnon-responders(secondphase)duringweeks9–16.
Aims of the study Theaimofthisrandomizedcontrolledtrialwastocomparetheefficacy,safetyandtolerabilityoftwotreatmentalgorithmsinpatientssufferingfromabipolardepression.Patientsusinglithium(firststep)witharelapseorrecurrenceofabipolardepressionwererandomizedtotheadditionoflamotrigineorplacebo(secondstep),20mgparoxetinewassubsequentlyaddedtonon-respondersoftheformer2steps(thirdstep).
Material and methods
Study design Thisarticledescribesthecombinedresultsofboththefirstandsecondphaseofaninvestigatorinitiated(WN)study.Inthefirstphase,124patientswererecruitedin23out-patientcentersintheNetherlands(n=112)and3centersinSpain(n=12)between2002and2005(15).Duringthesecondphaseofthisstudyparoxetine20mgwasopenlabeladdedtonon-respondersatweek8.Lithium(openlabel)andlamotrigineorplacebo(double-blind)wascontinuedatthesamedose.ThestudywasapprovedbytheethicalreviewboardoftheUniversityMedicalCenterUtrecht,Utrecht,theNetherlandsandbylocalinstitutionalreviewboardsintheNetherlandsandinSpain.Allpatientssignedinformedconsentpriortothestartofanystudyprocedures.
77
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 77
Patients Patients(age18–65)wereeligibleforthisstudyiftheysufferedfrombipolardisorderwithamajordepressiveepisodeaccordingtoDSM-IVcriteriaconfirmedbytheMINIplus(16),ascoreof≥18ontheMADRS(6)andaClinicalGlobalImpressionforBipolarIllness(CGI-BP)(17)severityscoreof≥4(moderatelyill).Allpatientswereonlong-termtreatmentwithlithium,withalithiumplasmalevelbetween0.6and1.2mmforatleast2weeksbeforethestartofthestudy.Patientswithpsychoticfeatures,withasevererapidcyclingpattern(morethan10episodesintheprecedingyear)withseveresuicidality(scoreonitem10oftheMADRS≥5)orwithahistoryofalcoholorsubstanceabusewithin1monthpriortothestartofthestudyordependencewithin12months,wereexcluded.Nopatientshadneurologicalorothersomaticillnessesknowntoaffectmood.Femalepatientswerenotpregnant(negativepregnancytestpriortothestudy)andwererequiredtouseaneffectivecontraceptivemethod.Patientswerenotallowedtotakepsychotropicsotherthanstudymedications,exceptforbenzodiazepinesatamaximumof2mglorazepamequivalents⁄day.
Treatments Duringthefirstphaseofthestudy(week0–8)patients(n=124)receiveddouble-blindtreatmentwithlamotrigine(uptitratedto200mg⁄day)orplaceboaddedtoongoingtreatmentwithlithium(119patientshadplasmalevelsbetweenthepredefinedrangeof0.6–1.2mm;fivepatientsbetween0.53and0.6mm.Beforedeblindingitwasdecidedtoacceptthisminorprotocolviolation,thusincludingthesepatientsintheanalysis.Duringthesecondphase(week9–16)openlabelparoxetinewasaddedatafixeddoseof20mg⁄dayinnon-respondersatweek8(CGI-BPchangeof3ormore,i.e.minimallyimproved,unchangedorworsecomparedwithbaseline),whiledosagesoflithiumandlamotrigineorplacebo(stillgivendouble-blind)werekeptstablethroughoutthesecondphase.Respondersattheendofthefirstphasewerealsofollowedandmaintainedtheirsamedosagesoflithiumandlamotrigineorplacebo.
78 Chapter 478
Outcome measures Patientvisitswerescheduledatbaseline(week0)andfromthenonwardevery2weeks.MADRSscoresandtheCGI-BPSeverityofDepressionandManiascoreswereassessedateachvisit.TheprimaryoutcomeforthesecondstudyphasewaschangefrombaselineonthetotalMADRSscoreatweek16.SecondaryoutcomemeasuresweretotalMADRSscoreatweek16orendpoint,CGI-BPseverityofdepressionandofmaniaatweek16orendpointandresponse.ResponsewasdefinedasadecreaseontheMADRSof≥50%and⁄orGCI-BPchangeof1or2(verymuchormuchimproved)comparedwithbaseline.Anadditionaloutcomemeasurewasswitchto(hypo)mania,definedasascoreof≥3(mildlyill)ontheCGI-BPseverityofmaniascale.Posthocwealsoidentifiedpatientswhohadrespondedwithoutaswitchto(hypo)mania.Ateachvisitadverseeventswereassessedandifpresentratedaccordingtotheirseverityasmild,moderateorsevere.
Statistics Mixedmodelanovaforrepeatedmeasures(MMRM)wasprospectivelychosenasmethodofanalysisforMADRSscores.Theindependentvariablesinthisanalysiswere:time,treatmentandtheirinteraction.TimeascategoricalvariableallowedestimatingandtestingmeandifferencesinMADRSbetweenthetwotreatmentsatanyvisit,includingtheprimaryefficacymeasureforthisstudyphase:changefrombaselineatweek16.Forthispurpose,therelevantcontrastswerespecifiedinthemodelforwhichtheanovaproducedtheestimates,SEs,confidenceintervalsandappropriatet-testspervisit.Tomakeinferenceaboutanoveralltreatmenteffectoverallvisitsineitherphaseofthestudy,timewasconsideredanumerictrendvariableinamixedmodelthatallowedatrend-break(‘brokenstick’)atthetransitionfromthefirsttothesecondphase.Inthismodel,adifferenceintimetrendbetweenthetwotreatmentgroupsineitherphaseandchangesintimetrendbetweenthetwophasesineithertreatmentgroupwereestimatedandtested.OnthebasisofthismodelpredictedMADRSscoreswerecalculated(with95%confidenceintervals)andtestedbetweenthetwotreatmentgroupsatweek8(endofphaseI)andatweek16(endofphaseII).In
79
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 79
accordancewiththeintenttotreatprinciple,allrandomizedsubjectscontributedtotheseanalyzes,missingvaluesofMADRSscoresbeingproperlyadjustedforbytherestrictedmaximumlikelihoodestimationprocedureusedinthemixedmodelanova’s. ClinicalGlobalImpressionforBipolarIllnessseverityscoresweresimilarlyanalyzedusingmixedmodelanovawithtimeascategoricalvariable.Dichotomousoutcomescores(response,switchorpresenceofadverseeffects)werecomparedbetweenthetwotreatmentgroupsusingFisher’sexacttestandlastobservationcarriedforwardformissingdata.DifferencesinthedistributionofcategoricalnominalvariablesbetweenthetwotreatmentgroupsweretestedusingFisher’sexacttest,forcategoricalordinalvariablestheexactChi-squaretrendtestwasused.Foreachtestatwo-sidedP-valuebelow0.05wasconsideredtodenotestatisticalsignificance.
Results
Theflowchartofthestudyispresentedinfigure1.Duringthefirstphase64patientsreceivedadd-onlamotrigineand60patientsreceivedadd-onplacebo.Therewerenostatisticalsignificantdifferencesbetweenthetwogroupsinpatientscharacteristicsorillnessseverityatbaseline(15)(table1).Inthelamotriginegroup52patients(81.3%)completedthefirst8weeksofthestudy,37ofthemasrespondersand15asnon-responders.Afterthefirstphase,ninepatients(14.1%)droppedoutleaving43patientswhoagreedtoparticipateinthesecondphase;34respondersand9non-responders.Duringthesecondphaseanotherfourpatientsdroppedout.Intheplacebogroup50patients(83.3%)completedthefirst8weeks,28asrespondersand22asnon-responders.Sixpatients(10%)droppedout,leaving44patients(26respondersand18non-responders)whocontinuedthestudy.Duringthesecondphaseanothersixpatientsdroppedout.
80 Chapter 480
Figure 1. Flowchartofthestudy
Notmeetinginclusioncriteria:3Nottakenstudymedication:1
Responders:34 Responders:26
Phas
eII
Phas
eI
Assessed:128
Randomised:124
PlusLamotrigine:64
Completed:52
Non-responders:15Responders:37
Continued:34
Completed:31 Completed:8 Completed:14
Continued:26
Completed:24
Plusparoxetine:9 Plusparoxetine:18
Responders:28
PlusPlacebo:60
Completed:50
Non-responders:22
Drop-outs:10
Drop-outs:3
Lackofefficacy:1Withdrawnconsent:1Protocolviolation:1
Drop-outs:4
Drop-outs:12
Drop-outs:2
Lackofefficacy:1Adverseevents:1
Drop-outs:6
Noncompliance:1
Lackofefficacy:2Adverseevents:2
81
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 81
Table 1. Patientandillnesscharacteristics
MADRS=Montgomery-ÅsbergDespressionRatingScale,CGI-BP=ClinicalGlobalImpressionforBipolarIllnes,TCA=tricyclicantidepressant,SSRI=selectiveserotoninre-uptakeinhibitor,SNRI=serotonin-noradrenalinre-uptakeinhibitor,MAO=monoamineoxidaseinhibitor.
Lamotriginen=64
Placebon=60
Totaln=124 Statistic Value df P
Femalegender(n,%)
37 57.8 30 50 67 54.0 Fisher’s - - 0.471
Age(years)(mean,SD)
45.2 12.1 47.6 11.6 46.4 11.9 t-test 1.13 122 0.261
IlnesscharacteristicsBipolarIdisorder(n,%)
43 67.2 41 68.3 84 67.7 Fisher’s - - 1.000
Rapidcyclingcourse–last12months
12 18.8 4 6.7 16 12.9 Fisher’s - - 0.061
MADRS(mean,SD)
28.25 5.97 28.82 6.24 28.52 6.08 t-test 0.52 122 0.606
CGI-BPdepressionseverity(mean,SD)
4.56 0.64 4.53 0.57 4.55 0.60 ChiSq.trend
0.07 1 0.882
CGI-BPmaniaseverity(mean,SD)
1.03 0.18 1.03 0.18 1.03 0.18 Fisher’s - - 1.000
Lithiumplasmalevelatbaseline(mEq)(mean,SD)
0.82 0.16 0.84 0.16 0.83 0.16 t-test 0.48 122 0.634
Previousothertreatmentsforindexdepressiveepisode(n,%)TCA 6 9.4 4 6.7 10 8.1 Fisher’s - - 0.745SSRI/SNRI 15 23,4 16 26.7 31 25.0 Fisher’s - - 0.836MAO-inhibitor 1 1.6 3 5.0 4 3.2 Fisher’s - - 0.353Antipsychotic,typical
4 6.3 3 5.0 7 5.6 Fisher’s - - 1.000
Antipsychotic,atypical
15 23.4 11 18.3 26 21.0 Fisher’s - - 0.317
Valproicacid 5 7.8 2 3.3 7 5.6 Fisher’s - - 0.247Carbamazepine 1 1.6 3 5.0 4 3.2 Fisher’s - - 0.285Benzodiazepine 44 68.8 35 58.3 79 63.7 Fisher’s - - 0.154Other 3 4.7 4 6.7 7 5.6 Fisher’s - - 0.464
82 Chapter 482
Efficacy Theefficacyresultsoverbothstudy-phasesfromamixedmodelanovawithtimeascategoricalvariablearepresentedintable2.After8weeks,thedifferencebetweenlithiumpluslamotriginevs.lithiumplusplacebointhechangeoftheMADRSscoresfrombaselinetoweek8wassignificant(15);15.37vs.11.16(P=0.029).After16weekstherewasnostatisticallysignificantdifferenceinchangeofMADRSscoresfrombaselinetoweek16betweenlithiumpluslamotrigine(plusparoxetineinnon-responders)vs.lithiumplusplacebo(plusparoxetineinnon-responders);17.91vs.15.40(P=0.253).ThedifferencebetweentotalMADRSscoreswasalsonolongersignificantatweek16:10.34vs.13.42(P=0.134)(fig2).The95%confidenceintervalofthemeandifference(lamotrigineminusplacebo)inMADRSscoreatweek16wasfrom7.13to0.97.
83
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 83
Table 2. EfficacyResult:severityscales
MADRS=Montgomery-ÅsbergDepressionRatingScale,CGI-BP=ClinicalGlobalImpressionforBipolarIllness.Boldvaluesindicatesignificantlevels<0.05
Lamotriginen=64
Placebon=60 Difference Statistic Value df P
ChangeinMADRSscorefrombaseline(primaryoutcomemeasure)(mean,SE)Week2 -5.30(0.87) -3.74(0.91) -1.56(1.26) t-test -1.23 121 0.220Week4 -9.22(1.25) -6.20(1.30) -3.02(1.81) t-test -1.67 110 0.098Week6 -12.84(1.35) -9.35(1.40) -3.49(1.95) t-test -1.79 104 0.076Week8 -15.37(1.32) -11.16(1.37) -4.22(1.90) t-test -2.22 104 0.029
Week10 -16.88(1.30) -12.14(1.34) -4.74(1.87) t-test -2.54 101 0.013
Week12 -15.68(1.51) -13.22(1.55) -2.46(2.16) t-test -1.14 90 0.258Week14 -17.04(1.39) -15.96(1.43) -1.08(1.99) t-test -0.54 90 0.588Week16 -17.91(1.53) -15.40(1.56) -2.51(2.19) t-test -1.15 83 0.253MADRSscoreateachvisit(mean,SE)Baseline 28.25(0.76) 28.82(0.79) -0.57(1.10) t-test -0.52 122 0.606Week8 12.88(1.23) 17.66(1.28) -4.78(1.78) t-test -2.69 104 0.008
Week16 10.34(1.42) 13.42(1.45) -3.08(2.03) t-test -1.52 76 0.134CGI-BPseverityofdepressionateachvisit(mean,SE)Baseline 4.56(0.08) 4.53(0.08) 0.03(0.11) t-test 0.27 122 0.789Week8 2.63(0.18) 3.08(0.19) -0.45(0.26) t-test -1,69 103 0.093Week16 2.20(0.18) 2.56(0.19) -0.36(0.26) t-test -1.38 82 0.171CGI-BPchangeofdepressionfrombaseline(mean,SE)Week8 2.34(0.17) 2.69(0.17) -0.35(0.24) t-test -1.45 96 0.151Week16 1.79(0.14) 2.15(0.14) -0.36(0.20) t-test -1.80 70 0.076CGI-BPseverityofmaniaateachvisit(mean,SE)Baseline 1.03(0.02) 1.03(0.02) 0.00(0.03) t-test -0.07 122 0.948Week8 1.15(0.06) 1.14(0.06) 0.01(0.08) t-test 0.11 64 0.914Week16 1.38(0.16) 1.30(0.16) 0.07(0.22) t-test 0.32 7 0.761
84 Chapter 484
Figure 2. SeverityofdepressionaccordingtothemeanMADRSscoreateachvisitforpatientsonplaceboandlamotrigine
Responserateswere68.8%(44outof64patients)tothelithium-lamotrigine-paroxetinealgorithm,and51.7%(31outof60)(P=0.066)tothelithium-placebo-paroxetinealgorithm,whiletheresponseratesamongcompletersofthestudywere87%(34outof39patients)and73%(27outof37patients)respectively(table3).Othersecondaryoutcomecriteria(allCGI-BPoutcomes)alsodidnotrevealsignificantdifferencesatweek16.
***
*** P<0.05**P<0.01 Additionofparoxetine
Weeks
Mea
nM
AD
RSs
core
0 2 4 6 8 10 12 14 16
5
10
15
20
25
30
PlaceboLamotrigine
85
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 85
Table 3. Efficacyresults:responseandswitchto(hypo)maniaafter8and16weeks
MADRS=Montgomery-ÅsbergDepressionRatingScale;CGI-BP=ClinicalGlobalImpressionforBipolarIllness.Boldvaluesindicatesignificantlevels<0.05*1missing**CGI-BPseverityofmania≥3***ReductionMADRS≥50%and/orCGI-BPchangeofdepression≤2andCGI-BPseverityof
mania<3
Lamotrigine(n=64)
Placebo(n=60) Statistic P
8weeksResponse N % N %ReductionMADRS≥50% 33 (51.6) 19 (31.7) Fisher 0.030
CGI-BPchangeofdepression≤2 41 (64.1) 29 (49.2)* Fisher 0.105Eitherorboth 42 (65.6) 29 (49.2) Fisher 0.065Switchto(hypo)mania** 5 (7.8) 2 (3.3) Fisher 0.441Responseandnoswitchto(hypo)mania***
39 (60.9) 28 (46.7) Fisher 0.149
16weeksResponse N % N %ReductionMADRS≥50% 33 (51.6) 27 (45.0) Fisher 0.478CGI-BPchangeofdepression≤2 43 (67.2) 31 (51.7) Fisher 0.100Eitherorboth 44 (68.8) 31 (51.7) Fisher 0.066Switchto(hypo)mania** 8 (12.5) 5 (8.3) Fisher 0.562Responseandnoswitchto(hypo)mania***
38 (59.4) 29 (48.3) Fisher 0.280
86 Chapter 486
Intable4,theresultsofthepiecewiselinearmodelarepresented.TheestimateddownwardtrendsintimeoftheMADRSscorewhichweresignificantlydifferentbetweentreatmentgroupsinthefirstphase(P=0.009),becamesignificantlylesssteepinthesecondphase(P=0.015intheplacebogroupandP<0.0005inthelamotriginegroup).Inthesecondphase,thedownwardtrendswerenotsignificantlydifferentanymorebetweenthetreatmentgroups(P=0.19).TheMADRSscoresaspredictedbytheestimatedpiecewiselinearmodelinbothtreatmentgroupswassignificantlydifferent(P=0.009)atweek8(endofphase1)andnotsignificantlydifferent(P=0.22)anymoreatweek16(theendofphase2).
Table 4. PredictedMADRSscores(95%CI)atweeks8and16(righttwocolums)andtimetrend(SE)inMADRS-scoreper2weeks(leftfourcolums)accordingtoa‘brokenstick’modelwithatrendbreakatweek8.Theintercept(SE)equals28.23(0.54).
MADRS=Montgomery-ÅsbergDespressionRatingScale
Eightpatients(12.5%)inthelithium-lamotrigine-paroxetinegroupswitchedto(hypo)mania(fivepatients(7.8%)duringthefirst8weeksand3(4.7%)aftertheadditionofparoxetineinnonresponders).Six(9.4%)ofthesepatientshadalsoreachedtheresponsecriterionfordepression.Inthelithium-placebo-paroxetinegroupfivepatients(8.3%)switchedto(hypo)mania(2(3.3%)inthefirstphaseand3(5%)inthesecondphase).Twoofthem(3.3%)hadalsoreachedtheresponsecriterionfordepression(table3).
TimetrendinMADRSscoreper2weeks PredictedMADRSscore
Phase1:0-8weeks
Phase2:8-16weeks
Differencebetweenphases
P-value(testbetweenphases) Atweek8 Atweek16
Placebogroup -2.68(0.31) -1.39(0.31) 1.29(0.52) 0.015 17.5(15.1to19.9) 11.9(9.4to14.5)
Lamotriginegroup -3.81(0.30) -0.82(0.30) 2.99(0.51) <0.0005 13.0(10.7to15.3) 9.7(7.2to12.2)
Differencebetweengroups
-1.12(0.42) 0.57(0.43) –4.5(–7.8to–1.2) –2.2(–5.8to1.3)
P-value(testbetweengroups)
0.009 0.19 0.009 0.22
87
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 87
Safety
Overall16weeksofthestudy,therewere15seriousadverseevents(SAE)involvingeightpatientsinthelithium-lamotrigine-paroxetinegroup(onepatientexperiencedtwoSAEs)andfivepatientsinthelithium-placebo-paroxetinegroup(alsoonepatientwithtwoSAEs).ThefourSAEsoccurringduringthefirstphasehavebeenreportedbefore(15).Duringthesecondphasetherewere11SAEsinvolvingninepatients.Inthelithium-lamotrigine-paroxetinegrouptwopatients(noadditionofparoxetine)developedamanicepisode,onepatientattemptedsuicide(noadditionofparoxetine),onepatientreceivingparoxetineadditiondevelopedseveresuicidalideation,andonepatientwithhighbloodpressureinthefirstphasehadanatrialflutterinthesecondphase(noparoxetineaddition).Inthelithium-placebo-paroxetinegrouptwopatients(noparoxetineaddition)becameseverelydepressed,onepatienthadaninfectionoftheurinarytract(noparoxetineaddition),onepatientwiththeadditionofparoxetinewasadmittedtoapsychiatrichospital(reasonunknown)withco-occurringhyperthyroidism(secondphase).Allpatientsrecovered.Oftheadverseeventsonlytremorshowedadifferencebetweenthelithium-lamotrigine-paroxetineandthelithium-placebo-paroxetinegroup(23.4%vs.5%P=0.042)(table5).
88 Chapter 488
Table 5. Adverseeventsoccurringin≥5%ofpatientsinanygroup(linear-by-linearassociation,twosided)
Boldvaluesindicatesignificantlevels<0.05
Lamotrigine(n=64)
Placebo(n=60)
PN % N %Sexproblems 1 1.6 5 8.3 .106Pulmonaryproblems 4 6.3 0 0 .120Blurredvision 4 6.3 2 3.3 .746Hallucinations 4 6.3 0 0 .120Throatproblems 3 4.7 3 5.0 1.000Headache 32 50.0 18 30.0 .338Obstipation 7 10.9 1 1.7 .179Diarhea 4 6.3 2 3.3 .746Alopecia 4 6.3 1 1.7 .366Fatigue 13 20.3 12 20.0 1.000Nausea 20 31.3 11 18.3 .209Flu-likesymptoms 13 20.3 10 16.7 .728Insomnia 11 17.2 4 6.7 .105Tremor 15 23.4 3 5.0 .042
Skinproblems/mildrash 9 14.1 4 6.7 .426Dizziness 5 7.8 7 11.7 .590Abdominalpain 6 9.4 4 6.7 .493Rash 5 7.8 4 6.7 1.000Joint/musclepain 8 12.5 9 15.0 .843Backpain 6 9.4 5 8.3 1.000Coordinationproblems 4 6.3 0 0 .245Eyeproblems 5 7.8 0 0 .120Polyuria 1 1.6 3 5.0 .488Agitation 1 1.6 5 8.3 .169
89
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 89
Discussion
Althoughthetermtreatmentresistantishardlyoperationalized(18)inbipolardepression,inclinicalpractice‘break-throughdepressions’duringlong-termtreatmentincludinglithium,aremoretherulethantheexception.Thereisadiscrepancybetweenthehighproportionofpatientsreceivingpolypharmacy(byoneestimate80%ofpatientswithbipolardisorder)(19,20)andthescarcenessofresearchdataontheefficacyofpolypharmacy.Toourknowledge,thisisthefirststudyinbipolardisorderinwhichtwodifferenttreatmentalgorithmsconsistingofthreestepswerecompared.Patientswhodevelopedadepressiverelapseorrecurrence(break-throughdepression)duringlong-termlithiumtreatment(thefirststep)receivedadditionoflamotrigineorplaceboasasecondstep(firstphaseofthestudy)for8weeks.Inthethirdstep,non-respondersafterthesecondstepwereofferedfurtheradditionofparoxetineduringanother8weeks(secondphaseofthestudy).Attheendofthesecondstep(week8)therewasaclinicallyandstatisticallysignificantadvantageofchangeinMADRSscoresfrombaseline(theprimaryoutcomecriterion)andonseveralsecondaryoutcomesinfavoroftheadditionoflamotriginecomparedwiththeadditionofplacebo.However,bytheendofthethirdstep(week16)therewerenosignificantdifferencesbetweenthetwotreatmentalgorithmsonprimaryorsecondaryoutcomes.Wehavethreepossibleexplanationsfortheseresults.First,andinourviewmostlikely,theadditionofparoxetineinthethirdstepwasmorebeneficialtopatientsreceivingadditionofplacebointhesecondstepthanitwasforpatientswhohadreceivedadditionoflamotrigine,allowingtheformergroupto‘catchup’toatleastsomeextentwiththelattergroup.Whereasthelamotriginegrouphadplateauedalreadybyweek8–10,theplacebogrouphadmoreroomforimprovement.Inthelamotriginegroup,allpatientsstartedapotentiallyeffectiveadd-ontreatment(lamotrigine)frombaseline,whileintheplacebogroupthenonresponderstolithiumplusplacebostartedapotentiallyeffectiveadd-ontreatment(paroxetine)atweek8.Indeed,asub-analysisshowedagreatereffectofparoxetineinthenon-responderstoplacebothaninthenon-responderstolamotrigine(table4).Aninterestingfinding
90 Chapter 490
inthisrespectisalsothatthesignificancelevelbetweenlamotrigineandplacebowhichwaspresentatweek8,wasevengreateratweek10.Apparently,the‘catchup’effectofparoxetine(intheplacebogroup)occurredafterthefirst2weeksofitsaddition.ThemajorobjectionagainstthisexplanationisthatthereismoreevidenceagainstratherthaninfavoroftheefficacyofparoxetineorotherSSRIsinbipolardepression(9,12,13).Asecondpossibleexplanationfortheseresultsmaybethattheyareareflectionofthenaturalwaxingandwaningcourseofbipolardisorder.However,weconsiderthisasunlikelygiventherelativeshortperiod(week12–16)duringwhichthedifferenceexistingatweek8(andevenmorestronglyatweek10)receded,butithasbeenreportedthatplaceboresponsemayincreaseovertimeinbipolardisorder(21).Athirdpossibleexplanationcouldbethatanadd-onstudydesignreducesthepossibilitytoshowsignificantresults,andthisproblemmayevenincreasewithmultipleadd-onsteps(21).Wedoubthoweverthatthisistheexplanationasthesignificancelevelwasatitsmaximumatweek10,i.e.evenaftermostpatientswhodroppedoutafterthefirstphase,hadalreadyleftthestudy.Inadditiontotheongoingdebateconcerningtheefficacyofantidepressantsinbipolardepression(9,12,22,23),itisinterestingtofurtherhighlightthepossibleefficacyoftheadditionofparoxetineinnon-responderstolithiumplusplacebointhesecondphaseofthestudy.Itisremarkablethatthissuggestionforefficacyofparoxetinewasonlyfoundinpatientswhohadreceivedlithiumplusplacebo,andnotinthepatientswhohadalreadyreceivedlithiumpluslamotrigine.Weconsideritunlikelythatthisresponsetoparoxetinewasaplaceboeffectasallpatientshadalreadyreceivedplacebointhefirstphase.Perhapsparoxetineiseffectiveinpatientswithabreak-throughdepressionduringlong-termtreatmentwithlithium,butnotinpatientsalsoreceivingvariousotherdrugs,suchaslamotrigine(asshowninourstudy)ortreatmentsotherthanlithium,suchasvalproate,carbamazepine,atypicalantipsychoticsand⁄oradditionalpsychotherapy(asintheSTEP-BDadd-onstudyoftheefficacyofadd-ontreatmentwithantidepressantsincludingtheSSRIsertraline)(12)Tofindananswertothisquestion,onemightconsiderathree-armRCTcomparingtheadditionofbothlamotrigineandparoxetinewithplaceboinpatientswithabreak-throughdepressionduringtreatmentwithlithium.
91
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 91
Overallthetoleranceofthecombinationoflithiumwithlamotrigine(orplacebo)andsubsequentlyparoxetinewasverywell.Oftheoriginalsampleof124patients,76patients(61.3%)completedbothstudy-phases,whilesevenpatients(10.9%)inthelithium-lamotrigine-paroxetinegroupand5(8.3%)inthelithium-placebo-paroxetinegroupdroppedoutasaresultofadverseevents.Exceptforonepatientwhowaslosttofollow-up,allpatientswithSAEsrecovereduneventfully.RegardingSAEstherewasnostatisticaldifferencebetweenthelithium-lamotrigineparoxetinegroupandthelithium-placebo-paroxetinegroup.ItisdifficulttodiscernwhethersomeoftheSAEs(e.g.suicidalideation,mania)wereaneffectofthetreatmentorpartofthenaturalcourseoftheillness,butarelationshiptodrugtreatmentcannotberuledout.Onlytremorwasreportedmorefrequentlyinthelithium-lamotrigine-paroxetinegroupthaninthelithium-placebo-paroxetinegroup. Amajorlimitationofthestudywastheoverallrelativelylimitedsamplesize,andmorespecificallytherelativesmallnumberofpatientsmovingfromphase1tophase2.Withthesignificantdifferenceafterphase1butnotafterphase2,wecannotconcludethatthealgorithmwithlamotrigineisonlyeffectiveat8weeksandnotaftertheadditionofparoxetineat16weeks.Itremainspossiblethatwithalargersamplesize,thedifferencewouldalsohavebecamesignificantatweek16.Moreover,asaconsequenceofthedesignwithopenlabeladditionofparoxetine,thestudywasnotcapableofmeasuringtheindividualcontributionofparoxetineinthetreatmentofbipolardepressioninpatientsnotrespondingtolithiumpluslamotrigineorlithiumplusplacebo.Toevaluatetheefficacyofparoxetine,itwouldhavebeennecessarytocompareitwithplaceboandtore-randomizepatientsafterphase1.However,forsuchastudythesamplesizeofourtrialwasmuchtoosmall.Finally,thedurationofthisstudy,althoughlongbycurrentclinicaltrialstandards,doesnotprovidedatahowtocontinuefurthertreatmentinresponders.Thiswillbeaddressedinanotherpaperinwhichwewilldescribetheresultsofa1yearfollow-upinrespondersofbothphase1andphase2. Inconclusion,thepresentresultsshowsthatinpatientswithabreak-throughdepressionduringlong-termtreatmentwithlithium,theadditionof
92 Chapter 492
lamotrigineiseffective(firstphaseofthisstudy)whilefurtheradditionofparoxetineinnonresponderstolamotrigine(secondphase)doesnotappeartoprovidemuchextrabenefit.Ontheotherhand,thefindingfromthesecondphaseofanincreasedresponsetoparoxetineinnonresponderstotheadditionofplacebosupportsthenotionthattheadditionofparoxetine,andperhapsotherSSRIs,maybereasonablechoicesforthetreatmentofpatientswithabipolardepressiondespitetreatmentwithlithium.Clearlymorestudiesemployingdifferenttreatmentalgorithmsareneededtohelpdiscernthemostoptimalformsofpolypharmacyforbipolardisorder.
93
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 93
References
1. SpornJ,SachsG.Theanticonvulsantlamotrigineintreatment-resistantmanic-depressiveillness.JClinPsychopharmacol1997;17:185–189.
2. KusumakarV,YathamLN.Anopenstudyoflamotrigineinrefractorybipolardepression.PsychiatryRes1997;72:145–148.
3. CalabreseJR,FatemiSH,WoyshvilleMJ.Antidepressanteffectsoflamotrigineinrapidcyclingbipolardisorder.AmJPsychiatry1996;153:1236.
4. HamiltonM.Aratingscalefordepression.JNeurolNeurosurgPsychiatry1960;23:56–62.
5. CalabreseJR,BowdenCL,SachsGS,AscherJA,MonaghanE,RuddGD.Adouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithbipolarIdepression.Lamictal602StudyGroup.JClinPsychiatry1999;60:79–88.
6. MontgomerySA,ÅsbergM.Anewdepressionscaledesignedtobesensitivetochange.BrJPsychiatry1979;134:382–389.
7. CalabreseJR,HuffmanRF,WhiteRLetal.Lamotrigineintheacutetreatmentofbipolardepression:resultsoffivedouble-blind,placebo-controlledclinicaltrials.BipolarDisord2008;10:323–333.
8. GeddesJ,HuffmanRF,PaskaW,EvoniukG,LeadbetterR.Lamotrigineforacutetreatmentofbipolardepression:additionalclinicaltrialdataandaretrospectivepooledanalysisofresponseratesacrossallrandomizedtrialsconductedbyGSK.BipolarDisord2007;8(Suppl.1):32.
9. NemeroffCB,EvansDL,GyulaiLetal.Double-blind,placebo-controlledcomparisonofimipramineandparoxetineinthetreatmentofbipolardepression.AmJPsychiatry2001;158:906–912.
10. SheltonRC,StahlSM.Risperidoneandparoxetinegivensinglyandincombinationforbipolardepression.JClinPsychiatry2004;65:1715–1719.
11. VietaE,Martinez-AranA,GoikoleaJMetal.Arandomizedtrialcomparingparoxetineandvenlafaxineinthetreatmentofbipolardepressedpatientstakingmoodstabilizers.JClinPsychiatry2002;63:508–512.
94 Chapter 494
12. SachsGS,NierenbergAA,CalabreseJRetal.Effectivenessofadjunctiveantidepressanttreatmentforbipolardepression.NEnglJMed2007;356:1711–1722.
13.McElroySL,ChangW,NordenhemA,PaulssonB,BrecherM,YoungAH.Adouble-blind,placebo-controlledstudywithacuteandcontinuationphaseofquetiapineinadultswithbipolardepression(emboldenII).27-1-2008.3rdbiennialconferenceoftheinternationalsocietyforbipolardisorders.Delhi,India27–28January2008.
14.GoodwinGM,AndersonI,ArangoCetal.ECNPconsensusmeeting.Bipolardepression.Nice,March2007.EurNeuropsychopharmacol2008;18:535–549.
15. vanderLoosML,MulderPG,HartongEGetal.Efficacyandsafetyoflamotrigineasadd-ontreatmenttolithiuminbipolardepression:amulticenter,double-blind,placebocontrolledtrial.JClinPsychiatry2009;70:223–231.
16. SheehanDV,LecrubierY,SheehanKHetal.TheMini-International NeuropsychiatricInterview(M.I.N.I.):thedevelopmentandvalidationofastructureddiagnosticpsychiatricinterviewforDSM-IVandICD-10.JClinPsychiatry1998;59(Suppl.20):22–33.
17. SpearingMK,PostRM,LeverichG,BrandtD,NolenWA.Modificationoftheclinicalglobalimpressions(CGI)scaleforuseinbipolarillness(BP):theCGI-BP.PsychiatryRes1997;73:159–171.
18. PacchiarottiI,MazzariniL,ColomFetal.Treatmentresistantbipolardepression:towardsanewdefinition.ActaPsychiatrScand2009;120:429–440.
19.GhaemiSN,HsuDJ,ThaseMEetal.Pharmacologicaltreatmentpatternsatstudyentryforthefirst500STEPBDparticipants.PsychiatrServ2006;57:660–665.
20. SimonNM,OttoMW,WeissRDetal.Pharmacotherapyforbipolardisorderandcomorbidconditions:baselinedatafromSTEP-BD.JClinPsychopharmacol2004;24:512–520.
21. VietaE,CarneX.Theuseofplaceboinclinicaltrialsonbipolardisorder:anewapproachforanolddebate.PsychotherPsychosom2005;74:10–16.
22.GijsmanHJ,GeddesJR,RendellJM,NolenWA,GoodwinGM.Antidepressantsforbipolardepression:asystematicreviewofrandomized,controlledtrials.AmJPsychiatry2004;161:1537–1547.
95
4
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine 95
23. LichtRW,GijsmanH,NolenWA,AngstJ.Areantidepressantssafeinthetreatmentofbipolardepression?AcriticalevaluationoftheirpotentialrisktoinduceswitchintomaniaorcycleaccelerationActaPsychiatrScand2008;118:337–346.
96
97
5
MarcLMvanderLoosa,PaulMulderb,ErwinGThMHartongc,MarcBJBlomd,AntonCVergouwene,MartijnSvanNoordenf,ManuelaATimmermansg,EduardVietahandWillemANolenifortheLamLitStudyGroup*
aDepartmentofPsychiatry,IsalaKliniekenLocationSophia,Zwolle,bDepartmentofBiostatistics,ErasmusUniversityMedicalCenter,Rotterdam,cDepartmentofPsychiatry,Canisius-WilhelminaHospital,Nijmegen,dParnassiaPsychiatricInstitute,TheHague,eDepartmentofPsychiatry,SintLucasAndreasHospital,Amsterdam,fDepartmentofPsychiatry,LeidenUniversityMedicalCenter,Leiden,gPraktijkondersteuningZuidOostBrabant,Veldhoven,TheNetherlands,hBipolarDisordersProgram,CIBERSAMInstituteofNeuroscience,HospitalClinic,UniversityofBarcelona,IDIBAPS,Barcelona,Catalonia,Spain,iDepartmentofPsychiatry,UniversityMedicalCenterGroningen,UniversityofGroningen,Groningen,TheNetherlands
Bipolar Disord 2011: 13: 111–117.© 2011
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design
98 Chapter 598
Abstract
Objective:Intwopreviousmanuscripts,wedescribedtheefficacyoflamotrigineversusplaceboasadd-ontolithium(followedbytheadditionofparoxetineinnonresponders)intheshort-termtreatmentofbipolardepression.Inthispaperwedescribethelong-term(68weeks)outcomeofthatstudy. Methods:Atotalof124bipolardepressedpatientsreceivinglithiumwererandomizedtoadditionoflamotrigineorplacebo.Aftereightweeks,paroxetinewasaddedtononrespondersforanothereightweeks.Responderscontinuedmedicationandwerefollowedforupto68weeksoruntilarelapseorrecurrenceofadepressiveormanicepisode. Results:Aftereightweeks,theadditionoflamotriginetolithiumwassignificantlymoreefficaciousthanadditionofplacebo,whileafteradditionofparoxetineinnonrespondersbothgroupsfurtherimprovedwithnosignificantdifferencebetweengroupsatweek16.Duringfollow-uptheefficacyoflamotriginewasmaintained:timetorelapseorrecurrencewaslongerforthelamotriginegroup(mediantime10.0months(confidenceinterval:1.1–18.8)versustheplacebogroup3.5months(confidenceinterval:0.7–7.0)). Conclusion:Inpatientswithbipolardepression,despitecontinueduseoflithium,additionoflamotriginerevealedacontinuedbenefitcomparedtoplacebothroughouttheentirestudy.
99
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 99
Introduction
Bipolardisordersarecharacterizedbyrecurrentmoodepisodes.While98%ofpatientsachievesyndromaticrecoveryfromanacutemanicordepressiveepisodewithintwoyears(1),80–90%ofpatientssufferfromnewepisodesthereafter(1–3).Despitetheuseofmoodstabilizerssuchaslithiumorvalproate,especiallydepressiveepisodesanddayswithdepressivesymptomsarefrequentandmayprovedifficulttotreat(2,4,5).Lithiumandperhapstoalesserextentvalproatehavesomebutlimitedefficacyinthetreatmentandpreventionofdepressiveepisodes(6–8).Thereisacontroversyregardingtheuseofantidepressants,bothinthetreatmentofacutedepressiveepisodes(9,10)aswellasinlong-termtreatmentofbipolardisorder(11–13).Oftheatypicalantipsychotics,onlyquetiapine(14–17)andolanzapine(especiallyincombinationwithfluoxetine)(18)demonstratedefficacyinacutebipolardepression.Moreover,olanzapine(19)andquetiapine(asadd-ontolithiumorvalproate)(20,21)werefoundeffectiveinthepreventionofdepressiverecurrences. Anothertreatmentoptionforbipolardepressionislamotrigine.Theresultsfromtheacutestudiesinbipolardepressionarecontradictory.Thefirstrandomized,controlledtrial(RCT)foundasignificantdifferencebetweenlamotrigineandplaceboinfavouroflamotrigine,althoughonlyonsecondaryoutcomemeasures(22).FouradditionalRCTsthereafterfoundnodifferencebetweenlamotriginemonotherapyandplacebo,probablybecauseofahighplaceboresponseinthesestudies(23,24).Nevertheless,inameta-analysisofallfivestudies,lamotriginewasmoreeffectivethanplacebo(25).Inaddition,lamotriginehasbeencomparedwithplaceboandlithiuminlong-termtreatmentofbipolardisorder. Intwostudies(26,27)lamotriginewasfoundeffectiveinpreventingdepressiverecurrences,whilelithiumwaseffectiveinpreventingmanicrecurrences. Intwopreviouspapers,wedescribedtheshort-termresultsofaplacebo-controlledRCTinvestigatingtheeffectsoftheadditionoflamotriginetolithium
100 Chapter 5100
inpatientswithbipolardepressiondespitelong-termtreatmentwithlithium.Inthefirstphaseofthatstudy(weeks1–8),lamotriginewasfoundtobemoreeffectivethanplacebo(28);inthesecondphase(weeks9–16),furtheradditionofparoxetineinnonresponderstoeitherlamotrigineorplacebo(pluslithium)wasassociatedwithfurtherimprovementinbothgroups,whilethedifferencebetweenlamotrigineandplacebowasnolongersignificantatweek16(29).Inthispaper,wedescribetheresultsofthelong-termoutcomeofthatstudy.
Methods
Study design Inthispaper,wedescribethefollow-upofaninvestigator(WAN)-initiated,randomized,double-blind,placebo-controlledtrialwiththreephases.Thedesignofthestudyisshowninfigure1andhasbeendescribedindetailelsewhere(28,29). Duringthefirsteightweeksofthestudy(phase1),124patientswithabipolarIorIIdisorderandadepressiveepisodewith≥18pointsontheMontgomery-ÅsbergDepressionRatingScale(MADRS)(30)despitelong-termtreatmentwithlithiumreceivedlamotrigineorplaceboinadditiontoongoingtreatmentwithlithium(28).Non-responders(n=37)totheadditionofeitherlamotrigineorplaceboatweek8wereofferedtheopportunitytoreceivefurtheradditionofparoxetine(openlabel)incombinationwithongoinglithiumpluslamotrigineorplaceboduringweeks9–16(phase2)(29). Respondersat8or16weekswerefolloweduntilmaximallyweek68(phase3)oruntiltheyreachedtheprimaryendpoint(adepressiveormanicrelapseorrecurrence).Themedicationregime(lithium,double-blindlamotrigineorplacebo,andinsomepatientsparoxetineaswell)waskeptstableduringtheentirefollow-up.Patientswholeftthestudywithoutarelapseorrecurrencewereconsidereddropouts;reasonsfordropoutwererecorded. ThestudywasapprovedbytheethicalreviewboardoftheUniversityMedicalCenterUtrecht,TheNetherlands,andbylocalinstitutionalreviewboardsinbothcountries.Allpatientsgavewritteninformedconsentpriortoinitiationofanystudyprocedure.
101
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 101
Figure 1. Designofthestudy
Treatments Allpatientswerealreadyreceivinglithium,whichwasmaintainedataplasmalevelof0.6–1.2mmol⁄Lthroughoutthestudy.Duringphase1,lamotrigine(orplaceboinidenticaltablets)wasup-titratedto200mg⁄dayatweek6andmaintainedatthisdosethroughoutthestudy.Innonresponders,atweek8paroxetinewasstartedat20mg⁄dayandalsomaintainedatthisdosethroughoutthestudy.Inadditiontothestudymedication(lithium,lamotrigineorplacebo,andparoxetine)patientswerenotallowedtotakeotherpsychotropicdrugs,withtheexceptionofbenzodiazepinesatamaximumof2mglorazepamequivalents⁄day.
Assessments and outcome measures Afterbaseline,patientswereseeneverytwoweeksuntiltheendofphase2(week16).Duringfollowup(phase3),patientswereassessedatweek20andthereaftereverytwomonths.Duringallvisits,patientswerescoredontheMADRSandtheClinicalGlobalImpression–Bipolarversion(CGIBP)(31);adverseevents
Lithium+Lamotrigine+Paroxetineinnon-reponders
Lithium
Lithium
Lithium
+Lamotrigine
+Placebo
Phase 1 Phase 2 Follow-up of respondersPhase 3
Lithium+Placebo+Paroxetineinnon-responders
Week 0 8 16 68
Responders
102 Chapter 5102
andstudymedicationcompliancewerealsoassessed.Lithiumplasmalevelsweremeasuredeveryfourmonths. Responseduringphase1and2leadingtofollow-upwasdefinedasascoreof1or2(verymuchormuchimproved)accordingtotheCGI-BPimprovementofdepressionscale.Outcomeofthestudywastherelapseorrecurrenceofamanicordepressiveepisodedefinedasascore≥4(atleastmoderatesymptoms)ontheCGI-BPseverityofdepressionormaniascale.Inaddition,itwasinvestigatedhowlongtheMADRSscorewasmaintainedat<50%ofitsbaselinevalueafterpatientsreachedthislevelforthefirsttimeduringphase1or2.
Statistics Allanalysesconcerningefficacyduringfollow-up(phase3)havetobeconsideredinadescriptivesensewithoutstatisticaltesting.Thisisbecausethegroupsenteringfollow-upwereselectedbythetreatment-dependentoutcome(very)muchimprovementofdepressionontheCGI-BPandconsequentlyhadbecomeformallyincomparableatthisstage. Theevolutionofnosymptomsoronlymildsymptoms(bothCGI-BPmaniaanddepressionseverityscore<4)duringthewholestudywasdescribedbycalculatingpercentageswithnooronlymildsymptomsoftheoriginalgroupsizesateachvisit.Inaddition,thesustainabilityofaMADRSscore<50%ofbaselineafterthefirstattainmentofthislevelwascomparedbetweenthetwotreatmentgroupsusingaKaplan–Meiersurvivalanalysis. Thefrequenciesofthevarioustypesofadverseeventsoccurringinmorethan5%ofthepatientsduringthecontinuationphasewerecomparedbetweenthetwotreatmentgroupsusingachi-squaretrendtest.
Results
Patientcharacteristicsatbaselinearepresentedintable1.Treatmentgroupswerebalancedatbaseline,consideringtheuniformdistributionofp-valuesovertheinterval(0.1).Theflowchartofthestudy,includingreasonsfordroppingoutduringthethreephases,ispresentedinfigure2.
103
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 103
Table 1. Patientandillnesscharacteristicsatstudyentry
Lamotrigine(n=64)
Placebo(n=60)
Total(n=124) Statistic Value df P-value
Femalegender(n,%) 37 57.8 30 50 67 54.0 Fisher’s - - 0.471
Age(years)(mean,SD) 45.2 12.1 47.6 11.6 46.4 11.9 t-test 1.13 122 0.261
Ilnesscharacteristics
BipolarIdisorder(n,%) 43 67.2 41 68.3 84 67.7 Fisher’s - - 1.000
Rapidcyclingcourse–last12months
12 18.8 4 6.7 16 12.9 Fisher’s - - 0.061
MADRS(mean,SD) 28.25 5.97 28.82 6.24 28.52 6.08 t-test 0.52 122 0.606
CGI-BPdepressionseverity(mean,SD)
4.56 0.64 4.53 0.57 4.55 0.60 ChiSq.trend
0.07 1 0.882
CGI-BPmaniaseverity(mean,SD)
1.03 0.18 1.03 0.18 1.03 0.18 Fisher’s - - 1.000
Lithiumplasmalevelatbaseline(mEq)(mean,SD)
0.82 0.16 0.84 0.16 0.83 0.16 t-test 0.48 122 0.634
Previousothertreatmentsforindexdepressiveepisode(n,%)
TCA 6 9.4 4 6.7 10 8.1 Fisher’s - - 0.745
SSRI/SNRI 15 23,4 16 26.7 31 25.0 Fisher’s - - 0.836
MAO-inhibitor 1 1.6 3 5.0 4 3.2 Fisher’s - - 0.353
Antipsychotic,typical 4 6.3 3 5.0 7 5.6 Fisher’s - - 1.000
Antipsychotic,atypical 15 23.4 11 18.3 26 21.0 Fisher’s - - 0.317
Valproicacid 5 7.8 2 3.3 7 5.6 Fisher’s - - 0.247
Carbamazepine 1 1.6 3 5.0 4 3.2 Fisher’s - - 0.285
Benzodiazepine 44 68.8 35 58.3 79 63.7 Fisher’s - - 0.154
Other 3 4.7 4 6.7 7 5.6 Fisher’s - - 0.464
MADRS=Montgomery-ÅsbergDespressionRatingScale,CGI-BP=ClinicalGlobalImpressionforBipolarIllnes,TCA=tricyclicantidepressant,SSRI=selectiveserotoninre-uptakeinhibitor,SNRI=serotonin-noradrenalinre-uptakeinhibitor,MAO=monoamineoxidaseinhibitor.
104 Chapter 5104
Randomized:124
Pluslamotrigine:64 Plusplacebo:60
Completed:52 Completed:50
Drop-outs:10Drop-outs:12
Nonresponders:15 Nonresponders:22Responders:37 Responders:28
Drop-outs:6
Drop-out:1
Drop-out:1
Drop-out:3
Drop-out:3
Drop-outs:3 Drop-outs:2
Drop-outs:2
Drop-out:1
Drop-outs:4
Drop-outs:4
Drop-outs:2
Plusparoxetine:9 Plusparoxetine:18Continued:34 Continued:26
Completed:8
Responders:5 Responders:8Remainedresponders:29
Remainedresponders:20
Completed:31 Completed:24 Completed:14
Startfollow-up:30 Startfollow-up:25Phase3
Phas
e2
Phas
e1
Figure 2. Flowchartofthestudy
Inphase1,atotalof124patientswererandomizedtolamotrigine(n=64)orplacebo(n=60);102completedthisphase.Aftereightweeks,thedifferenceinchangeofMADRSscore(theprimaryoutcomecriterionduringphase1)wassignificant(15.37versus11.16,respectivelyp=0.029)(28).
Inphase2,nonresponderstolamotrigine(n=9)orplacebo(n=18)receivedadditionofparoxetine(phase2).Attheendofphase2,bothgroupswerefurtherimproved,whilethedifferencebetweengroupsinchangeofMADRSscorewasnolongersignificant(17.91forthelithium–lamotrigine–paroxetinealgorithmversus15.40(p=0.253)forthelithium–placebo–paroxetinealgorithm)(29).
105
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 105
Lithiumplasmalevelsweremeasuredatbaselineandatweeks8,16,32,48,and64.Theoverallvariationinmeanplasmalevelswas0.73–0.82mmol⁄Lforthelamotriginegroupversus0.72–0.83mmol⁄Lfortheplacebogroup.
Long-term efficacy Responders,accordingtotheCGI-BP,duringeitherphase1orphase2wereeligibleforfollowup.Ateachvisitduringfollow-up,thenumberofpatientswhomaintainedresponderstatus(CGIBPseverityofdepressionormaniascore<4)wascalculatedaspercentageofthegroupwhostartedwitheitherlamotrigineorplaceboinphase1.Thesepercentagesmaintainedhigherlevelsinthelamotriginegroupthanintheplacebogroupthroughoutthestudy(fig3).Noformalstatisticaltestwasdoneherebecauseoftheselectedgroupforfollow-up(seeMethods).Thedropinpercentagebetweenweeks16and20iscausedbythetreatment-dependentselectionofpatientsenteringfollow-up. WealsocalculatedtimetofirstrelapseorrecurrencebasedontheMADRSscoreafterhavingachievedresponderstatusaccordingtotheMADRS(i.e.,<50%ofbaseline)forthefirsttimeduringphase1orphase2.Inthisanalysis,patientswholeftthestudyforanyreasonwerecensored. Thetimetorelapseorrecurrencewaslongerforthelamotriginegroupthanfortheplacebogroup:mediantime10.0months(95%confidenceinterval(CI):1.1–18.8)versus3.5months(95%CI:0.7–7.0),respectively(seefig4).Noformalstatisticaltestwasperformed. Attheendofthestudy(68weeks),18patients(28.1%)fromthelamotriginegroupwerestillinthestudyversus14patientsfromtheplacebogroup(23.3%).
106 Chapter 5106
Figure 3. Responders(ClinicalGlobalImpression–Bipolarversionimprovementofdepressionscoreof1or2)aspercentageoftheinitialgroup(n=124;lamotriginen=64,placebon=60)throughoutallthreephasesofthestudy.
Weeks
Perc
enta
gere
spon
ders
30
40
50
60
70
80
90
100
20
10
0
PlaceboLamotrigine
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
107
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 107
Figure 4. Probabilityofmaintainingresponse(score<50%ofMontgomery-ÅsbergDepressionRatingScale(MADRS)scoreatbaseline)withoutrecurrence(score≥50%ofinitialMADRS)afterhavingachievedresponderstatusforthefirsttimeduringphase1orphase2.Mediantimetorelapseorrecurrenceforthelamotriginegroupwas10.0months(95%confidenceinterval:1.1–18.8)versus3.5months(95%confidenceinterval:0.7–7.0)fortheplacebogroup.
Safety
Occurrenceofsevereadverseevents(SAEs)andanyadverseevents(AEs)duringthefirst16weeksofthisstudyweredescribedindetailpreviously(28,29).Duringfollow-up,5SAEswereobserved:2inthelamotriginegroup(1patientdevelopedanatrialflutterand1hadhighbloodpressure),and3intheplacebogroup(2patientshadaseveredepressiverecurrenceand1anurinarytractinfection).NoneoftheSAEswereconsideredtoberelatedtostudymedicationandallpatientsrecovered.TheAEsoccurringinmorethan5%ofanygrouparelistedintable2.Therewasnodifferencebetweenlamotrigineandplacebointhepreva-lenceofanyAE.ThetotalamountofAEsinbothgroupswasremarkablylowfora68-weekfollow-up.
Months
Prob
abili
tyo
fno
recu
rrenc
e
30
40
50
60
70
80
90
100
20
10
0
PlaceboLamotrigine
0 3 6 9 12 15 18
108 Chapter 5108
Fivepatientsinthelamotriginegroupand8patientsintheplacebogroupdevelopeda(hypo)manicepisodeduringfollow-up.
Table 2. Adverseeventsoccuringin≥5%ofpatientsinanygroup(linear-by-linearassociation,two-sided)
Discussion
Inthispaper,wedescribethelong-termfollow-upofanRCTconsistingofthreephases.Withthisquitenoveldesignwewereabletocomparetwodifferenttreatmentalgorithms,onewithlamotrigineaddedtolithiumandonewithplaceboaddedtolithium(phase1),bothfollowedbyadditionofparoxetineinnonresponders(phase2)andasubsequentfollow-upinrespondersafterphase1or2(phase3).Wefoundthatthealgorithmwithlamotrigineadditionwasnotonlymoreeffectivethanthealgorithmwithplaceboadditionintheacutetreatmentofbipolardepressionbutalsoappearedtoretainitsefficacythroughouttheentirestudy.Thepercentageofrespondersaswellasthetimetorelapseafter
Lamotrigine(n=30)
Placebo(n=25)
PN % N %Pulmonaryproblems 3 10.0 0 0 .242Blurredvision 2 6.7 0 0 .495Hallucinations 2 6.7 0 0 .495Throatproblems 3 10.0 2 8.0 .383Joint/musclepain 2 6.7 3 12.0 .1000Headache 3 10.0 2 8.0 .383Nausea 4 13.3 1 4.0 .301Flu-likesymptoms 3 10.0 1 4.0 .492Insomnia 3 10.0 2 8.0 .745Abdominalpain 3 10.0 0 0 .242Hypertension 2 6.7 0 0 .495Backpain 1 3.3 2 8.0 .585Coordinationproblems 2 6.7 0 0 .495Eyeproblems 2 6.7 0 0 .495
109
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 109
initialresponsewasfavourableforthelamotriginegroupversustheplacebogroup. Inouropinion,thedesignofourstudyhasseveraladvantagesanddisadvantages.Thefirstadvantageisthattheadd-ondesigncloselyresemblesreallife,inwhichmanybipolardisorderpatientsreceivemultiplemedicationsratherthanmonotherapy(32–34).InadditiontotheusualdesignofanRCTcomparinglamotrigineorplaceboaddedtolithium,wealsocouldprovidedataontheadditionofathirddrug(paroxetine)tolithiumandlamotrigine(orplacebo)andonthelong-termfollow-up.Thus,ourstudyprovidesusefulinformationontheefficacyandsafetyofadjunctivelamotriginecomparedtoplacebointheacuteaswellasthelong-termtreatmentofbipolardepression. Asecondadvantageisthatnonrespondersafterphase1couldreceiveactivemedication(paroxetine)inphase2,thusincreasingthefeasibilityofthestudy.Wehypothesizethatitmayalsopartlyexplaintherelativelowdropoutrateinourstudy(only38%duringthefirsttwophasesand74%overtheentirestudyof68weeks),whichismuchlowerthaninthetwopreviouslong-termtrialswithlamotrigine(26,27).Inthesestudies,98%and85%ofthosewhowererandomizedtolamotrigineorplacebo,respectively,weredropoutsafter68weeks. Themaindisadvantageofthisdesignisthattheselectionofnonrespondersforreceivingparoxetineafterphase1andtheselectionofrespondersafterphase1and2forcontinuationofthestudyledtoanunequalnumberofpatientsleavingthestudyatthesedecisionpoints.Thiseventuallyhamperedpossibilitiesforananalysiswithstatisticaltestingoftheresultsofphase3. Themainlimitationofourstudyistherelativelysmallsamplesize.Thiswasalreadyaproblemintheanalysisofphase1,inwhich124patientsparticipatedwhilethestudywasoriginallyplannedtorecruit220patients,anditdefinitelyhamperedstatisticalanalysisafterphase2.Thus,ourfindingsmustbeinterpretedwithsomecaution. Nevertheless,weconcludethatlamotriginewasmoreeffectivethanplaceboasadd-ontreatmenttolithiuminpatientswithbreakthroughbipolar
110 Chapter 5110
depressionandwaswelltoleratedincombinationwithlithium.Moreover,lamotriginecouldsafelybecombinednotonlywithlithiumbutalsowithparoxetineandappearedtoretainitsefficacyandgoodtolerabilitythroughoutfollow-up.
111
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 111
References
1. TohenM,ZarateCAJr,HennenJetal.TheMcLean-HarvardFirst-EpisodeManiaStudy:predictionofrecoveryandfirstrecurrence.AmJPsychiatry2003;160:2099–2107.
2. KupkaRW,LuckenbaughDA,PostRMetal.Comparisonofrapid-cyclingandnon-rapid-cyclingbipolardisorderbasedonprospectivemoodratingsin539outpatients.AmJPsychiatry2005;162:1273–1280.
3. GoodwinFK,JamisonKR.Courseandoutcome.In:ManicDepressiveIllness;BipolarDisordersandRecurrentDepression,2ndedn.NewYork:OxfordUniversityPress,2007:119–154.
4. JuddLL,AkiskalHS,SchettlerPJetal.Thelong-termnaturalhistoryoftheweeklysymptomaticstatusofbipolarIdisorder.ArchGenPsychiatry2002;59:530–537.
5. JuddLL,AkiskalHS,SchettlerPJetal.Aprospectiveinvestigationofthenaturalhistoryofthelong-termweeklysymptomaticstatusofbipolarIIdisorder.ArchGenPsychiatry2003;60:261–269.
6. GeddesJR,BurgessS,HawtonK,JamisonK,GoodwinGM.Long-termlithiumtherapyforbipolardisorder:systematicreviewandmeta-analysisofrandomizedcon-trolledtrials.AmJPsychiatry2004;161:217–222.
7. BowdenCL,CalabreseJR,McElroySLetal.Arandomized,placebo-controlled12-monthtrialofdivalproexandlithiumintreatmentofoutpatientswithbipolarIdisorder.DivalproexMaintenanceStudyGroup.ArchGenPsychiatry2000;57:481–489.
8. GeddesJR,GoodwinGM,RendellJetal.LithiumplusvalproatecombinationtherapyversusmonotherapyforrelapsepreventioninbipolarIdisorder(BALANCE):arandomisedopen-labeltrial.Lancet2010;375:385–395.
9. GijsmanHJ,GeddesJR,RendellJM,NolenWA,GoodwinGM.Antidepressantsforbipolardepression:asystematicreviewofrandomized,controlledtrials.AmJPsychiatry2004;161:1537–1547.
10. SachsGS,NierenbergAA,CalabreseJRetal.Effectivenessofadjunctiveantidepressanttreatmentforbipolardepression.NEnglJMed2007;356:1711–1722.
112 Chapter 5112
11. LichtRW,GijsmanH,NolenWA,AngstJ.Areantidepressantssafeinthetreatmentofbipolardepression?Acriticalevaluationoftheirpotentialrisktoinduceswitchintomaniaorcycleacceleration.ActaPsychiatrScand2008;118:337–346.
12.GhaemiSN,WingoAP,FilkowskiMA,BaldessariniRJ.Long-termantidepressanttreatmentinbipolardisorder:meta-analysesofbenefitsandrisks.ActaPsychiatrScand2008;118:347–356.
13. VietaE.Antidepressantsinbipolardepression.ActaPsychiatrScand2008;118:335–336.
14.CalabreseJR,KeckPEJr,MacfaddenWetal.Arandomized,double-blind,placebo-controlledtrialofquetiapineinthetreatmentofbipolarIorIIdepression.AmJPsychiatry2005;162:1351–1360.
15. ThaseME,MacfaddenW,WeislerRHetal.EfficacyofquetiapinemonotherapyinbipolarIandIIdepression:adouble-blind,placebo-controlledstudy(theBOLDERIIstudy).JClinPsychopharmacol2006;26:600–609.
16. YoungAH,McElroySL,BauerMetal.Adouble-blind,placebo-controlledstudyofquetiapineandlithiummonotherapyinadultsintheacutephaseofbipolardepression(EMBOLDENI).JClinPsychiatry2010;71:150–162.
17.McElroySL,WeislerRH,ChangWetal.Adouble-blind,placebo-controlledstudyofquetiapineandparoxetineasmonotherapyinadultswithbipolardepression(EMBOLDENII).JClinPsychiatry2010;71:163–174.
18. TohenM,VietaE,CalabreseJetal.Efficacyofolanzapineandolanzapine-fluoxetinecombinationinthetreatmentofbipolarIdepression.ArchGenPsychiatry2003;60:1079–1088.
19. TohenM,CalabreseJR,SachsGSetal.Randomized,placebo-controlledtrialofolanzapineasmaintenancetherapyinpatientswithbipolarIdisorderrespondingtoacutetreatmentwitholanzapine.AmJPsychiatry2006;163:247–256.
20. SuppesT,VietaE,LiuS,BrecherM,PaulssonB.MaintenancetreatmentforpatientswithbipolarIdisorder:resultsfromaNorthAmericanstudyofquetiapineincombinationwithlithiumordivalproex(Trial127).AmJPsychiatry2009;166:476–488.
21. VietaE,SuppesT,EggensI,PerssonI,PaulssonB,BrecherM.Efficacyandsafetyofquetiapineincombina-tionwithlithiumordivalproexformaintenanceofpatientswithbipolarIdisorder(InternationalTrial126).JAffectDisord2008;109:251–263.
113
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 113
22.CalabreseJR,BowdenCL,SachsGS,AscherJA,MonaghanE,RuddGD.Adouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithbipolarIdepression.Lamictal602StudyGroup.JClinPsychiatry1999;60:79–88.
23.CalabreseJR,HuffmanRF,WhiteRLetal.Lamotrigineintheacutetreatmentofbipolardepression:resultsoffivedouble-blind,placebo-controlledclinicaltrials.BipolarDisord2008;10:323–333.
24.GeddesJ,HuffmanR,PaskaW,EvoniukG,LeadbetterR.Lamotrigineforacutetreatmentofbipolardepression:additionalclinicaltrialdataandaretrospectivepooledanalysisofresponseratesacrossallrandomizedtrialsconductedbyGSK.BipolarDisord2006;8(Suppl.1):32.
25.GeddesJR,CalabreseJR,GoodwinGM.Lamotriginefortreatmentofbipolardepression:independentmeta-analysisandmeta-regressionofindividualpatientdatafromfiverandomisedtrials.BrJPsychiatry2009;194:4–9.
26. BowdenCL,CalabreseJR,SachsGetal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlymanicorhypomanicpatientswithbipolarIdisorder.ArchGenPsychiatry2003;60:392–400.
27.CalabreseJR,BowdenCL,SachsGetal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlydepressedpatientswithbipolarIdisorder.JClinPsychiatry2003;64:1013–1024.
28. vanderLoosML,MulderPG,HartongEGetal.Efficacyandsafetyoflamotrigineasadd-ontreatmenttolithiuminbipolardepression:amulticenter,double-blind,placebo-controlledtrial.JClinPsychiatry2009;70:223–231.
29. vanderLoosML,MulderP,HartongEGetal.Efficacyandsafetyoftwotreatmentalgorithmsinbipolardepressionconsistingofacombinationoflithium,lamotrigineorplaceboandparoxetine.ActaPsychiatrScand2010;122:246–254.
30.MontgomerySA,ÅsbergM.Anewdepressionscaledesignedtobesensitivetochange.BrJPsychiatry1979;134:382–389.
31. SpearingMK,PostRM,LeverichG,BrandtD,NolenWA.Modificationoftheclinicalglobalimpressions(CGI)scaleforuseinbipolarillness(BP):theCGI-BP.PsychiatryRes1997;73:159–171.
32.GhaemiSN,HsuDJ,ThaseMEetal.Pharmacologicaltreatmentpatternsatstudyentryforthefirst500STEP-BDparticipants.PsychiatrServ2006;57:660–665.
114 Chapter 5114
33. SimonNM,OttoMW,WeissRDetal.Pharmacotherapyforbipolardisorderandcomorbidconditions:baselinedatafromSTEP-BD.JClinPsychopharmacol2004;24:512–520.
34.GoldbergJF,BrooksJOIII,KuritaKetal.Depressiveillnessburdenassociatedwithcomplexpolypharmacyinpatientswithbipolardisorder:findingsfromtheSTEP-BD.JClinPsychiatry2009;70:155–162.
115
5
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design 115
116116
117
6
Discussion
118 Chapter 6118
Introduction
Bipolardisorderisacommonanddebilitatingdisorderwithalifetimeprevalenceofaround2%(1)Althoughthereisconvincingevidencethatpatientsaremoreoftenandlongerdepressedthanmanic(2-4),therewasuntilrecentlynoapproveddrugforthetreatmentofbipolardepression.Currentlyonlyquetiapine(bothinEuropeendeUS)andthecombinationofolanzapinewithfluoxetine(intheUS)havebeenapprovedfortheacutetreatmentofbipolardepression,whilelamotrigine(bothinEuropeandintheUS)hasbeenapprovedforlong-termtreatment,specificallytopreventdepressiveepisodes. Theunderpinningofexistingguidelines,whichalsoadvocatesothertreatmentsincludingantidepressants,isconfinedduetothefactthatresearchinthisfieldislimited.Aslongasthehigheststandardofevidenceinresearch,i.e.randomizedplacebo-controlledtrials,dependsmostlyonfundingfrompharmaceuticalcompaniesandtherewas,withafewexceptions(seeabove),notmuchinterestamongthesecompaniestoapplyforaspecificindication‘bipolardepression’,thefutureofnewrandomizedcontrolledtrialsinbipolardepressionisbleak(5).Inadditiontotheadd-ontrialwithlamotrigineaspresentedinthisthesisandtheotherlamotriginemonotherapytrials,onlyafewothertreatmentshavebeeninvestigatedindouble-blind,randomizedtrialswithsometimesseveremethodologicalproblems.
Antidepressants
Noneofthemorethan20availableantidepressantshasspecificallybeenstudiedanddevelopedbypharmaceuticalcompaniesfortheindication‘bipolardepression’.Asaresult,thereisanalmostcompletelackof(large)randomizedplacebo-controlledtrialsontheefficacyofantidepressantsasmonotherapyinbipolardepression(6;7).Nextwewillbrieflyreviewavailableevidencefromtherandomizedplacebo-controlledtrials. In1980Mendlewiczetal.comparedL-deprenil(MAO-B-inhibitor)incombinationwithL-5-hydroxytryptophantoplaceboin58depressedpatients
119
6
Discussion 119
(bothunipolarandbipolar)(8).Thecombinationoutperformedplaceboinclinicalimprovement. In1982Himmelhochetal.comparedtranylcyprominewithplaceboin59anergicmajordepressedpatients(9).Althoughthepatientswerenotformallydiagnosedasbipolar,theauthorsstatedthat‘anergicmajordepressionmosttypicallyoccursinprimarybipolarillnesses’.Theyreportedthattranylcypromineshowedsuperiorityoverplacebobytheendofthefirstweek,andthisimprovementincreasedinsignificanceateachsuccessivevisituntilweek6. In1989Cohnetal.comparedfluoxetine,imipramineandplaceboina6-weekstudyinvolving89patientsofwhom22werealreadyusinglithium(10).Responsetofluoxetinewasgreaterthantoimipramineorplacebowhileresponsetoimipraminewasalsogreaterthantoplacebo.Duetosmallnumbers,thedifferenceswerehowevernotsignificant. In2001Nemeroffetal.comparedtheadditionofparoxetine,imipramineandplaceboasadditiontolithiumin117bipolardepressedpatients(11).Therewasnosignificantdifferencebetweenthethreegroupsinefficacy.However,inapost-hocanalysisbothantidepressantsweresuperiorinasubgroupwithlithiumbloodserumlevelsbelow0.8mmol/l. In2007Sachsetal.publishedthelargestandperhapsalsomostinfluentialstudyofantidepressantsinbipolardepression:theSTEP-BDstudywithatotalof366patients.(12).Inthisdouble-blindtrialbupropion,paroxetineorplacebowereaddedtoongoingtreatment.Allpatientswereonlithium,valproateoracombinationofthesetwowiththenotionthat27%ofthepatientsreceivedaninadequatedoseoflithiumorvalproate.Later,wheninclusionbecameaproblem,alsootherFDAapprovedantimanicagents(especiallyatypicalantipsychoticssuchasolanzapineandquetiapine)wereallowed.Otherantidepressantshadtobetaperedoffbeforeorduringthefirstweekofthetrial.Othermedicationscouldalsobestartedduringthestudy.Besidesparticipatinginthismedicationtrial69%ofthepatientswereatthesametimeincludedinarandomizedpsychotherapytrialcomparingcognitivebehavioraltherapy,interpersonalpsychotherapyandfamilyfocusedtherapywithpsychoeducation.Themainfindingofthestudyisthattheantidepressantshadnoadditionaleffect
120 Chapter 6120
overplacebo.However,duetothemajorlimitationsitisobviousthatwiththechosendesignthewidelydrawnconclusionfromthisstudythatantidepressantsareineffectiveinbipolardepression,isnotwarranted. In2010McElroyetal.reporteda8weeksstudyinwhichshecompared300mg.and600mgquetiapinetoparoxetine20mg(n=122)andplacebo(n=126)inbipolardepression(13).Bothdosesofquetiapineweremoreefficaciousthanplacebobuttherewasnodifferencebetweenparoxetineandplaceboinresponseorremission. Asaconsequenceofthe(almost)lackofrandomizedplacebo-controlledtrials,andespeciallyofwellpoweredmonotherapytrialswithantidepressants,thereisstillmuchdiscussionabouttheuseofantidepressantsinbipolardepression.Someargueorevenconcludethattheyareineffectiveinbipolardepression(12)whileothersstillconsiderthemas(potential)effective,althoughwithasmallriskofswitchingto(hypo)maniaandcycleaccelerationinsomeantidepressants(14;15).Inaddition,someconsiderthemasunsafeastheycancauseaswitchto(hypo)maniaandcycleacceleration(15),whileothersclaimthatthereisnogoodproofforthis(16).Nevertheless,accordingtoanotherSTEP-BDstudyupto60%ofthebipolarpatientsuseantidepressants(12),whileinyetanotherstudytheusageofantidepressantsinbipolardisorderintheU.S.wasfoundevenhigher:79,33%versus63,57%inEurope(17).
Lithium, valproate and carbamazepine
Althoughlithiumhasbeenthegoldenstandardfortreatmentofbipolardisordersformorethan50years,theproofforefficacyinthetreatmentoftheacutebipolardepressionislimited.In1993areviewof9studieswaspublishedwithatotalof163patients(18).Allstudieswere(mostlypartial)cross-overdesignswithmostlyunknownplasmalevelsoflithiumandwithvariousdurationsofthestudiesupto43days.In8outof9studieslithiumwasreportedtobesuperiortoplacebo.However,duetomethodologicallimitations,thereisnorealproofofefficacyinthesestudies.Subsequently,lithiumhasonlybeencomparedinonestudywithplaceboandquetiapine300mgor600mg/day(19).While
121
6
Discussion 121
bothdosesofquetiapineweremoreefficaciousthanplacebo,lithium(n=136,dosebetween600-1800mg/day)wasnotdifferentfromplacebo(n=129).Inconclusion,thereisnoevidencefortheefficacyoflithiumintheacutetreatmentofbipolardepression. Twometa-analysesoffoursmallplacebo-controlledtrialswithvalproateinacutebipolardepression(totaln=142)werepublishedin2010(20;21).Whileinonlyoneoftheseindividualstudiesvalproatewasmoreeffectivethanplacebo,thepooledresultsshowedsuperiorityofvalproateoverplaceboinmeandepressionscoresaswellasinresponserateswithanestimatednumberneededtotreatof5. Carbamazepinewascomparedtoplaceboinonestudy(n=124)withathirdarmwithcarbamazepineincombinationwithaherbalmedicinecalled‘Freeandeasywandererplus’(FEWP)(22).Carbamazepinemonotherapyhadahigherclinicalresponserateatendpointthanplacebo,buttheadditionofFEWPproducedanevenhigherresponseratethancarbamazepinemonotherapy.
Atypical antipsychotics
Thecombinationofolanzapinewithfluoxtinehasbeeninvestigatedin2003byTohen(23).Olanzapinemonotherapywassignificantmoreefficaciousthanplacebobutthecombinationofolanzapinewithfluoxetinewassuperiortoplaceboandtoolanzapinemonotherapy.BasedonthisstudythecombinationbecamethefirstFDAapprovedtreatmentofbipolardepressionintheU.S. Subsequentlyalsoquetiapinehasbeentestedinseveralstudies(13;19;24;25).Inallstudiestherewasarobustdifferencebetweenquetiapineandplaceboinfavorofquetiapine.Nowadaysquetiapinehasbeenapprovedfortheacutetreatmentofbipolardepression(andalsofortheacutetreatmentofmaniaandformaintenancetreatment)intheU.S.andinEurope. Finally,aripiprazolhasbeenstudiedinbipolardepression,butsurprisinglyitwasnotfoundefficaciousincomparisontoplaceboinseveralstudies(7).
122 Chapter 6122
Lamotrigine
Inthisthesiswereportastudyontheefficacyoflamotrigineinthetreatmentofbipolardepression.Whenourstudystartedtheclassicalmoodstabilizerlithiumwasconsideredthegoldstandardinthelong-termtreatmentofbipolardisorderwitha(presumed)strongereffectinthepreventionofmanicepisodesthanofdepressiveepisodes(26).Moreover,theanticonvulsantsvalproateandcarbamazepineappearedtohaveasimilarprofile. Atthesametime,therewassomeevidencethatlamotriginemightbeeffectiveasmonotherapyinthetreatmentofacutebipolardepression(27),whileitalsohadbeenfoundeffectiveaslong-termtreatmentinthepreventionofdepressiveepisodes(28;29).(seealsochapter2)Oneotherstudycomparedlamotrigineandolanzapine/fluoxetine(30):therewasaslightdifferenceinefficacyinfavorofthecombination,butthedrop-outrateduetoadverseeffectswaslowerforlamotrigine.Thisbroughtustothefundamentalideaofourstudy:theadditionoflamotriginetolithiummightprovideabetterefficacyinthetreatmentofacutebipolardepressionandmightprovideagreaterstabilitythereafterduringlong-termfollow-up. Thestudywasdesignedasanadditionstrategycomparablewithtreatmentdecisionsmadeinreallifeclinicalpractice.Weselectedbipolarpatientswhodespitelong-termmaintenancetreatmentwithlithiumhaddevelopedadepressiveepisode.Twodifferenttreatmentalgorithmswerecompared;onetreatmentarmwithadditionoflamotriginetoongoingtreatmentwithlithiumandonetreatmentarmwithadditionofplacebotolithium(phaseI). After8weeksparoxetinewasaddedinnon-respondersinbothgroups(phaseII).Respondersinbothgroupswerefolloweduntilarelapse,arecurrenceoruntilendofstudyat68weeks(phaseIII).
Results Phase I (chapter 3)
Themainfindingofourstudyisagreaterefficacyoftheadditionoflamotriginetolithiumat8weeksthantheadditionofplacebotolithium
123
6
Discussion 123
inpatientswithabipolardepression.Assuch,itisthefirststudytoprovidestatisticalsignificantevidencefortheefficacyoflamotrigineasaddontolithiuminbipolardepressedpatients.Afterfivemonotherapystudieswithonlylimitedpositiveresults,thispositivetrialaddsprovetoanothertreatmentoptioninbipolardepressioninadditiontoquetiapine,olanzapine(especiallyincombinationwithfluoxetine)andtosomeextendtheantidepressants. Thequestionremainswhythistrialhadapositiveoutcomeincontrastwiththepreviousfivemonotherapytrials.Themaindifferencebetweenourstudyandthepreviousstudiesistherelativelowresponserateofplaceboinourstudy(31,7%).Theplaceboresponserateofthefirststudy(whichwaspositiveonsecondaryoutcomecriteria)was29%(27)buttheplaceboresponserateofthefourfollowingstudieswasintherangeof40-50%.(32)Aboutthereasonsforsuchahighplaceboresponsewecanonlyhypothesize.ThepreviousstudieswereallcarriedoutintheU.S.withlotsofpatientswithouthealthinsurance.Forthesepatientseverytreatment,evenanexperimentaltreatment,maybeanimprovementcomparedtoregularcare.Asresponseisoftenrequestedforfurthercontinuationinastudy(andthusreceivingtreatment)theremayalsobeahighpressureonpatientstobecomearesponder.Aseverypatientinourstudyhadaninsurance,suchapressurewasnotthecaseinourpatients,whichmay(inpart?)explainthedifference. Anotherremarkabledifferenceisthemuchlowerdropoutrateinourstudy(17,7%after8weeks)comparedtothepreviousstudies(varyingbetween29%and41%).Apossibleexplanationforthisisthatalmostallourinvestigatorswerealsothetreatingphysiciansofthepatients.This‘personalized’approachmayhaveaddedtothereliabilityandstabilityoftheresults. Afinalreasonmightbethatallourpatientswereusinglithiumandthereforetheywereusedtolaboratorycheckseveryfewmonths.Wehypothesizethatthismayhaveaddedtotreatmentadherencealsofortheothermedications(lamotrigine,placeboandparoxetine)inourstudy.
124 Chapter 6124
Results Phase II (chapter 4)
InphaseIIweadded20mg.paroxetinetoongoingtreatmentwithlithiumandplaceboorlamotrigineinnon-respondersafter8weeks.Althoughbothgroupsimprovedfurtherbetweenweek8and16,thestatisticaldifferencebetweenbothgroupsdisappeared. Thereareafewpossibleexplanationsforthiseffect.FirstthetotalamountofpatientswasfurtherdiminishedduringphaseII.Toremainstatisticalsignificantthedifferenceinoutcomebetweenthetwogroupsshouldhaveincreasedasthenumberofpatientshaddecreased.Giventhetendencyofregressiontothemeanafteralongerperiodoftime,thechanceforsuchanoutcomewassmall. Anotherexplanationisthatithastodowithanantidepressanteffectofparoxetineinthesebipolarpatients.Asthereweremorenon-respondersintheplacebogroupafter8weeks,moreplacebopatientsreceivedparoxetineinphaseII,resultingina‘catchup’ofthenon-respondersintheplacebogroup.However,thisdoesnottakeintoaccountthatpreviousstudieswithparoxetinedidnotfoundparoxetineeffectiveinbipolardepression(11-13).
Results Phase III (chapter 5)
After16weeksallpatientswhowerestillonlithiumwithadditionoflamotrigineorplaceboduringphaseIandwiththepartialadditionofparoxetineinphaseIIandwhohadreachedresponderstatusatweek16,remainedinthestudyandwerefolloweduntilamanicordepressiverelapseoruntiltheendofthestudyat68weeks. Overall68weeksthedifferencebetweenthetreatmentalgorithmwithlamotrigineversusthetreatmentalgorithmwithplaceboappearedtoremainstable.Survivalwithoutrelapseorrecurrencewaslongerforthealgorithmwithlamotriginethanforthealgorithmwithplacebo.Moreover,throughoutthestudytolerabilityingeneralwasgoodasreflectedbyalowdrop-outrateduetoadverseeffectsandtheoveralllowamountofseriousandnon-seriousadverseevents.
125
6
Discussion 125
Design of the study: advantages and disadvantages
Thedesignofourstudyhadadvantagesanddisadvantages.Themainadvantageofthisstudyisthecomparabilitywithclinicalpracticeinwhichmanypatientswithbipolardisorderreceivecombinationtherapyratherthanmonotherapy.Therefore,theresultsappearapplicabletoreallifepatients.Moreover,weconsideradesignwithaplaceboarmduringthefirst8weeks(phaseI)followedbytheadditionofanactivetreatmenttonon-responderstoeithertheinvestigationaldrugorplaceboduringthefollowing8weeks(phaseII),anadvantagefortheparticipatingpatients,resultinginagreaterchancetoobtaininformedconsentfrompatientstoparticipateinatrialinwhichtheyhaveachancetoreceiveplacebo.Nevertheless,inclusionwasaproblemandthenumberof124includedpatientswaslowerthantheoriginallyplanned220patients.Thislimitedthepowerofthestudy. Disadvantages/limitationsofthedesignarethatwedidnotrandomizeagainatweek8(afterphaseI),thatnotallpatientsparticipatedinphaseIIandthatnotallpatientsenteredfollow-upafterweek16(phaseIII)whichseriouslyhamperedthepossibilitiesforformalstatisticaltesting.Therefore,wehadtousedescriptivestatisticsfortheanalysisofthefollow-upperiod. Nevertheless,weconcludethatwehaveprovedthefeasibilityofperformingaplacebo-controlledeffectivenessstudywithmultipleadditionsandalongfollow-up.Inouropinion,thisopensthewaytootheradditiontrials.
Clinical implications
Aspolypharmacyisthemainstayinthetreatmentofbipolardisorder,weconsidertheresultsofourstudyclinicallyimportantasweprovedthattheadditionoflamotriginetolithiumisindeedanoptioninthetreatmentofbipolardepressedpatients:itwasnotonlyfoundeffectiveasacutetreatmentbutalsoappearedtosustainit’sefficacyduringfollowup.Sofartheapprovedarmoryforthetreatmentofbipolardepressionwaslimitedtoquetiapine,olanzapinein
126 Chapter 6126
combinationwithfluoxteineandlamotrigine(forlong-termtreatment).Besideslithium,valproateandantidepressantsmightbeconsideredaspotentialoptions.Whentheresultsofourstudywouldbeconfirmedinfuturestudies,thereshoulddefinitelybeaplaceforlamotrigineintheacutetreatmentofbipolardepression,atleastincombinationwithlithium. Animportantadvantageoflamotrigineisitsbenignadverseeffectprofilewithnoweightgain,sedationormetabolicsyndrome.Theonlyseriousriskisasevererash,butwithcarefuldosingthechanceforsucharashislimitedandextremelyrare.
The long-term efficacy of drugs in the maintenance treatment of bipolar disorder
Inbipolardisordersthefocusshouldalwaysbeonmaintenancetreatment:thepreventionagainstnewepisodesusingmedicationwithapositivebenefit(effectiveness)/risk(adverseeffects)profile. Maybethebiggestprobleminlong-termstudiesistochoosetherightdesign,whichinpracticeisalwaysacompromisebetweenpossibilitiesandimpossibilities.Thereisadelicatebalancebetween‘hardcore’randomizedplacebo-controlledefficacytrialswithhighlyselectedpatients,and‘realpractice’effectivenesstrialswithadesignwhichfocusesmoreongeneralizability.Itisquestionablewhethertheusualstandardforefficacystudies(therandomizedplacebo-controlledmonotherapytrial)isthebestwaytofindnewstrategiesforthelong-termtreatmentofbipolardisorder. Forregistrationpurposes,double-blindplacebo-controlledefficacytrialsarerequestedbytheauthorities.ThemainideabehindRCT’sistomakeequalandcomparablegroupsallowingacomparisonbetweentheinvestigatedcompoundandplacebo(orothercontroltreatments),whichisessentialinefficacystudies.Inacutetreatmentstudies(ofmaniaordepression)patientsaredirectlyrandomizedtostartwiththeinvestigationaldrugorplacebo(withthepossibilityofathirdarmwithadrugwithprovenefficacy,thesocalledstandardtreatment). Forlong-termtrialstherearehoweverafewdesignoptionswith
127
6
Discussion 127
advantagesanddisadvantages.Mostlong-termstudiesuseso-calledenricheddesigns(35).Inthesestudiesallpatientsstartopenlabelwiththeinvestigationaldrug,forinstanceastreatmentofanacutemanicordepressiveepisode.Thereafter,responderstotreatmentarerandomizedtocontinuationoftheinvestigationaldrugortoswitchtoplacebo(againwiththepossibilityofathirdarmwithadrugwithprovenefficacy,thesocalledstandardtreatment).Goodexamplesofthisarethetwolong-termlamotriginestudies(28;29)inwhichmanicordepressedpatientsfirstreceivedopenlabeltreatmentwithlamotrigine.Responderstolamotriginewererandomizedtocontinuewithlamotrigineortoswitchtoplaceboortolithium(thestandardtreatment).Thisenricheddesignalsohasitslimitations.Itfavorstheinvestigationaldrug(intheexamplelamotrigine)overthestandardcomparisondrug(intheexamplelithium)asonlyresponderswhoalsotoleratedtheinvestigationaldrugentertherandomizedphase. AnexampleofanotherdesignistheBALANCEstudy(36).Inthisstudycomparingtheprophylacticeffectoflithium,valproateendthecombinationofboth,patientsenteredthestudyduringanepisodefowhichtheyweretreatedwiththecombinationofbothdrugs.Stabilizedpatientswererandomizedtocontinuetreatmentwitheitherlithium(monotherapy),valproate(monotherapy)ortocontinuewiththecombinationofboth.Thisisalsoanenricheddesignwithaselectiononresponseandtolerancetolithiumandvalproate,butwithoutfavoringoneofthecompounds. AthirdexampleofmaintenancetrialsisreflectedbythreestudiesbyGreiletal(37),Hartongetal.(38)andLichtetal.(39)Inthesestudieslithiumwascomparedtocarbamazepine(Greil/Hartong)orvalproate(Licht).Patientsenteredthestudyduringorafteranacutemanicordepressedepisodethatwastreatedwithmedicationsotherthantheinvestigationaldrugs(lithiumandcarbamazepineorvalproate).Afterrecoveryfromtheepisodepatientswererandomizedtothestudydrugsandsimultaneouslytheotherdrugsweretaperedoff.Subsequentlypatientswerefolloweduntiltherecurrenceofanewepisodeoruntilendoffollow-up. Inourstudyweusedanextensiondesignwithextendedblindfollow-upafterashort-termdouble-blindrandomizedtrial(phaseI)inwhichpatients
128 Chapter 6128
receivedadditionofeitherlamotrigineorplacebo.Aftertheacutetrial(phaseIandphaseII)wefollowedtherespondersupto68weekswithoutnewrandomizationafterrecovery,butwithkeepingthetreatments(lamotrigineofplacebo)blindedthroughoutfollow-up.Assuch,ourstudydoesnotprovethatlamotriginehasaprophylacticeffect.Forthatpurposeweshouldhavere-randomizedallresponderstolamotrigineafterphaseItocontinuedouble-blindwithlamotrigineortoswitchtoplacebo(asinthefirstexampleabovewiththeenricheddesign).Besidesthatwedidnotaimforthatgoal,wealsohadtoofewpatientsforsuchastudy.Forrandomizingtwiceduringonestudy,manymorepatientsshouldhavebeenrequired.Moreover,itcanleadtoanoverpoweredfirstpartofthestudyoranunderpoweredsecondpartofthestudy(andnottomentiontheextraproblemswiththeadditionofparoxetineinnon-respondersafter8weeks).Therefore,wechooseforanaturalistic,blindfollow-upinresponders.
Limitation of the add-on design
Alimitationofourstudyisthatweonlygatheredinformationonaddingnewmedication(s).Wehavenoinformationonhowtocontinuetreatment.Wouldithavebeenpossibletotaperofflithiumorlamotrigine,andwhattodowithparoxetine?Thisproblemisuntilnowanalmostunmetneed.Moststudiessofararedesignedtogatherinformationonshort-andlong-termefficacyandtolerabilityofstartingnewcompoundsandcombinations,buthardlyonhowtheymightbestopped.Thisisprobablypartlyrelatedtothefactthatsponsoringofatrialinvestigatingstoppingofmedicationisnotinterestingforpharmaceuticalcompanies.Moreover,thelong-termmaintenancestudies(withenricheddesigns)aresetuptoproofefficacy(andtolerability)butnottofindoutwhichpatientsareinneedoflong-termtreatmentandwhichpatientsarenot.Medicationsareoftenaddedtotheineffective(oronlypartiallyeffective)treatment,withoutknowingwhetheritwouldalsohavebeenanoptiontoswitchfromthe(partially)ineffectivetreatmenttoanotherdrug.I.e.woulditalsobepossibletostopthefirstdrug(inourstudylithium)insteadofaddingnewmedicationtothefirstdrug.
129
6
Discussion 129
Patientscanbereluctanttostopmedicationorcombinationsofmedications.Atleastsomepatientswanttocontinuemedicationiftheybelievethatthesedrugskeptthemstableoveralongtime.Thisisunderpinnedbyanintendedstudyinwhichbipolardepressedresponderstotheadditionofanantidepressant(toongoingtreatmentwithmoodstabilizers)(40)wereaskedtoconsenttoberandomizedtodouble-blindcontinuingorstoppingoftheaddedantidepressant.Itprovedalmostimpossibletofindpatientswhoacceptedtoberandomizedafterasuccessfullytreateddepressiveepisode.Somepatientsonlywantedtokeeptheirmedication,buttherewerealsopatientswhowerereluctanttocontinuetheirmedication,forinstancebecauseofadverseeffects,orbecausetheywereill-affectedtotake(toomany)drugs.Finallythestudywascompletedbycomparingtwonon-randomizedgroupsofpatientswhothemselveshaddecidedtostoptheantidepressantortocontinuetheantidepressantwithquestionableresults. Theonlyrandomizeddiscontinuationtrialwithantidepressantsinbipolardepression(41)showednosignificantbenefitfromcontinuingantidepressantsinthelong-termtreatmentofbipolarpatientsontheprimaryoutcome(meanchangeonthedepressivesubscaleoftheCMF).Onlytimetoafirstnewdepressiveepisodewassignificantlylongerforthegroupthatcontinuedwiththeantidepressant.However,alsotheseresultsarequestionable,giverthefactthatthiswasafollow-upstudyoftheSTEP-BDtrialwithallit’smethodologicallimitationsdescribedabove.
Conclusion
Inourstudytheadditionoflamotriginetoongoingtreatmentwithlithiumwasmoreeffectivethantheadditionofplacebointhetreatmentofacutebipolardepression.Moreover,wefoundafterfurthercontinuationoftreatment,thatlamotrigineappearedtomaintainitseffect.Duetothefactthatwedidnotre-randomizepatientsafterthefirst8(or16)weeksoftreatment,theresultsofthefollow-upphasecannotbeconsideredasevidenceforthelong-termeffectivenessoflamotrigine.However,thereissuchevidencefromtwootherstudies,inwhich
130 Chapter 6130
responderstolamotriginewererandomizedtocontinuewithlamotrigineortoswitchtoplacebo(orlithium)(28;29). Furtherresearchonthetreatmentofbipolardepressionshouldbedirectedtofind(other)long-termtreatment(s)withmaximumeffectivenessandwithminimaladverseeffects.Inaddition,futureresearchshouldnotonlybedirectedtotheeffectivenessandsafetyofstartingmedication(s)butalsototherisksandbenefitsofstoppingmedication(s).Moreover,theoptimalbalancebetweenefficacyandadverseeffectsisdifferentforeachindividualandthereforeachallengetothecooperationbetweendoctorandpatient.Psychoeducationisnotamatterofconvincingpatientstoacceptadverseeffects,itismoreaquesttofindtherightmedicationorcombinationofmedicationsfitfortheindividualpatientwithoptimalfunctioninginallaspectsofhumanlife.
131
6
Discussion 131
References
1. RegeerEJ,tenHM,RossoML,Hakkaart-vanRL,VolleberghW,NolenWA.Prevalenceofbipolardisorderinthegeneralpopulation:aReappraisalStudyoftheNetherlandsMentalHealthSurveyandIncidenceStudy.ActaPsychiatrScand2004Nov;110(5):374-82.
2. JuddLL,AkiskalHS,SchettlerPJ,CoryellW,EndicottJ,MaserJD,etal.Aprospectiveinvestigationofthenaturalhistoryofthelong-termweeklysymptomaticstatusofbipolarIIdisorder.ArchGenPsychiatry2003Mar;60(3):261-9.
3. JuddLL,AkiskalHS,SchettlerPJ,EndicottJ,MaserJ,SolomonDA,etal.Thelong-termnaturalhistoryoftheweeklysymptomaticstatusofbipolarIdisorder.ArchGenPsychiatry2002Jun;59(6):530-7.
4. KupkaRW,AltshulerLL,NolenWA,SuppesT,LuckenbaughDA,LeverichGS,etal.ThreetimesmoredepressionthanmaniainbothbipolarIandbipolarIIdisorder.Bipolardisorders2007;9:531-535.
5. VietaE.Antidepressantsinbipolardepression.ActaPsychiatrScand2008Nov;118(5):335-6.
6. GijsmanHJ,GeddesJR,RendellJM,NolenWA,GoodwinGM.Antidepressantsforbipolardepression:asystematicreviewofrandomized,controlledtrials.AmJPsychiatry2004Sep;161(9):1537-47.
7. VietaE,LocklearJ,GuntherO,EkmanM,MiltenburgerC,ChattertonML,etal.Treatmentoptionsforbipolardepression:asystematicreviewofrandomized,controlledtrials.JClinPsychopharmacol2010Oct;30(5):579-90.
8. MendlewiczJ,YoudimMB.Antidepressantpotentiationof5-hydroxytryptophanbyL-deprenilinaffectiveillness.JAffectDisord1980Jun;2(2):137-46.
9. HimmelhochJM,FuchsCZ,SymonsBJ.Adouble-blindstudyoftranylcyprominetreatmentofmajoranergicdepression.JNervMentDis1982Oct;170(10):628-34.
10.CohnJB,CollinsG,AshbrookE,WernickeJF.Acomparisonoffluoxetineimipramineandplaceboinpatientswithbipolardepressivedisorder.IntClinPsychopharmacol1989Oct;4(4):313-22.
11.NemeroffCB,EvansDL,GyulaiL,SachsGS,BowdenCL,GergelIP,etal.Double-
132 Chapter 6132
blind,placebo-controlledcomparisonofimipramineandparoxetineinthetreatmentofbipolardepression.AmJPsychiatry2001Jun;158(6):906-12.
12. SachsGS,NierenbergAA,CalabreseJR,MarangellLB,WisniewskiSR,GyulaiL,etal.Effectivenessofadjunctiveantidepressanttreatmentforbipolardepression.NEnglJMed2007Apr26;356(17):1711-22.
13.McElroySL,WeislerRH,ChangW,OlaussonB,PaulssonB,BrecherM,etal.Adouble-blind,placebo-controlledstudyofquetiapineandparoxetineasmonotherapyinadultswithbipolardepression(EMBOLDENII).JClinPsychiatry2010Feb;71(2):163-74.
14. PostRM,AltshulerLL,LeverichGS,FryeMA,NolenWA,KupkaRW,etal.Moodswitchinbipolardepression:comparisonofadjunctivevenlafaxine,bupropionandsertraline.BrJPsychiatry2006Aug;189:124-31.
15. LeverichGS,AltshulerLL,FryeMA,SuppesT,McElroySL,KeckPE,Jr.,etal.Riskofswitchinmoodpolaritytohypomaniaormaniainpatientswithbipolardepressionduringacuteandcontinuationtrialsofvenlafaxine,sertraline,andbupropionasadjunctstomoodstabilizers.AmJPsychiatry2006Feb;163(2):232-9.
16. LichtRW,GijsmanH,NolenWA,AngstJ.Areantidepressantssafeinthetreatmentofbipolardepression?Acriticalevaluationoftheirpotentialrisktoinduceswitchintomaniaorcycleacceleration.ActaPsychiatrScand2008Nov;118(5):337-46.
17. PostRM,LeverichGS,AltshulerLL,FryeMA,SuppesT,KeckPE,etal.Differentialclinicalcharacteristics,medicationusage,andtreatmentresponseofbipolardisorderintheUSversusTheNetherlandsandGermany.IntClinPsychopharmacol2011Mar;26(2):96-106.
18. ZornbergGL,PopeHG,Jr.Treatmentofdepressioninbipolardisorder:newdirectionsforresearch.JClinPsychopharmacol1993Dec;13(6):397-408.
19. YoungAH,McElroySL,BauerM,PhilipsN,ChangW,OlaussonB,etal.Adouble-blind,placebo-controlledstudyofquetiapineandlithiummonotherapyinadultsintheacutephaseofbipolardepression(EMBOLDENI).JClinPsychiatry2010Feb;71(2):150-62.
20. BondDJ,LamRW,YathamLN.Divalproexsodiumversusplacebointhetreatmentofacutebipolardepression:asystematicreviewandmeta-analysis.JAffectDisord2010Aug;124(3):228-34.
133
6
Discussion 133
21. SmithLA,CorneliusVR,AzorinJM,PerugiG,VietaE,YoungAH,etal.Valproateforthetreatmentofacutebipolardepression:systematicreviewandmeta-analysis.JAffectDisord2010Apr;122(1-2):1-9.
22. ZhangZJ,KangWH,TanQR,LiQ,GaoCG,ZhangFG,etal.Adjunctiveherbalmedicinewithcarbamazepineforbipolardisorders:Adouble-blind,randomized,placebo-controlledstudy.JPsychiatrRes2007Apr;41(3-4):360-9.
23. TohenM,VietaE,CalabreseJ,KetterTA,SachsG,BowdenC,etal.Efficacyofolanzapineandolanzapine-fluoxetinecombinationinthetreatmentofbipolarIdepression.ArchGenPsychiatry2003Nov;60(11):1079-88.
24.CalabreseJR,KeckPE,Jr.,MacfaddenW,MinkwitzM,KetterTA,WeislerRH,etal.ARandomized,Double-Blind,Placebo-ControlledTrialofQuetiapineintheTreatmentofBipolarIorIIDepression.AmJPsychiatry2005Jul;162(7):1351-60.
25. ThaseME,MacfaddenW,WeislerRH,ChangW,PaulssonB,KhanA,etal.EfficacyofquetiapinemonotherapyinbipolarIandIIdepression:adouble-blind,placebo-controlledstudy(theBOLDERIIstudy).JClinPsychopharmacol2006Dec;26(6):600-9.
26.GeddesJR,BurgessS,HawtonK,JamisonK,GoodwinGM.Long-termlithiumtherapyforbipolardisorder:systematicreviewandmeta-analysisofrandomizedcontrolledtrials.AmJPsychiatry2004Feb;161(2):217-22.
27.CalabreseJR,BowdenCL,SachsGS,AscherJA,MonaghanE,RuddGD.Adouble-blindplacebo-controlledstudyoflamotriginemonotherapyinoutpatientswithbipolarIdepression.Lamictal602StudyGroup.JClinPsychiatry1999Feb;60(2):79-88.
28. BowdenCL,CalabreseJR,SachsG,YathamLN,AsgharSA,HomplandM,etal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlymanicorhypomanicpatientswithbipolarIdisorder.ArchGenPsychiatry2003Apr;60(4):392-400.
29.CalabreseJR,BowdenCL,SachsG,YathamLN,BehnkeK,MehtonenOP,etal.Aplacebo-controlled18-monthtrialoflamotrigineandlithiummaintenancetreatmentinrecentlydepressedpatientswithbipolarIdisorder.JClinPsychiatry2003Sep;64(9):1013-24.
30. BrownE.,KeckP.E.,DeldarA.,AdamsD.H.,WilliamsonD.J.Olanzapine/FluoxetineCombinationversusLamotrigineinthetreatmentofBipolarIDepression.2005.
134 Chapter 6134
31. vanderLoosML,MulderPG,HartongEG,BlomMB,VergouwenAC,deKeyzer
HJ,etal.Efficacyandsafetyoflamotrigineasadd-ontreatmenttolithiuminbipolar
depression:amulticenter,double-blind,placebo-controlledtrial.JClinPsychiatry
2009Feb;70(2):223-31.
32.CalabreseJR,HuffmanRF,WhiteRL,EdwardsS,ThompsonTR,AscherJA,etal.
Lamotrigineintheacutetreatmentofbipolardepression:resultsoffivedouble-blind,
placebo-controlledclinicaltrials.BipolarDisord2008Mar;10(2):323-33.
33. vanderLoosML,MulderP,HartongEG,BlomMB,VergouwenAC,vanNoorden
MS,etal.Efficacyandsafetyoftwotreatmentalgorithmsinbipolardepression
consistingofacombinationoflithium,lamotrigineorplaceboandparoxetine.Acta
PsychiatrScand2010Sep;122(3):246-54.
34. vanderLoosML,MulderP,HartongEG,BlomMB,VergouwenAC,vanNoorden
MS,etal.Long-termoutcomeofbipolardepressedpatientsreceivinglamotrigineas
add-ontolithiumwiththepossibilityoftheadditionofparoxetineinnonresponders:
arandomized,placebo-controlledtrialwithanoveldesign.BipolarDisord2011
Feb;13(1):111-7.
35. ZimmermanM,PosternakMA,RuggeroCJ.Impactofstudydesignontheresultsofcontinuationstudiesofantidepressants.JClinPsychopharmacol2007Apr;27(2):177-81.
36.GeddesJR,GoodwinGM,RendellJ,AzorinJM,CiprianiA,OstacherMJ,etal.LithiumplusvalproatecombinationtherapyversusmonotherapyforrelapsepreventioninbipolarIdisorder(BALANCE):arandomisedopen-labeltrial.Lancet2010Jan30;375(9712):385-95.
37.GreilW,Ludwig-MayerhoferW,ErazoN,SchochlinC,SchmidtS,EngelRR,etal.Lithiumversuscarbamazepineinthemaintenancetreatmentofbipolardisorders--arandomisedstudy.JAffectDisord1997Apr;43(2):151-61.
38.HartongEG,MolemanP,HoogduinCA,BroekmanTG,NolenWA.Prophylacticefficacyoflithiumversuscarbamazepineintreatment-naivebipolarpatients.JClinPsychiatry2003Feb;64(2):144-51.
135
6
Discussion 135
39. LichtRW,NielsenJN,GramLF,VestergaardP,BendzH.LamotrigineversuslithiumasmaintenancetreatmentinbipolarIdisorder:anopen,randomizedeffectivenessstudymimickingclinicalpractice.The6trialoftheDanishUniversityAntidepressantGroup(DUAG-6).BipolarDisord2010Aug;12(5):483-93.
40. PostRM,LeverichGS,NolenWA,KupkaRW,AltshulerLL,FryeMA,etal.Are-evaluationoftheroleofantidepressantsinthetreatmentofbipolardepression:datafromtheStanleyFoundationBipolarNetwork.BipolarDisord2003Dec;5(6):396-406.
41.GhaemiSN,OstacherMM,El-MallakhRS,BorrelliD,BaldassanoCF,KelleyME,etal.Antidepressantdiscontinuationinbipolardepression:aSystematicTreatmentEnhancementProgramforBipolarDisorder(STEP-BD)randomizedclinicaltrialoflong-termeffectivenessandsafety.JClinPsychiatry2010Apr;71(4):372-80.
136
137
Summary
138138
Design of the study
Inthisthesiswedescribeaninvestigator(W.A.Nolen)initiateddouble-blindrandomizedplacebo-controlledtrial(RCT)comparingtwodifferenttreatmentalgorithmswithafollow-upuntilamaximumof68weeks. Inbipolaroutpatients(menorwomenagedatleast18years),withadepressiondespitelong-termtreatmentwithlithium(atserumlevelsof0.6-1.2mmol/l)lamotrigineorplacebowasaddedtoongoingtreatmentwithlithium.Innon-respondersafter8weeksparoxetinewasopen-labeladdedtoongoingtreatmentwithlithiumpluslamotrigineorplacebo.Respondersafter8or16weekswerefolloweduntilarelapseorrecurrenceoruntilthemaximumdurationofthestudy;68weeks(fig1).
Figure 1. Designofthestudy
ThestudywasapprovedbytheethicalreviewboardoftheUniversityMedicalCenterUtrecht,theNetherlandsandbylocalinstitutionalreviewboardsintheNetherlandsandinSpain.Allpatientsgavewritteninformedconsent.
Lithium+Lamotrigine+Paroxetineinnon-reponders
Lithium
Lithium
Lithium
+Lamotrigine
+Placebo
Phase 1 Phase 2 Follow-up of respondersPhase 3
Lithium+Placebo+Paroxetineinnon-responders
Week 0 8 16 68
Responders
139Summary 139
Results
Figure 2.Flowchartofthestudy
124Patientswererandomised,112intheNetherlandsand12inSpain.
Phase 1: week 1-8 (chapter 3) Ofthe64patientswhostartedinthelamotriginegroup(fig2),52patients(81%)completedthefirst8weeksversus50(83%)ofthe60patientsintheplacebogroup.Ontheprimaryoutcomemeasure(changeinMADRSscorefrombaselinetoweek8;-15.38vs.-11.03respectively;P=0.024)aswellasonsomesecondaryoutcomemeasureslamotriginewassignificantlymoreefficaciousthanplacebo(fig3).
Randomized:124
Pluslamotrigine:64 Plusplacebo:60
Completed:52 Completed:50
Drop-outs:10Drop-outs:12
Nonresponders:15 Nonresponders:22Responders:37 Responders:28
Drop-outs:6
Drop-out:1
Drop-out:1
Drop-out:3
Drop-out:3
Drop-outs:3 Drop-outs:2
Drop-outs:2
Drop-out:1
Drop-outs:4
Drop-outs:4
Drop-outs:2
Plusparoxetine:9 Plusparoxetine:18Continued:34 Continued:26
Completed:8
Responders:5 Responders:8Remainedresponders:29
Remainedresponders:20
Completed:31 Completed:24 Completed:14
Startfollow-up:30 Startfollow-up:25Phase3
Phas
e2
Phas
e1
140140
Figure 3. SeverityofdepressionaccordingtothemeanMADRSscoreateachvisitforpatientsonplaceboandlamotrigine
Phase 2: week 9-16 (chapter 4) After8weeksresponderstothelithium-lamotrigineandthelithium-placebocombinationcontinuedthestudywithlithiumand(stilldouble-blind)lamotrigineorplacebo,whileopen-labelparoxetinewasaddedinnon-responders.Althoughbothgroupsimprovedfurther,thedifferenceafter16weeksbetweenlithiumpluslamotrigine(plusparoxetineinnon-responders)versuslithiumplusplacebo(plusparoxetineinnonresponders)wasnotstatisticallysignificantanymore(changeinMADRSscorefrombaselinetoweek16-17.91versus-15.40respectively;p=0.253).Othersecondaryoutcomecriteriaalsodidnotrevealsignificantdifferencesatweek16(fig4).
*p=.031**p=.006
30
25
20
15
10
5
0Baseline Wk2 Wk4 Wk6 Wk8
PlaceboLamotrigine
***
MA
DRS
Sco
re,m
ean
141Summary 141
Figure 4. SeverityofdepressionaccordingtothemeanMADRSscoreateachvisitforpatientsonplaceboandlamotrigine(plusadditionofparoxetineinnon-respondersatweek8)
Phase 3: week 17-68 (chapter 5) Duringfollow-uprespondersafter8or16weeksweremaintainedonstudymedicationsuntilamanicordepressiveepisodeoruntilthemaximumdurationofthestudy,i.e.untilweek68.Descriptivestatisticsshowedthatthedifference(aspercentageofrespondersoftheinitialgroup)betweenthelamotriginegroupversustheplacebogroupremainedstablethroughoutthefollow-upperiod(fig5and6).
***
*** P<0.05**P<0.01 Additionofparoxetine
Weeks
Mea
nM
AD
RSs
core
0 2 4 6 8 10 12 14 16
5
10
15
20
25
30
PlaceboLamotrigine
142142
Figure 5. Responders(CGI-BPimprovementofdepressionscoreof1or2)aspercentageoftheinitialgroup(n=124,lamotriginen=64,placebon=60)throughoutallthreephasesofthestudy
Alsotimefromfirstresponse(score<50%ofMADRSscoreatbaseline)torecurrence(score≥50%ofinitialMADRS)showedasimilarpatterninfavourofthelamotriginegroup. Themediansurvivaltimeforrespondersofthelamotriginegroupwas10.0months(95%CI:1.1-18.8)versus3.5months(CI:0.7–7.0)fortherespondersintheplacebogroup.
Weeks
Perc
enta
gere
spon
ders
30
40
50
60
70
80
90
100
20
10
0
PlaceboLamotrigine
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
143Summary 143
Figure 6. Probabilityofmaintainingresponse(score<50%ofMADRSscoreatbaseline;n=79;lamotrigine:n=41;placebo:n=38)withoutrecurrence(score≥50%ofinitialMADRS)sincehavingachievedresponderstatusduringphase1orphase2
Safety and Adverse Events
Duringthe68weeksofthestudytherewere20SeriousAdverseEvents(SAE),15duringthefirst16weeksand5thereafter.10patientsinthelamotriginegroup(2patientshad2SAEs)groupversus8patientsintheplacebogroupexperiencedaSAE.MostSAEsconcernedseriousmoodswingsascouldbeexpectedinatrialwith124bipolarpatients.Statisticallytherewerenodifferencesbetweenlamotrigineandplacebo.Theonlystatisticaldifferencebetweenlamotrigineandplaceboinadverseeventswastremorat16weekswhichoccurredmoreofteninthelamotriginegroupversustheplacebogroup.So,wecanconcludethattheadditionoflamotriginetolithium(withfurtheradditionofparoxetineinnon-responders)wassafeandhadanadverseeventsprofilecomparabletotheadditionofplacebotolithium.
Months
Prob
abili
tyo
fno
recu
rrenc
e
30
40
50
60
70
80
90
100
20
10
0
PlaceboLamotrigine
0 3 6 9 12 15 18
144144
Conclusions
Afterthisstudyseveralconclusionsconsideringthetreatmentandfutureresearchofpatientswithabipolardepressioncanbedrawn.
1. Theadditionoflamotriginetolithiuminpatientswithbipolardepressionisefficaciousandoverallwelltolerated.
2. Afterthefurtheradditionofparoxetineinnon-responderstothecombinationoflithiumpluslamotrigineorplacebothestatisticalsignificancebetweenthetreatmentarmwithlamotriginegroupandthetreatmentarmwithplacebogroupdisappearedwithongoingimprovementinbothgroups.However,thetreatmentarmwithlamotrigineremainednumericallymoreeffective,alsoduringfollow-upuptooneyear.
3. Thesefindingsindicatethatlamotrigine-inadditiontoitsuseinthelong-termpreventionofdepressiveepisodes-alsodeservesaplaceintheacutetreatmentofbipolardepression.
4. Thegapbetweenscientificresearchwithrandomizedplacebo-controlledtrialsandclinicalpracticecanbebridgedbydesigningstudiescomparingcombinationsofmedications.
145Summary 145
146146
147
Samenvatting
148148
Design van de studie
InditproefschriftbeschrijvenwijeendoorW.A.Nolengeinitialiseerddubbelblindplacebogecontroleerdonderzoekwaarintweebehandelingalgoritmesvergelekenwerdenmeteenvervolgtoteenmaximumvan68weken.Bijbipolairedepressievepatiënten(manofvrouw,ouderdan18jaar)meteenbipolairedepressieondankslangdurigebehandelingmetlithium(bloedspiegels0.6-1.2mmol/lwerdlamotrigineofplacebotoegevoegd. Naachtwekenkregennon-respondersinbeidegroepen(lithium+lamotrigineoflithium+placebo)‘openlabel’paroxetine(20mg)extratoegevoegd.Respondersna8of16wekenwerdengevolgdtoteenterugvalineendepressieveof(hypo)manischeepisodeoftotheteindvandestudiena68weken.
Figuur 1. Ontwerpvandestudie
VoorafgaandaandestudiewastoestemmingverleenddoordemedischethischetoetsingscommissievanhetUMCUtrechtendoorde
Lithium+Lamotrigine+Paroxetineinnon-reponders
Lithium
Lithium
Lithium
+Lamotrigine
+Placebo
Fase 1 Fase 2 Follow-up of respondersFase 3
Lithium+Placebo+Paroxetineinnon-responders
Week 0 8 16 68
Responders
149Samenvatting 149
lokaletoetsingscommissiesinNederlandeninSpanje.Allepatiëntengavenvoorafgaandaandestudie‘informedconsent’.
Results
Figuur 2. ‘FlowChart’vandestudie
124patiëntenwerdengerandomiseerd,112inNederlanden12inSpanje.
Fase I: week 1-8 (hoofdstuk 3) 52vande64patiënten(81%)indelamotriginegroepdieindestudiestarttenvoltooidendeeerste8wekenvanhetonderzoekversus50vande60patiënten(83%)indeplacebogroep(fig2).Opdeprimaireuitkomstmaat;de
Randomized:124
Pluslamotrigine:64 Plusplacebo:60
Completed:52 Completed:50
Drop-outs:10Drop-outs:12
Nonresponders:15 Nonresponders:22Responders:37 Responders:28
Drop-outs:6
Drop-out:1
Drop-out:1
Drop-out:3
Drop-out:3
Drop-outs:3 Drop-outs:2
Drop-outs:2
Drop-out:1
Drop-outs:4
Drop-outs:4
Drop-outs:2
Plusparoxetine:9 Plusparoxetine:18Continued:34 Continued:26
Completed:8
Responders:5 Responders:8Remainedresponders:29
Remainedresponders:20
Completed:31 Completed:24 Completed:14
Startfollow-up:30 Startfollow-up:25Phase3
Phas
e2
Phas
e1
150150
veranderinggemetenvan‘baseline’totenmetweek8opdeMontgomery-ÅsbergDepressionRatingScale(MADRS)(enopsommigesecundaireuitkomstmaten)bleekdetoevoegingvanlamotrigineaanlithiumstatistischsignificant(-15,38versus-11.03p=0.024)effectieverdandetoevoegingvanplaceboaanlithium(fig3).
Figuur 3.ErnstvandedepressiegemetenalsgemiddeldeMADRSscoretijdenselkevisitevoorpatiëntenoplamotrigineenplacebo
Fase II: week 9-16 (hoofdstuk 4) Na8wekenvervolgdenrespondersopzoweldelithiumlamotriginecombinatiealsderespondersopdelithiumplacebocombinatiedestudiemetdezelfde(nogsteedsdubbelblinde)medicatie.Bijnon-respondersinbeidegroepenwerd‘openlabel’20mgparoxetinetoegevoegd. Beidegroepenverbeterdenverder,maarhetverschiltussendegroepmetlithium+lamotrigine+paroxetine(vanaf8wekeninnon-responders)versusdegroepmetlithium+placebo+paroxetine(vanaf8wekeninnon-responders)wasnietlangerstatistischsignificant(-17.91versus-15.40p=0.253)(fig4).Ookanderesecundaireuitkomstmatenwarennietstatistischsignificant.
*p=.031**p=.006
30
25
20
15
10
5
0Baseline Wk2 Wk4 Wk6 Wk8
PlaceboLamotrigine
***
MA
DRS
Sco
re,g
emid
deld
151Samenvatting 151
Figuur 4. ErnstvandedepressievolgensdeMADRSopelkebezoekvoorpatiëntenmetlamotrigineenplacebotoevoegingaanlithium(plusadditievanparoxetinena8wekenbijnon-respons)
Fase III: week 17-68 (hoofdstuk 5) Respondersna8of16wekenwerdenverdergevolgdmetbehoudvandezelfde(deelsdubbelblinde)medicatietoteennieuwedepressieveof(hypo)manischeepisodeoftotheteindvandestudiena68weken.Uitbeschrijvendestatistiekbleekdathetverschiltussendelamotriginegroependeplacebogroep(gemetenalspercentagerespondersvande2oorspronkelijkegroepen)stabielbleefgedurendede‘follow-up’(fig5en6).
***
*** P<0.05**P<0.01 Plusadditievanparoxetine
Weken
Gem
idde
lde
MA
DRS
sco
re
0 2 4 6 8 10 12 14 16
5
10
15
20
25
30
PlaceboLamotrigine
152152
Figuur 5. Responders(volgensdeCGI-BPverbeteringdepressiescore1of2)alspercentagevandeoorspronkelijkegroep(n=124,n=64voorlamotrigineenn=60voorplacebo)gedurendealledriedefasesvandestudie
Ookdetijdvanafdeeerstekeerdateenpatiëntresponderswas(MADRSscore<50%vandeinitiëlescore)totterugval(MADRSscore≥50%vandeinitiëlescore)liethetzelfdepatroonzien.Degemiddeldetijdalsrespondervoordelamotriginegroepwas10.0maanden(95%CI:1.1-18.8)versus3.5maanden(95%CI0.7-7.0)voorderespondersindeplacebogroep.
Weken
Perc
enta
gere
spon
ders
30
40
50
60
70
80
90
100
20
10
0
PlaceboLamotrigine
0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68
153Samenvatting 153
Figuur 6. Kansomresponderteblijven(score<50%ofMADRSscoreopbaseline;n=79;lamotrigine:n=41;placebo:n=38)zonderterugval(score≥50%vandeoorspronkelijkeMADRS)nadatmenrespondergewordenisgedurendefase1offase2
Veiligheid en bijwerkingen
Gedurendede68wekenvandezestudiewarener20SAE’s(SeriousAdverseEvents),15gedurendedeeerste16wekenen5daarna.10patiëntenindelamotriginegroep(2patiëntenhadden2SAE’s)versus8patiëntenindeplacebogroepkregeneenSAE.DemeesteSAE’swarenheftigestemmingswisselingen.Ditwasnietonverwachtineengroepvan124bipolairepatiënten.Overdegeheleperiodewaseralleenna16wekenvoorwatbetreft.tremoreenstatistischverschiltussenlamotrigineenplacebotengunstevanplacebo.Voorderestwasergeenenkelstatistischsignificantverschiltussenlamotrigineenplacebooverdegehelestudie. Concluderendkunnenwestellendatdetoevoegingvanlamotrigineaanlithium(metdaarnadetoevoegingvanparoxetinebijnon-respons)veiligwasen
Maanden
Waa
rsch
ijnlij
khei
dva
nte
rugv
al
30
40
50
60
70
80
90
100
20
10
0
PlaceboLamotrigine
0 3 6 9 12 15 18
154154
datdebijwerkingenvandetoevoegingvanlamotrigineaanlithiumvergelijkbaarwarenmetdetoevoegingvanplaceboaanlithium.
Conclusies
Nadezestudiekunnenweeenaantalconclusiestrekkenoverdebehandelingentoekomstigonderzoekbijpatiëntenmeteenbipolairestoornisgedurendeeendepressievefase.
1. Detoevoegingvanlamotrigineaanlithiumbijpatiëntenmeteenbipolairestoornisgedurendeeendepressievefaseiseffectiefenveilig.
2. Nadetoevoegingvanparoxetineop8wekenbijnon-respondersverdweenhetstatistischsignificanteverschiltussendebehandelingmetlamotrigineenlithiumversusdebehandelingmetplaceboenlithium.Beidegroepenverbeterdennogwelverdertussende8en16weken.Ooktijdenshetvervolgtot68wekenbleefdebehandelarmmetlamotrigineinaantaleffectieverdandebehandelarmmetplacebo.
3. Dezeresultatenlatenziendatlamotrigine-intoevoegingaanhetgebruikvoordepreventieopdelangetermijnvannieuwedepressieveepisoden-ookeenplaatsverdientindeacutebehandelingvandebipolairedepressie.
4. Deklooftussenwetenschappelijkonderzoekendedagelijksebehandelpraktijkkanoverbrugdwordendoorhetontwerpenvanstudiesdiekijkennaarcombinatiesvanmedicatie.
155Samenvatting 155
156156
157
Curriculum VitaeM.L.M. van der Loos
158158
Curriculum Vitae
MarcvanderLooswerdop10maart1958geboreninAmsterdam.NadeafrondingvanhetVWOstarttehijaandeAmsterdamseAcademievoorLichamelijkOefeningdeopleidingtotgymnastiekleraar.AansluitendstudeerdehijgeneeskundeaandeUniversiteitvanAmsterdam. IndezelfdeperiodewerktehijalsslowmotionredacteurenlateralsregisseurbijNOSStudioSport. DespecialisatiepsychiatriewerdgevolgdbijhetHaags-LeidsOpleidingsConsortiummetProf.HGM.Rooijmansalsopleider. Sinds1997ishijwerkzaamalspsychiaterbijdeIsalaKliniekenlok.SophiainZwolle.
Publicaties
Lamotrigine bij de behandeling van bipolaire stoornissen.TijdschriftvoorPsychiatrie49(2007)2,95-103M.L.M.vanderLoos,P.Kölling,E.A.M.Knoppert-vanderKlein,W.A.Nolen
Efficacy and safety of lamotrigine as add-on to lithium in the treatment of bipolar depression: a multi-center, double-blind, placebo-controlled trial J.ClinPsychiatryvol70;223-31MarcL.M.vanderLoosMD1;PaulMulderPhD2;ErwinG.Th.M.HartongMDPhD3;MarcB.J.BlomMD4;AntonC.Vergouwen,MDPhD5;HermanJ.U.E.MdeKeyzerMD6;PeterJ.H.NottenMD7;MarijkeL.LuteijnMD8;ManuelaA.TimmermansM.Sc9;EduardVietaMDPhD10;WillemA.Nolen,MDPhD11andtheLamLitStudyGroup*
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine.ActaPsychiatrScand.2010;122:246-54.
159159Curriculum Vitae M.L.M. van der Loos
MarcL.M.vanderLoosMD1;PaulMulderPhD2;ErwinG.Th.M.HartongMDPhD3;MarcB.J.BlomMD4;AntonC.Vergouwen,MDPhD5;MartijnSvanNoorden6;ManuelaA.TimmermansM.Sc7;EduardVietaMDPhD8;WillemA.Nolen,MDPhD9;fortheLamLitStudyGroup*
Treatment of Unipolar Psychotic DepressionA randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapineActaPsychiatricaScandinavica;2010Mar.121(3);190-200JaapWijkstra,HuibertBurger,WalterW.vandenBroek,TomK.Birkenhager,JoostG.E.Janzing,MarcoP.M.Boks,JanA.Bruijn,MarcL.M.vanderLoos,LeonieM.T.Breteler,GuillaumeM.G.I.Ramaekers,RobbertJ.Verkes,WillemA.Nolen,
Long term response to successfull acute pharmacological treatment of psychotic depressionJournalofaffectivedisorders;2010Jun;123(1-3);238-42JaapWijkstra,HuibertBurger,WalterW.vandenBroek,TomK.Birkenhager,JoostG.E.Janzing,MarcoP.M.Boks,JanA.Bruijn,MarcL.M.vanderLoos,LeonieM.T.Breteler,RobbertJ.Verkes,WillemA.Nolen,
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design.BipolarDisord.2011;13:111-7vanderLoosML,MulderP,HartongEG,BlomMB,VergouwenAC,vanNoordenMS,etal.
160160
Voordrachten
Lamotrigine as add-on to lithium in bipolar depression5-10-2006Barcelona,InternationalSocietyofBipolarDepressionStanleyConferencemeeting,presentation
Lamotrigine as add-on to lithium in bipolar depression followed by open label paroxetine addition in non-responders26-10-2007Kopenhagen,DUAGsymposiumPresentation
Workshop; ‘Farmacologische behandeling bipolaire depressie’15-10-2009,Apeldoorn:Nationaalfarmacotherapiecongres
Presentatie: Farmacotherapie in de onderhoudsfase10-11-2009Utrecht:NajaarssymposiumBipolairestoornissen
Posters
Verhoogde plasma vasopressine spiegels bij opgenomen patienten met een depressie21eVoorjaarscongres,NedelandseVerenigingvoorPsychiatrie,Lunteren1994LondenL.van,LoosMLMvander,GoekoopJG,KempenGMJvan,DeWiedD,RooijmansHGM
Lamotrigine as add-on to lithium in bipolar depressionMLMvanderLoos,EVieta,WANolen28-5-2007SanDiego,AmericanPsychiatricAssociation
161161Curriculum Vitae M.L.M. van der Loos
Lamotrigine as add-on to lithium in bipolar depression followed by open label paroxetine addition in non-respondersMLMvanderLoos,EVieta,WANolen8-6-2007Pittsburg,InternationalSocietyofBipolarDisorders
Boekhoofdstukken
Handboek Bipolaire StoornissenRed:.RalphKupka,EliseKnoppert-vanderKlein,WillemNolenUitgeverijdeTijdstroomHoofdstuk14AnticonvulsivaErwinHartong,MarcvanderLoos,WillemNolen
Bipolar Psychopharmacotherapy; Caring for the patient, second editionRed.HagopS.Akiskal,MauricioTohenChapter4:PharmalogicalprofileandclinicalutilityoflamotrigineinmooddisordersM.L.M.vanderLoos,JosephR.Calabrese,WillemA.Nolen,DavidJ.Muzina
The essentials of psychopharmacology, third edition (in press)Red:Dr.SchatzbergandDr.NemeroffChapter:LamotrigineDavidE.Kemp,MarcvanderLoos,KemingGao,JosephR.Calabrese
162
163
Dankwoord
164164
Dankwoord (Acknowledgments)
Nanegenjaarishetmoeilijkomiedereenpersoonlijktebedankendieaanditprojecthebbenmeegewerkt.Vandaardatditdankwoordeerdereensamenvattinggenoemdmoetworden.
WillemNolenwasdegenedieaandewiegvanditonderzoekheeftgestaan.Toenikin2002solliciteerdenaardefunctievan‘hoofdonderzoeker’voorzaghijtweemogelijkeproblemen.Demogelijkheidvangeenofonvoldoenderesultatendoortegeringeinclusiewasheteerstemogelijkeobstakel.Doordesamenwerking,betrokkenheidenhetenthousiasmevanzowelpatiëntenalslokaleonderzoekersluktehetechternietalleenomvoldoendepatiëntenteincluderen,maarookomhetaantaluitvallersopmerkelijklaagtehouden.Mijnwaarderingvoormetnamedepatiëntendievaak68wekenlangaanallestudieproceduresmeewerktenisgroot. HettweedemogelijkeprobleemschoolvolgensWillemNoleninmijnonervarenheidalsonderzoekerenschrijvervanartikelen.DitprobleembleekechtermaarvangeringbelangtezijnomdatWillemnietalleeneenuitmuntendonderzoekerismaaromdathijinhetbespreken,corrigerenenuitleggeneenprofessorindewarezinvanhetwoordbleektezijn.Willem,hetiseenzeldzameengrotekwaliteitvanjouomstevigekritiektekunnenleverenzonderooitontmoedigendtezijn,meweer30jaarjongertelatenvoelenalsstudentzonderpatriarchaaltezijnenveeltebegeleidenzonderhetovertenemen.NooitreedikteruguitGroningenzondernieuwenthousiasmeeneengoedhumeur. DaaromWillem,zeerbedanktvoorjebegeleiding,steun,hulpenloyaliteit.Ditproefschrifthadernietzozeerandersuitgezienzonderjouwbegeleiding,hethadnooitbestaan.
HetwerkdatdoorManuelaTimmermansisgedaanverdiendzekermijngrotedank.WerkendvoorGSKzorgdejijvoordeorganisatievanhetprotocol,
165165Dankwoord
afsprakenmetonderzoekers,controleerdedata,organiseerde‘investigatormeetings’etc.Manuela,doorjouwhulpisditonderzoekvoormijgeenlogistiekenachtmerriegeworden.
PaulMulder,jouwilikgraagbedankenvoorhetgrotegeduldwaarmeejijmijdebasalestatistiekvoordezestudiewistuitteleggenzonderdatikeniginzichtindebenodigdecomputerprogramma’shad.Jouwgebrekaanopgewondenheidoverresultatenplaatstezowelmee-alstegenvallersvandeuitkomstendirectineengeheelanderlicht.Meestalineenwatgedemptereschakering.
DefinanciëleenorganisatorischesteunvanGSKmaaktedezestudiemogelijk.OoknahetaflopenvanhetpatentoplamotriginebleefGSKondersteuningbieden.Hiermeeisduidelijkgemaaktdatineengoedesamenwerkingtussenpatiënten,onderzoekersendefarmaceutischeindustrieervooriedereenvoordeelvalttebehalen.
DedirectievandeIsalaKliniekengafmijtijdvoorditprojectwaardoorhetmogelijkbleekomnaasthet‘gewonewerk’dezestudieopeengoedeentochnog‘socialewijze’afteronden.
DenauwkeurigheidenvolhardingwaarmeeJaapJansenenHenkHallie(UMCG)deenormehoeveelheiddataindedatabaseinvoerdenverdiendgrotedank.
Veelwaarderinggaatuitnaarmijntweecollega’sJanPieterSmitenDouweKromdijk.TemiddenvanbijtijdenwijleheftigeberoeringishetonstotnutoegeluktomonzegezamenlijkevisieopdeplaatsvandeziekenhuispsychiatrieindeIsalaKliniekenvormtegeven.Ikhoopvanhartedathetonsookindekomendejarenzalblijvenlukken.
166166
Inhetbeginvanmijndankwoordnoemdeikaldelokalemede-onderzoekers.Zijvormdenderuggengraatvandeze‘multicentretrial’enikwilgraagmijndankwoordeindigenmethunallenhiertenoemen:
R.W.J.Baas,MD,P.R.Bakker,MD,M.B.J.Blom,MD,W.Brouwer,MD,P.H.M.vanDongen,MD,D.M.H.vanHyfte,MD,K.Geling,MD,G.Glas,MDPhD,E.G.Th.M.Hartong,MDPhD,O.Habekotté,MD,A.Keegan,MD,H.deKeyzer,E.deJong,MD,E.A.M.Knoppert-vanderKlein,MDPhD,P.Kölling,MD,D.Koning,MD,A.G.Kunst,MD,R.W.Kupka,MDPhD,G.Kuut,MD,J.J.vanLieshout,MD,D.H.Kromdijk,MD,F.R.Kruisdijk,MD,E.vanLeeuwen,MD,M.deMaat,MD,M.vanNoorden,MD,P.J.H.Notten,MD,M.L.Luteijn,MD,P.Schoof,MD,J.M.J.F.Offermans,MD,D.Bloemkolk,MD,R.R.Ploeger,MD,J.Segeren,MD,S.Smit,MD,D.H.Postma,MD,M.J.W.T.Scherders,MD,A.C.M.Vergouwen,MDPhD,T.Vos,MD,J.vanZaane,MDinNederlandenEVieta,MDPhD,R.Arce,MD,L.Livianos,MD,A.González-Pinto,MDPhD,E.Álvarez,MDPhDinSpanje.
167167Dankwoord